<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?subarticle report7225?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Res</journal-id><journal-id journal-id-type="iso-abbrev">F1000Res</journal-id><journal-id journal-id-type="pmc">F1000Research</journal-id><journal-title-group><journal-title>F1000Research</journal-title></journal-title-group><issn pub-type="epub">2046-1402</issn><publisher><publisher-name>F1000Research</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4329672</article-id><article-id pub-id-type="doi">10.12688/f1000research.5654.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group><subject>Articles</subject><subj-group><subject>Bioinformatics</subject></subj-group><subj-group><subject>Genomics</subject></subj-group><subj-group><subject>Structure: RNA</subject></subj-group><subj-group><subject>Structure: Transcription &#x00026; Translation</subject></subj-group></subj-group></article-categories><title-group><article-title>Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis</article-title><fn-group content-type="pub-status"><fn><p>v1; ref status: indexed</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Caminsky</surname><given-names>Natasha</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mucaki</surname><given-names>Eliseos J.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rogan</surname><given-names>Peter K.</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a2">2</xref></contrib><aff id="a1"><label>1</label>Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, ON, N6A 2C1, Canada</aff><aff id="a2"><label>2</label>Departments of Biochemistry and Computer Science, Western University, London, ON, N6A 2C1, Canada</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:progan@uwo.ca">progan@uwo.ca</email></corresp><fn fn-type="con"><p>PKR conceived, coordinated, and directed this study. NGC compiled the literature and determined which articles were eligible for inclusion. NGC and EJM summarized the articles. NGC, EJM and PKR wrote the manuscript, which has been approved by all authors.</p></fn><fn fn-type="conflict"><p><bold>Competing interests: </bold>PKR is the inventor of US Patent 5,867,402 and other patents pending, which underlie the prediction and validation of mutations. He is one of the founders of Cytognomix, Inc. which is developing software based on this technology for complete genome or exome splicing mutation analysis.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>3</volume><elocation-id>282</elocation-id><history><date date-type="accepted"><day>10</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2014 Caminsky N et al.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license><license license-type="open-access" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="f1000research-3-6038.pdf"/><abstract><p>The interpretation of genomic variants has become one of the paramount challenges in the post-genome sequencing era. In this review we summarize nearly 20 years of research on the applications of information theory (IT) to interpret coding and non-coding mutations that alter mRNA splicing in rare and common diseases. We compile and summarize the spectrum of published variants analyzed by IT, to provide a broad perspective of the distribution of deleterious natural and cryptic splice site variants detected, as well as those affecting splicing regulatory sequences. Results for natural splice site mutations can be interrogated dynamically with Splicing Mutation Calculator, a companion software program that computes changes in information content for any splice site substitution, linked to corresponding publications containing these mutations. The accuracy of IT-based analysis was assessed in the context of experimentally validated mutations. Because splice site information quantifies binding affinity, IT-based analyses can discern the differences between variants that account for the observed reduced (leaky) versus abolished mRNA splicing. We extend this principle by comparing predicted mutations in natural, cryptic, and regulatory splice sites with observed deleterious phenotypic and benign effects. Our analysis of 1727 variants revealed a number of general principles useful for ensuring portability of these analyses and accurate input and interpretation of mutations. We offer guidelines for optimal use of IT software for interpretation of mRNA splicing mutations.</p></abstract><kwd-group kwd-group-type="author"><kwd>mRNA</kwd><kwd>splicing</kwd><kwd>mutation</kwd><kwd>genetic disease</kwd><kwd>rare disease</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>Canadian Breast Cancer Foundation</funding-source></award-group><award-group id="fund-2"><funding-source>Canadian Foundation for Innovation</funding-source></award-group><award-group id="fund-3"><funding-source>Canada Research Chairs Secretariat</funding-source></award-group><award-group id="fund-4"><funding-source>Natural Sciences and Engineering Research Council of Canada</funding-source><award-id>NSERC Discovery Grant 371758-2009</award-id></award-group><award-group id="fund-5"><funding-source>Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit</funding-source></award-group><award-group id="fund-6"><funding-source>CIHR Strategic Training Program in Cancer Research and Technology Transfer Program</funding-source></award-group><funding-statement>PKR is supported by the Canadian Breast Cancer Foundation, Canadian Foundation for Innovation, Canada Research Chairs Secretariat and the Natural Sciences and Engineering Research Council of Canada (NSERC Discovery Grant 371758-2009). NGC received fellowships from the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, and the CIHR Strategic Training Program in Cancer Research and Technology Transfer Program.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Pre-mRNA splicing is a necessary step in the production of a functional protein product. It consists of the recognition of intron/exon boundaries, and the subsequent excision of the introns. It is important to distinguish between alternate splicing isoforms and mutant splice forms. The former consists of using different combinations of splice sites for the same gene. It is estimated to occur in over 60% of human genes, some of which will have multiple alternate isoforms
<sup><xref rid="ref-1" ref-type="bibr">1</xref>,
<xref rid="ref-2" ref-type="bibr">2</xref></sup>. For example,
<italic>NF1</italic> is reported to produce 46 splice variants
<sup><xref rid="ref-3" ref-type="bibr">3</xref></sup>. The cell regulates this naturally occurring process through the availability of tissue-specific splice factors. Alternative splicing is not generated by changes in the unspliced RNA sequence, whereas mutations that produce non-constitutive splice forms are the result of dysregulation of natural splice site recognition. Mutations can have various consequences to RNA processing, such as exon skipping, cryptic splicing, intron inclusion, leaky splicing, or less frequently, introduction of pseudo-exons into the processed mRNA. A broad range of molecular phenotypes are possible depending on the type and severity of the mutation, making it imperative to understand the consequences of splicing mutations. For the purposes of this review, we consider sequence changes in genes that affect transcript structure or abundance to be mutations, regardless of their allele frequencies. Although spliceosomal recognition and RNA binding factors are operative in mutation-derived and normal alternative mRNA splicing events, this review is focused on aberrant sequence changes that alter constitutive splicing, and often result in clinically abnormal phenotypes.</p><p>The process of U1/U2-based mRNA splicing involves the recognition of a number of key sequence components
<sup><xref rid="ref-4" ref-type="bibr">4</xref>,
<xref rid="ref-5" ref-type="bibr">5</xref></sup>, with exons defined by both intronic and exonic features
<sup><xref rid="ref-4" ref-type="bibr">4</xref>,
<xref rid="ref-6" ref-type="bibr">6</xref></sup>. The exonic and intronic sequences flanking the 5&#x000b4; end of an intron is termed the donor site and the 3&#x000b4; end, the acceptor site. In typical mRNA splicing, the natural donor and acceptor splice sites span intervals of 10 and 28 bases in length, respectively. It is a common misconception that these sequences (especially the dinucleotides immediately intronic to the exon) are invariant. Although highly conserved, these sequences vary at different splice junctions within a gene as well as between genes. The particular combination of nucleotides at each position within the same splice site determines its overall strength, which dictates the likelihood of recognition by the U1 and U2 spliceosomes.</p><p>In addition, binding sites for splicing regulatory elements have been shown to reside over a range of distances from the corresponding natural splice sites
<sup><xref rid="ref-7" ref-type="bibr">7</xref></sup>; the impact of these sites appears to be related to their binding affinities to the cognate RNA binding proteins and to their distance from the proximate intron/exon boundary
<sup><xref rid="ref-8" ref-type="bibr">8</xref></sup>. Recognition sites for these regulatory proteins can reside either within introns or exons. Those within exons are commonly referred to as exonic splice enhancers or silencers (ESE or ESS, respectively), whereas the corresponding designations for intronic elements are ISE or ISS. Sequence variants affecting these protein-binding sites (or mutations in the binding proteins themselves) have been documented as contributing to aberrant splicing and pathogenic phenotypes. We focus on variants occurring in
<italic>cis</italic> with target genes, as opposed to those in the splicing complex (in
<italic>trans)</italic>, leading to abnormal splicing. The efficiency and specificity of splicing depends on the combination of natural splice site strengths and the binding of splicing regulatory proteins that orchestrate exon recognition
<sup><xref rid="ref-9" ref-type="bibr">9</xref></sup>.</p><p>Mutations that affect pre-mRNA splicing account for at least 15% of disease-causing mutations
<sup><xref rid="ref-10" ref-type="bibr">10</xref></sup> with up to 50% of all mutations described in some genes
<sup><xref rid="ref-11" ref-type="bibr">11</xref>,
<xref rid="ref-12" ref-type="bibr">12</xref></sup>. Interpreting the effects that these variants have on splicing is not straightforward because natural and regulatory splice sites exhibit considerable sequence variation. Furthermore, performing
<italic>in vitro</italic> experiments to verify the consequences of each variant is costly and time consuming, and may not be practical.
<italic>In silico</italic> prediction methods have become essential resources for analyzing these variants. Software programs for splicing analysis use a wide variety of bioinformatic approaches. Several splice site prediction tools compare the predicted mutant sequence to a consensus sequence, based on a set of functional acceptor or donor splice sites
<sup><xref rid="ref-13" ref-type="bibr">13</xref></sup>. A drawback of this approach is that low-frequency nucleotides present in functional splice sites are not represented, which can lead to misinterpretation and false-positive mutation predictions. One example of this was illustrated by Rogan and Schneider (1995), in which the variant, IVS12-6T&#x0003e;C in
<italic>MSH2</italic>, described by Fishel
<italic>et al</italic>. (1993) was predicted to be benign, despite being located 6 nt from the natural acceptor splice junction
<sup><xref rid="ref-14" ref-type="bibr">14</xref>,
<xref rid="ref-15" ref-type="bibr">15</xref></sup>. The consensus sequence fails to indicate that C and T at this position are nearly equally probable, which reclassified this transition as a polymorphism rather than a pathogenic variant. This conclusion is supported by evidence that ~10% of normal individuals without predisposition to non-polyposis colon cancer harbour this alternate allele
<sup><xref rid="ref-16" ref-type="bibr">16</xref></sup>.</p><p>Over the last 20 years, we and others have developed an information theory (IT)-based approach for prediction of splicing mutations, and their impact on mRNA structure and abundance. The effects of these mutations is founded on the formal relationship between IT and the second law of thermodynamics, in that the change in information ascribed to a sequence variant within a splice site is directly related to thermodynamic entropy and free energy of binding
<sup><xref rid="ref-17" ref-type="bibr">17</xref>,
<xref rid="ref-18" ref-type="bibr">18</xref></sup>. A weight matrix consisting of the Shannon information (product of the probability of each nucleotide and &#x02013;log
<sub>2</sub> of its probability) at each position of the splice site is constructed. The individual information for a splice site (
<italic>R
<sub>i</sub></italic>, in bits) is defined as the dot product of this weight matrix and the unitary vector of a particular splice site sequence. The magnitude of the information content of a nucleotide within a given site is an indication of its level of conservation relative to a set of functional sites. This method retains all of the sequence variability inherent in each model of donor and acceptor splice sites. By contrast, each base in the consensus sequence has the maximum
<italic>R
<sub>i</sub></italic> value, which is actually rare in the human genome, and is generally not representative of the preponderance of natural splice sites. Prior to the introduction of IT-based approaches, consensus sequence-based methods were widely used
<sup><xref rid="ref-13" ref-type="bibr">13</xref></sup>. Also, the use of neural networks, trained on sequences experimentally determined to be &#x0201c;bound&#x0201d; and &#x0201c;unbound&#x0201d;, was another early approach used to predict splice sites
<sup><xref rid="ref-19" ref-type="bibr">19</xref></sup>. However, these unbound set of sequences are known to harbour some contaminating functional sites
<sup><xref rid="ref-20" ref-type="bibr">20</xref>,
<xref rid="ref-21" ref-type="bibr">21</xref></sup>, which can limit the sensitivity and specificity of these networks
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>.</p><p>There are instances when IT does not accurately predict the consequences of a splice variant. This can often be attributed to instances involving multiple sites or multiple regulatory factors, which are not components of current splicing models. In addition, splicing regulatory proteins can share overlapping and degenerate binding sites, and may exert conflicting effects (for example, serine-arginine [SR] vs. hnRNP proteins), making
<italic>in silico</italic> prediction less reliable and accurate in these cases
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>. Finally, functional cryptic splicing motifs occurring deep within the introns can be challenging to identify, because they tend to be less well conserved than natural splice sites
<sup><xref rid="ref-24" ref-type="bibr">24</xref>,
<xref rid="ref-25" ref-type="bibr">25</xref></sup>.</p><p>Nevertheless, a number of authors have recommended IT methods for analysis of splice site variants (N = 29;
<xref ref-type="other" rid="DS0">Supplementary Table 1</xref>). In fact, this approach has been described as equivalent to using a general reference textbook as a diagnostic tool, which complemented by functional assays, may provide a complete molecular diagnosis
<sup><xref rid="ref-26" ref-type="bibr">26</xref></sup>. Most of the applications of IT for splicing mutation analysis have involved predominantly rare diseases, as well as some low frequency variants associated with more common genetic conditions. This is because IT has been used to assess how well computed changes in binding affinity conform to levels of expression and/or patient phenotypes.</p><p>Many IT studies have focused on sequence variants in individual disorders or genes. Our synopsis of the broader implications of this work sets the stage for this compilation of peer-reviewed variants with accompanying IT analyses. We cover all publications retrieved through PubMed and Google Scholar that cite the use of IT (N = 367;
<xref ref-type="other" rid="SM">Supplementary Bibliography</xref>) before September 2014. These items include primary research articles, review articles, presentations, and theses. Of all references, 216 publications reported variants or other results or analyses pertinent to this review (
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>). In the remaining studies, analyses were either not performed, insufficient information was provided to reproduce the reported result, or authors described unrelated applications of IT-based analysis. We summarize the spectrum of variants analyzed to obtain a global perspective of splicing mutations resulting in genetic disease. We also highlight common errors that can occur in variant analysis and interpretation, and offer guidelines for optimal use of our software programs for interpretation of splicing mutations.</p></sec><sec><title>Information theory and splice site analysis</title><p>IT was first introduced by Claude Shannon in 1948 and is now used in a variety of disciplines to express the average number of bits (i.e. the information content) needed to communicate symbols in a message
<sup><xref rid="ref-27" ref-type="bibr">27</xref></sup>. Bits are the basic unit used in computing and can have one of two values (typically the answer to a yes/no, true/false, or +/- problem). In nucleic acid molecular biology, the symbols in the message comprise a group of related, aligned sequences, with the average number of bits in the set corresponding to the amount of information in the message. This is determined from the information content at each position in the sequence, summed over all positions
<sup><xref rid="ref-28" ref-type="bibr">28</xref></sup>. The average information is depicted graphically by a sequence logo, which stacks the individual nucleotides at each position ranked by frequency, and where the height of the stack is the position-specific contribution to the average information
<sup><xref rid="ref-29" ref-type="bibr">29</xref></sup>. If the set of sequences are functional binding sites recognized by the same factor, the individual information in each site (i.e.
<italic>R
<sub>i</sub></italic> value) is related to thermodynamic entropy, and thus, to the free energy of binding
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>.</p><p>The information content of a nucleic acid binding site is related to the affinity of its interaction with proteins and other macromolecular complexes, such as the case during mRNA splicing
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>. Information theory-based position weight matrices (PWM;
<italic>R
<sub>i</sub></italic> [b,l] - also referred to as a ribl - where b and l correspond to the nucleotide and position in the splice site) can be determined for set of known binding sites, in this case, for the purpose of calculating individual and average sequence information
<sup><xref rid="ref-28" ref-type="bibr">28</xref></sup>.
<xref ref-type="fig" rid="f1">Figure 1</xref> shows an example of sequence logos for the canonical acceptor (or 3&#x000b4;, recognized by the U2 spliceosome) and donor (or 5&#x000b4;, recognized by the U1 spliceosome) splice sites, computed from the majority of constitutive sites at annotated splice junctions in the human genome
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>. The information contained within the natural splice donor site is distributed between the last codon of each exon and the adjacent 6 nucleotides of intronic sequence, whereas the acceptor sites are almost entirely intronic, extending 26 nucleotides upstream from the exon boundary.</p><fig fig-type="figure" id="f1" orientation="portrait" position="float"><label>Figure 1. </label><caption><title>Distribution of deleterious natural site variants relative to information content.</title><p>
<bold>A</bold>) The sequence logo for human acceptor and donor splice sites based on the positive (+) strand of the October 2000 (hg5) genome draft. The logo shows the distribution of information contents (
<italic>R
<sub>i</sub></italic> in bits) at each position over the region of 28 nucleotides for acceptor [-25, +2] and 10 nucleotides for donor [-3, +6] from the first nucleotide of the splice junction (position 0). Nucleotide height represents its frequency at that position. The horizontal bar atop each stack indicates the standard deviation at that position. This figure was modified from Rogan
<italic>et al.</italic> (2003) to include splice sites in genes on both strands of the annotated human reference genome
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>.
<bold>B</bold>) The distribution of deleterious single-nucleotide variants reported at the natural acceptor (left) and donor (right) splice sites. The variants used to populate this graph (
<xref ref-type="other" rid="DS0">Supplementary Table 8</xref>) were included only if they were reported to negatively affect splicing (N = 419 for acceptors, 599 for donors). The image was aligned to the sequence logo (
<bold>A</bold>) to illustrate potential correlation of number of splicing variants at a position to the information content at that position.</p></caption><graphic xlink:href="f1000research-3-6038-g0000"/></fig><p>The distributions of
<italic>R
<sub>i</sub></italic> values for these sets are approximately Gaussian, with a couple of important exceptions, namely the distribution has defined upper and lower bounds
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>. The upper limit corresponds to the consensus sequence, as it is not possible to have stronger binding than an exact match to this sequence. The theoretical lower limit corresponds to
<italic>R
<sub>i</sub></italic> = 0 bits. An
<italic>R
<sub>i</sub></italic> value less than zero implies that energy would be required (&#x00394;
<italic>G</italic> &#x0003e; 0 kcal/mol) for a stable binding complex to form, i.e. that the event would not occur spontaneously without an exogenous source of energy. The minimum strength site is zero bits, the equilibrium state (&#x00394;
<italic>G</italic> = 0). Assuming the contacts at each position in the same binding site form independently, this approach is accurate and quantitative. Altering a nucleotide with high information (implying high prevalence and conservation at that position) will have a greater impact on binding, than if a less-well conserved base were altered. The change in information due to a mutation in a site (&#x00394;
<italic>R
<sub>i</sub></italic>) is the difference between
<italic>R
<sub>i,final</sub></italic> and
<italic>R
<sub>i,initial</sub></italic> values, where
<italic>R
<sub>i,final</sub></italic> is the information of the sequence containing the variant, and
<italic>R
<sub>i,initial</sub></italic> the information of the reference (wild-type) sequence. The minimum fold change in binding affinity resulting from the mutation is an exponential function based on &#x00394;
<italic>R
<sub>i</sub></italic>, or &#x02265; 2
<sup>&#x00394;
<italic>Ri</italic></sup> (Ref.
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>).</p></sec><sec><title>Software resources</title><sec><title>Delila package/system</title><p>Information analysis was originally performed using the Delila sequence analysis system, which included a language to process nucleic acid sequences, and a library of sequence tools to retrieve and process various types of sequence data
<sup><xref rid="ref-31" ref-type="bibr">31</xref>,
<xref rid="ref-32" ref-type="bibr">32</xref></sup>. Tools to measure information content of nucleic acid sequences were subsequently added to Delila
<sup><xref rid="ref-28" ref-type="bibr">28</xref></sup>. Initially, models of information content of bacteriophage T7 RNA polymerase binding sites and other bacterial control systems were studied, and mRNA splice sites were subsequently developed
<sup><xref rid="ref-28" ref-type="bibr">28</xref>,
<xref rid="ref-33" ref-type="bibr">33</xref></sup>. Later, tools to display binding sites as sequence logos of average information, and sequence walkers showing individual information were incorporated into Delila
<sup><xref rid="ref-20" ref-type="bibr">20</xref>,
<xref rid="ref-29" ref-type="bibr">29</xref></sup>. The Automated Splice Site Analysis (ASSA) server introduced in 2004, and its successor, Automated Splice Site and Exon Definition Analysis server (
<ext-link ext-link-type="uri" xlink:href="http://splice.uwo.ca">http://splice.uwo.ca</ext-link>; ASSEDA), have been freely available throughout the last decade, and have been used for IT-based calculations on nucleic acid sequences for the preceding 20 years
<sup><xref rid="ref-34" ref-type="bibr">34</xref>,
<xref rid="ref-35" ref-type="bibr">35</xref></sup>. Both ASSA and ASSEDA still use the Delila program suite to retrieve sequences, calculate information content, and create sequence walker representations of individual binding sites.</p></sec><sec><title>ASSA/ASSEDA</title><p>To simplify mutation analysis, we built a web interface for variant analysis using Delila software as the processing backbone
<sup><xref rid="ref-34" ref-type="bibr">34</xref></sup>. Our aim was to standardize and facilitate IT-based mutation analysis by using Human Genome Variation Society (HGVS)-approved variant nomenclature (which has since become the worldwide standard), employing server-based retrieval/processing, and reporting results as concise predictions in both tabular and sequence walker display formats. Initially, ASSA results described mutations in relation to genome annotations from the first finished genome release (hg15)
<sup><xref rid="ref-34" ref-type="bibr">34</xref></sup>. While many publications cited this version of ASSA for novel splicing mutation analysis, continued improvements have introduced more accurate reference sequences, annotations, and models (for both constitutive and regulatory splice sites) based on more comprehensive sets of binding sites. The ASSA server contained the original donor and acceptor information position weight matrices derived by manual curation of GenBank entries
<sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>, murine donor and acceptor weight matrices, a subset of splicing enhancer elements (SF2/ASF, SC35 and SRp40), and the lariat branch point recognition sequence
<sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. ASSA reported the strengths of all potential sites predicted within the window selected by the user, highlighted those with the largest changes in
<italic>R
<sub>i</sub></italic>, and computed the minimum fold change in binding affinity for each mutation or polymorphism. Tabular results were colour-coded. Unaltered sites above and below the
<italic>R
<sub>i,min</sub></italic> (described in
<xref ref-type="other" rid="MI">Minimum splice site information content and exceptions</xref>) were highlighted grey and white, respectively. Pre-existing sites abolished by the variant (where
<italic>R
<sub>i,final</sub></italic> &#x0003c;
<italic>R
<sub>i,min</sub></italic>) were marked in red, while leaky natural sites (
<italic>R
<sub>i,final</sub></italic> &#x02265;
<italic>R
<sub>i,min</sub></italic>) were highlighted in blue. Cryptic sites that were created, strengthened, or weakened were highlighted in pink, green and teal, respectively. The server parsed any mutation type described precisely by the HGVS notation, including substitutions, insertions, deletions, and combinations of these changes
<sup><xref rid="ref-36" ref-type="bibr">36</xref></sup>. Recapitulating variants described in articles before these guidelines were widely adopted proved to be time-consuming and error-prone
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. Multiple binding factors had to be analyzed simultaneously; however, results were reported independently. The analysis did not consider other factors relevant to splice site recognition, such as the resulting exon size, or potential formation of cryptically spliced exons.</p><p>ASSEDA, the successor software to ASSA, provides a new isoform-oriented type of mutation interpretation, updates the coordinate system to HG19 (GRCh37), adds current gene and single nucleotide polymorphism (SNP) annotations (dbSNP135), and provides additional ribls for other splicing regulatory sites (SRp55, TIA1, ELAVL1, hnRNP A1, hnRNP H, and PTB). All models, except those for SRp55 and hnRNP H, have been built using sequences from publicly available CLIP-seq data, and are based on a larger number of binding site sequences. They have been tested by comparing predictions to validated binding sites from published primary literature, and to any splice-altering variants found within them
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. ASSEDA introduces
<italic>in silico</italic> exon definition analysis by computing the total splicing information across an exon
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. Total exon information (
<italic>R
<sub>i,total</sub></italic>) is the sum of the corresponding donor and acceptor
<italic>R
<sub>i</sub></italic> values, and corrected for the gap surprisal term, which is based on the length of the potential exon formed using those sites (from RefSeq)
<sup><xref rid="ref-37" ref-type="bibr">37</xref></sup>. The gap surprisal function is based on the genome-wide distribution of constitutive exon lengths, also known as self-information. This term ensures that exons are computationally defined using donor and acceptor splice sites in close proximity
<sup><xref rid="ref-37" ref-type="bibr">37</xref>,
<xref rid="ref-38" ref-type="bibr">38</xref></sup>.</p><p>Exons of uncommon length lead to large negative gap surprisal terms, which reduces
<italic>R
<sub>i,total</sub></italic>. When applied to predicted exons that activate a cryptic splice site, comparison of
<italic>R
<sub>i,total</sub></italic> values can more accurately predict cryptic site use than the strength of this site alone. The gap surprisal term decreases the predicted
<italic>R
<sub>i,total</sub></italic> value of particularly long internal exons (eg. the 3.4 kb long exon 11 of
<italic>BRCA1</italic>;
<italic>R
<sub>i,total</sub> =</italic> 1.4 bits), which tends to compensate for this effect with strong splice sites and other sequence elements that enhance natural splice site recognition and suppress internal cryptic splice sites.</p><p>The exon definition paradigm extends to the assessment of the impact of mutations in ESE/ISS elements. ASSEDA calculates
<italic>R
<sub>i,total</sub></italic> by adding the
<italic>R
<sub>i</sub></italic> value of a regulatory splicing element to the contributions of constitutive splice sites, and applying a second gap surprisal term based on the frequency of distance from the splicing element to the nearest natural site. Currently, the effect of only a single splicing factor can be evaluated by the software, although the approach itself is generalizable to multiple regulatory binding sites. If a variant causes changes in the
<italic>R
<sub>i</sub></italic> values of multiple sites, such as the simultaneous creation of both splicing enhancer and repressor elements, there will be less confidence in ASSEDA&#x02019;s predictions.</p><p>Two distinct sets of IT-based models for donors and acceptors are available on ASSEDA. The manually curated ribls were originally determined from 1799 donor and 1744 acceptor sites
<sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. We subsequently derived a set of ribl matrices from genome-wide exon annotations
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>. These models were automatically curated using the criteria that enforced
<italic>R
<sub>i</sub></italic> &#x0003e; 0 for correctly annotated sites. The resultant models consisted of 108,079 acceptor and 111,772 donor splice sites, however these were not formally implemented on the ASSA server until 2011
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>. These genome-wide models are used in the calculation of
<italic>R
<sub>i,total</sub></italic> values. The &#x00394;
<italic>R
<sub>i</sub></italic> values for a single nucleotide splicing variant are similar for both sets of models. Variants having opposite predicted effects between the respective donor or acceptor ribls have not been reported. In general, the genome-wide models report slightly lower information contents, however the frequencies of nucleotides at the 5&#x000b4; end of the acceptor site differ significantly. This results in differences in the weights in the -4 to -20 nt region between the manually-curated and the genome-wide acceptor ribl matrix, which can significantly lower
<italic>R
<sub>i</sub></italic> values based on the genome-wide model. In the genome, thymine is more prevalent than cytosine at these positions and has a higher positive contribution to the overall
<italic>R
<sub>i</sub>.</italic> This can account for up to a 1.97 bit difference between the models. Guanine nucleotides within this sequence window significantly lower the
<italic>R
<sub>i</sub></italic> values computed from the genome-wide acceptor ribl, as well. While these differences contribute only a 0.1&#x02013;0.4 bit difference to the
<italic>R
<sub>i</sub></italic> per nucleotide, the cumulative effect of multiple differences within this window can lead to significant differences between the acceptor
<italic>R
<sub>i</sub></italic> values.</p></sec><sec><title>Shannon Pipeline and Veridical</title><p>High-throughput DNA sequencing is generating a deluge of novel variants in patients with genetic diseases, most of which currently have unknown significance (VUS). For example, 20% of the patients with Pelizaeus-Merzbacher disease possess VUS, among which are single or compound heterozygous, rare pathogenic mutations
<sup><xref rid="ref-39" ref-type="bibr">39</xref></sup>. Many solutions have been proposed, however prediction of pathogenicity by bioinformatic analyses is often inaccurate
<sup><xref rid="ref-40" ref-type="bibr">40</xref></sup>. The Shannon Human Splicing Mutation Pipeline software predicts mutations at genome scale to predict which variants may alter mRNA splicing and is based on the same principles and IT models used in ASSA and ASSEDA
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. However, this software processes ~5 million substitutions and/or indels in 10&#x02013;15 minutes. While initially only available for the CLC-Bio Genomics platform, this software is now offered as a web service (
<ext-link ext-link-type="uri" xlink:href="http://shannonpipeline.cytognomix.com">http://shannonpipeline.cytognomix.com</ext-link>). Variants are batched in standard variant call format (VCF). The pipeline reports any genic variant that affects a known natural site or a cryptic site where
<italic>R
<sub>i,initial</sub></italic> or
<italic>R
<sub>i,final</sub></italic> are &#x02265; 0 bits and &#x00394;
<italic>R
<sub>i</sub></italic> &#x02265; 1.0 bits, however more stringent criteria for selecting variants with significant information changes can be applied.</p><p>In Shirley
<italic>et al</italic>. (2013), all variants from the complete genomes of three cancer cell lines (A431, U2OS, U251; N = 816,275) were analyzed
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. Variants that were common (&#x02265; 1%) were removed. Variants that weakened natural sites, or strengthened cryptic sites to levels comparable to or exceeding the strength to the nearest natural site, were flagged. Variants that strengthen a natural site could have an effect on the splicing profile of a gene (i.e. reduce the frequency of exon skipping for the corresponding exon), but are less likely to cause a deleterious phenotype. The overall fraction of mutations flagged, after filtering out distant cryptic sites and small &#x00394;
<italic>R
<sub>i</sub></italic> values, averaged 0.016%, illustrating how the software can be used for prioritizing variants. Some of the prioritized variants occurred in genes with known defective functional and biochemical pathways in these cancer cell types, i.e. cytokine signalling (in A431), DNA replication and cell cycle (in U2OS). Natural splice mutations were confirmed by expression data to a greater extent than either leaky or cryptic splice site variants.</p><p>In a complete cancer cell line genome, the number of cryptic sites with altered
<italic>R
<sub>i</sub></italic> values greatly exceeds the number of affected natural splice sites. Many of these are weak decoys, which can occur throughout genes. Using the principle that novel cryptic sites that are likely to be activated must compete with the natural splice site for spliceosomal recognition, the relevant cryptic sites are restricted to those with
<italic>R
<sub>i</sub></italic> values comparable to or greater than the corresponding strength of the adjacent natural site of the same polarity
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. Additionally, the proximity of potential cryptic sites to the natural site should be considered in assessing whether an exon could be formed with the natural splice site of opposite polarity. Cryptic sites that are considerably weaker than the nearest natural site of the same type, or cryptic sites that would lead to unusually large exons, diminish the likelihood of cryptic site activation. Benaglio
<italic>et al.</italic> (2014) used the Shannon Pipeline to screen 303 sequenced patients and flagged five variants that each strengthened or created a different cryptic site
<sup><xref rid="ref-42" ref-type="bibr">42</xref></sup>. While comparable in strength to the natural site, these were all distant (&#x0003e;400 nucleotides away) and thus, less likely to be recognized. The authors also stated that the &#x00394;
<italic>R
<sub>i</sub></italic> values for three of these sites were discordant with results obtained with NNSplice, a neural network-based splicing prediction program. In fact, both the Shannon Pipeline and NNSplice demonstrated strengthening of these decoy cryptic splice sites.</p><p>Shirley
<italic>et al</italic>. (2013) evaluated the predictions of the Shannon Pipeline by manually inspecting RNAseq data for each variant with significant information changes in each cell line
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. However, manual review is unfeasible for many large datasets, especially from tumors, because of the large numbers of potential somatic mutations affecting splicing in each genome. Veridical, an
<italic>in silico</italic> method for validation of DNA sequencing variants that alter mRNA splicing, has been developed to provide high throughput, statistically-robust unbiased evaluation based on RNAseq data
<sup><xref rid="ref-43" ref-type="bibr">43</xref></sup>. The method has been implemented as software for analysis of potential splicing variants from large datasets and catalogues their effects. Veridical takes Shannon Pipeline output from predicted genomic variants with effects on splicing and performs a case-control analysis of corresponding expressed transcripts that cover the same genomic region, taken from normal tissues. Upon Yeo-Johnson transformation of the expressed read count distribution, parametric statistics are used to compare normal and abnormal mRNA species (exon skipping, intron inclusion, and cryptic site use). Veridical is designed to be used with large data sets, as the statistical analysis gains power with increasing numbers of control samples. A recent study of 442 breast cancer tumors from the Cancer Genome Atlas Project revealed 5,206 putative splicing mutations using the Shannon Pipeline. Veridical was then used to confirm exon skipping, leaky or cryptic splicing of 988 of these variants
<sup><xref rid="ref-44" ref-type="bibr">44</xref></sup>.</p></sec></sec><sec><title>Natural sites</title><p>The early splice site recognition literature often oversimplified the composition of the U1/U2-type 5&#x000b4; donor and 3&#x000b4; acceptor sites by presenting only consensus sequences and truncating the positions in each site
<sup><xref rid="ref-13" ref-type="bibr">13</xref>,
<xref rid="ref-45" ref-type="bibr">45</xref>,
<xref rid="ref-46" ref-type="bibr">46</xref></sup>. However, the conserved tracts extend well beyond the canonical GT and AG dinucleotides adjacent to intron/exon junctions. Furthermore, a small, albeit significant, proportion of natural donor sites (~800, or 0.7%) contain cytosine at position +2 in the genome. This is reflected by a corresponding small decrease in average information at this position (
<xref ref-type="fig" rid="f1">Figure 1</xref>). Sequences adjacent to these positions are more variable, but are nevertheless essential for the accurate recognition by the spliceosome. Specifically, the donor site is defined by the three terminal nucleotides of each exon and the first seven bases of the downstream intron. Conversely, acceptor sites are represented by the first two bases of the exon and the last 26 bases of the upstream intron. Because ASSA and ASSEDA use an integer-based coordinate system, there is a zero coordinate at the first intronic base of each splice site (
<xref ref-type="fig" rid="f1">Figure 1</xref>), which is not used in the conventional numbering system. The coordinate ranges for the donor and acceptor site positions are therefore [-3, +6] and [-25, +2], respectively. Individual information analysis computes the
<italic>R
<sub>i</sub></italic> values over these intervals for normal and variant-containing splice sites. As discussed below, information content present in intronic intervals justifies sequencing and analyses of sequences well beyond the locations of the splice junctions themselves.</p><p>Certain variants within donor and acceptor sites are tolerated and may even have benign effects, while others have a deleterious impact on spliceosomal recognition. IT accounts for all of these possible outcomes. Unusual donor sites (i.e. with cytosine at position +2) are detected by information analysis, but could be falsely called deleterious by consensus sequence-based methods. Although the terminal position of exons contributes significantly to donor splice sites with a preference for G, a significant proportion of sites naturally possess A or U at this position, or less frequently, C.</p><p>Of the published IT-based variant analyses, single nucleotide variants (SNVs) that were reported to affect a natural splice site (multi-nucleotide and insertion/deletion variants are listed separately in
<xref ref-type="other" rid="DS0">Supplementary Table 3</xref>) were compiled and reanalyzed. After reducing this set to only those variants occurring within the intervals covered by the splice site information weight matrices described above, 1152 SNVs were reported to affect the strengths of either natural donor or acceptor sites. A variant was considered deleterious if it was predicted to affect splicing (either leaky expression or exon skipping), or if it was experimentally shown to reduce or abolish splicing of the corresponding exon. In instances where prediction and validation did not concur, the latter were used to determine the effect of the variant. Variants predicted to have a neutral effect but demonstrated to be deleterious in the validation study were classified as damaging. In total, 1010 deleterious natural splice site variants were analyzed (
<xref ref-type="other" rid="DS0">Supplementary Table 4</xref>).</p><p>Sequence conservation has long been considered a surrogate measure of evolutionary constraint and, by inference, functional significance. The average information quantitates the relative conservation at each of the positions within a binding site. We compiled the mutation spectra for all mutations that significantly affected the strengths of donor and acceptor splice sites and compared these with the average information contents at each position. The panels in
<xref ref-type="fig" rid="f1">figure 1b</xref> respectively indicate, at each position of the natural acceptor and donor sites, the frequencies of variants deemed deleterious by information analysis. Interestingly, when the sequence logo is overlaid with the histogram of the corresponding mutation spectra, the relative frequencies of deleterious mutations and the average information are comparable. Indeed, these frequencies and the information contents across each type of site are strongly correlated (r=0.95 for acceptors and 0.89 for donors). Our interpretation is that the susceptibility to deleterious mutation at a position is related to its overall conservation within the splice site, which reflects the contribution of that ribonucleotide to the stability of the interaction with the corresponding spliceosome. Nevertheless, there is an unstated bias in ascertainment in these mutation spectra. Variants occurring at sites with low information and/or that are benign are underrepresented, as they are less likely to be associated with genetic disease, and were less likely to be reported. Also, the distribution is dependent on the region sequenced by the authors of the reviewed publications; in early work, the full sequence interval containing the entire splice site was sometimes not included or unavailable for analysis.</p><p>An interactive website was created to summarize this set of SNVs. This software application renders interpretations of variant effects in a more practical, useful way than the corresponding table of supplemental data (
<xref ref-type="other" rid="DS0">Supplemental Table 10</xref>). The &#x0201c;Splicing Mutation Calculator&#x0201d; (SMC;
<ext-link ext-link-type="uri" xlink:href="http://splicemc.cytognomix.com">http://splicemc.cytognomix.com</ext-link>) is a web service that amalgamates all published results for the same type of substitution in a natural splice site, regardless of genic context. Variants that create cryptic splice sites were not included, because we consider these cases to be sequence-specific as opposed to positional. With this program, users have the option of exploring mutation data (at present, only SNVs can be analyzed) linked to the original literature citations. SMC processes and provides literature support for the variants that occur within the defined regions spanned by natural splice sites. The user first selects the type of site (donor or acceptor), position (based on ASSEDA&#x02019;s integer-based system), wild-type or reference nucleotide, and the alternate substitution at that position (
<xref ref-type="fig" rid="f2">Figure 2a</xref>). The software tool outputs the &#x00394;
<italic>R
<sub>i</sub></italic> and the number of variants that have been reported and analyzed to date using IT (
<xref ref-type="fig" rid="f2">Figure 2b</xref>). SMC provisionally classifies the reported variants based on the degree to which these predicted effects are expected to decrease spliceosomal affinity, and consequently splicing. The following criteria are empirically based on affinity changes and a summary of published phenotypes associated with these changes: &#x0201c;Deleterious&#x0201d; (if the site is weakened by more than 7.0 bits), &#x0201c;Probably Deleterious&#x0201d; (if the site is weakened such that -4.0 bits &#x02265; &#x00394;
<italic>R
<sub>i</sub></italic> &#x02265; -7.0 bits), &#x0201c;Leaky&#x0201d; (the site is weakened such that -1.0 bits &#x02265; &#x00394;
<italic>R
<sub>i</sub> &#x02265; -</italic>4.0 bits), or &#x0201c;Benign, probable polymorphism&#x0201d; (if the site is weakened by less than 1.0 bits). In this first release of SMC, we have omitted &#x0201c;benign&#x0201d; variants, which are likely polymorphisms; these will be catalogued and included in a later version. It is important to appreciate that the &#x00394;
<italic>R
<sub>i</sub></italic> is a constant for a specific nucleotide change at a specific position, though the absolute strength of the splice site depends on the sequence context of the mutation. This context varies between mutations, and
<italic>R
<sub>i,initial</sub></italic> is not the same for each case, which can result in different
<italic>R
<sub>i,final</sub></italic> values for different mutations.</p><fig fig-type="figure" id="f2" orientation="portrait" position="float"><label>Figure 2. </label><caption><title>Sample retrieval of average change in information content (&#x00394;
<italic>R
<sub>i</sub></italic>) with splicing mutation calculator (SMC) for published mutations.</title><p>
<bold>A</bold>) Example mutation input for SMC (T&#x0003e;A at the 3
<sup>rd</sup> intronic position of natural acceptor). The type of splice site is selected by clicking on the corresponding sequence logo (acceptor [left] or donor [right]). The purple slider bar appearing below the logo is used to select the position of the mutation. The reference and mutant nucleotides are then designated, and the variant is submitted to the software (&#x02018;Submit your selection&#x02019;). SMC outputs a table indicating the user input, the number of instances in the literature where this substitution has been analyzed using IT, and the computed &#x00394;
<italic>R
<sub>i</sub></italic> values (in bits) using both the old (1992; top) and new (2003; bottom) ribls. The cell color for &#x00394;
<italic>R
<sub>i</sub></italic> values indicates the predicted severity of the inputted variant according to defined thresholds
<sup><xref rid="ref-22" ref-type="bibr">22</xref>,
<xref rid="ref-168" ref-type="bibr">168</xref></sup>.
<bold>B</bold>) Tabular output detailing each instance of the selected mutation from the source table. The user may view, in a separate window, extensive details of all variants referred to in SMC output (
<xref ref-type="other" rid="DS0">Supplementary Table 10</xref>).</p></caption><graphic xlink:href="f1000research-3-6038-g0001"/></fig><p>Besides published sources, the software also can predict effects of mutations by computing &#x00394;
<italic>R
<sub>i</sub></italic> values directly. Particular substitutions that have not been reported in
<xref ref-type="other" rid="DS0">Supplemental Table 10</xref> can nonetheless be provisionally interpreted. The &#x00394;
<italic>R
<sub>i</sub></italic> value is computed and reported from the ribl. While SMC enables rapid exploration of results for validated and novel mutations, it is, however, not a replacement for ASSEDA or the Shannon Pipeline, since it does not consider the sequence context, which can also influence the interpretation of deleterious, leaky, or benign variants.</p><sec id="MI"><title>Minimum splice site information content and exceptions</title><p>The minimum theoretical information content of a binding site,
<italic>R
<sub>i,min</sub></italic>, is zero bits
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>. Comparison of the
<italic>R
<sub>i,</sub></italic> values of a series of inactivated and minimally active splice sites revealed the minimum strength of functional splice sites (
<italic>R
<sub>i,min</sub></italic>) to be at least 2.4 bits for the original donor and acceptor models of Stephens and Schneider (1992) (based on 103 mutations with functional validation, including 57 natural and 46 cryptic site activating mutations)
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. This value was redefined based on information models from a genome-wide set of donor and acceptor models (
<xref ref-type="fig" rid="f1">Figure 1a</xref>) to be 1.6 bits using the identical set of mutations
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup>. It is likely that the differences between these values are not significant and are attributable to the increased precision of the ribl using the ~50-fold larger set of sites. Weakened natural sites, with significantly reduced
<italic>R
<sub>i</sub></italic> values that remain above these thresholds, are considered to be leaky (lower affinity binding), whereas those below this threshold are found to completely abolish natural splice site recognition, resulting in either exon skipping or activation of neighbouring cryptic splice sites. However, these outcomes are not mutually exclusive, since leaky splice site mutations may also result in exon skipping and/or activate neighboring cryptic sites. Natural splice sites below these thresholds are extremely rare, and their recognition is likely enhanced through the binding of specific RNA binding proteins that promote exon definition (eg.
<italic>XPC</italic> exon 4 acceptor and
<italic>MYBP3</italic> exon 12 acceptor
<sup><xref rid="ref-47" ref-type="bibr">47</xref>,
<xref rid="ref-48" ref-type="bibr">48</xref></sup>).</p><p>Leaky natural sites have
<italic>R
<sub>i</sub></italic> values exceeding the
<italic>R
<sub>i,min</sub></italic> threshold, which, in theory, retain some capacity to be recognized by the spliceosome. There were 84 variants predicted to cause leaky splicing, of which 19 were shown experimentally to lead to exon skipping without any detectable residual natural splicing (
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>: #32, 120, 128/380, 195, 276.5, 355, 360, 363, 364, 365, 379, 409, 477/496/934, 573, 842, 853, 883/1589, 886, and 918). Of those, seven are donor splice site mutations at position +5 (&#x00394;
<italic>R
<sub>i</sub></italic> ~ -3.5 bits; #128/380, 195, 355, 842, 853, 883/1589, 886), four alter the first exonic nucleotide of a donor site (&#x00394;
<italic>R
<sub>i</sub></italic> ~ -3.0 bits; #276.5, 360, 379, 409), and three are donor mutations at position +4 (&#x00394;
<italic>R
<sub>i</sub></italic> ~ -2.6 bits; #120, 365, 573). The
<italic>R
<sub>i,final</sub></italic> values of these 19 inactivated natural sites range from 2.7 to 8.8 bits, which suggests the possibility that the variant may also simultaneously affect other adjacent or overlapping sites that preclude recognition of the mutated natural site. Additionally, weakening of 11 of these variants activates a neighbouring cryptic splice site, in which no residual natural splicing was detected. However, changes in splice site preference due to small changes in binding affinity within exons are probably related to the processive nature of donor splice site selection
<sup><xref rid="ref-49" ref-type="bibr">49</xref></sup>.</p><p>Leaky splicing mutations are readily detected when the expressed transcript contains the causative variant or a neighbouring polymorphism. However, there are a number of practical limitations on the methods for experimental validation of leaky splicing mutations. RT-PCR alone would only be considered reliable for confirmation of homozygous mutations (and in one case, a compound heterozygote where two separate variants abolished natural splicing of the same exon), unless combined with a secondary quantitative methodology
<sup><xref rid="ref-50" ref-type="bibr">50</xref></sup>. Similarly, it is difficult to assess leaky splicing of heterozygotes using RNAseq data, as reduced levels of wild-type splicing are challenging to determine without adequate read coverage and controls for comparison. However, leaky splicing can be assessed by comparing the frequency of the causative allele to the normal allele in the same cell line when the variant is present within the sequenced reads
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. These are special cases however, as the variant itself must either be expressed within an exon or, if intronic, must lead to an activation of a cryptic site further into the corresponding intron.</p><p>We previously suggested that weaker splice sites are more susceptible to mutational inactivation relative to stronger sites
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. In the present study, all experimentally verified variants affecting natural sites (where leaky and abolished splicing could be differentiated) were analyzed (N = 98). Variants predicted to abolish splicing (
<italic>R
<sub>i,final</sub></italic> &#x0003c;
<italic>R
<sub>i,min</sub></italic> and/or &#x00394;
<italic>R
<sub>i</sub></italic> &#x0003c; 7.0 bits) were filtered out, as large changes in binding affinity will essentially abolish splicing, despite remaining binding strength and regardless of initial
<italic>R
<sub>i</sub></italic> value.
<xref ref-type="other" rid="SM">Supplementary Figure 1</xref> illustrates the frequency of inactivation by these variants relative to initial
<italic>R
<sub>i</sub></italic> value. Variants occurring at weak splice sites (
<italic>R
<sub>i,initial</sub></italic> &#x0003c; 4 bits) abolish splicing in 5 of 6 cases (where &#x00394;
<italic>R
<sub>i</sub></italic> &#x0003c; 7 bits), but are not represented as they all weaken the site below
<italic>R
<sub>i,min</sub></italic>. The remaining variant slightly weakens a site where R
<italic><sub>i,initial</sub></italic> is -0.1 bits (where &#x00394;
<italic>R
<sub>i</sub></italic> = 0.5 bits), and its recognition may be supported by SR elements
<sup><xref rid="ref-47" ref-type="bibr">47</xref></sup>. Moderate strength splice sites (5&#x02013;11.0) bits are inactivated in 25&#x02013;60% of cases, and mutations at strong splice sites (
<italic>R
<sub>i,initial</sub></italic> &#x02265; 12 bits) tend to be leaky (
<xref ref-type="other" rid="SM">Supplementary Figure 1b</xref>).</p><p>Mutations that abolish natural sites (without cryptic splice site activation) are expected to result in a complete loss of normal splicing. However, of the 94 variants that reduced natural splice site strength below
<italic>R
<sub>i,min</sub></italic>, 11 were reported to have residual normal splicing activity (
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>: #185/750, 275, 881, 914, 1315, 1321, 1325, 1326, 1361, 1380, and 1407)
<sup><xref rid="ref-22" ref-type="bibr">22</xref>,
<xref rid="ref-41" ref-type="bibr">41</xref>,
<xref rid="ref-51" ref-type="bibr">51</xref>,
<xref rid="ref-52" ref-type="bibr">52</xref></sup>. Two of these occurred at the G of the +1 position of the donor site (
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>: #185/750 and 1326), which is essentially invariant in functional splice sites. This suggests potential problems in IT or experimental analysis of these mutations. Surprisingly, the majority of these variants occur at the +2 position of a donor splice site and are T&#x0003e;G mutations, which are predicted to abolish splicing activity
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. However, the analysis of RNAseq data for these variants showed no splicing defects (
<xref ref-type="other" rid="DS0">Supplementary Table 7</xref>: #1315, 1321, 1325, 1361, 1380 and 1407). One explanation is that resultant aberrantly spliced transcripts were subjected to nonsense-mediated decay (NMD) and degraded. Another possibility is that the coverage of these splice junctions is insufficient to distinguish expression of a single allele from that same allele plus the leaky splice junction. The remaining variants differ in the position within the splice site and decrease natural site strengths to between 0.9 to 2.2 bits
<sup><xref rid="ref-22" ref-type="bibr">22</xref>,
<xref rid="ref-51" ref-type="bibr">51</xref></sup>.</p><p>Theoretically, a site lacking the canonical G at +1 (donor) or -1 (acceptor) position of a natural site may exceed
<italic>R
<sub>i,min</sub></italic>. Ozaltin
<italic>et al.</italic> (2011) and Di Leo
<italic>et al.</italic> (2009) each assessed mutations at positions +1 or -1, which weaken natural splice sites to
<italic>R
<sub>i</sub></italic> &#x0003e;
<italic>R
<sub>i,min</sub></italic>, and note that these sites are predicted to be leaky
<sup><xref rid="ref-53" ref-type="bibr">53</xref>,
<xref rid="ref-54" ref-type="bibr">54</xref></sup>. However, this is not the sole criterion for interpreting splice site mutations using IT-based methods. The overall change in binding affinity must also be considered, as both mutated sites were predicted to have only 0.4&#x02013;0.5% of the binding affinity of the corresponding natural splice sites
<sup><xref rid="ref-53" ref-type="bibr">53</xref>,
<xref rid="ref-54" ref-type="bibr">54</xref></sup>.</p></sec><sec><title>Branch-point mutations</title><p>Although branch-point site (BPS) recognition occurs independently and post-exon definition, mutations in this sequence have also been described, due to its proximity to the natural acceptor site. Following the recognition of and binding to the 5&#x000b4;ss (upstream donor site) by the U1 snRNP, the U2 is recruited to the 3&#x000b4;ss (downstream acceptor) and recognizes the BPS, resulting in the formation of the pre-spliceosome
<sup><xref rid="ref-55" ref-type="bibr">55</xref></sup>. Association of U2 with the BPS is essential, as it is the first energy-requiring step, allowing for the tri-snRNP complex of U4/U6 &#x000d7; U5 to be recruited to the BPS, which produces a catalytically active spliceosome
<sup><xref rid="ref-56" ref-type="bibr">56</xref></sup>. The BPS typically contains a conserved adenosine and a downstream polypyrimidine tract. It is located within 40 nt of the natural 3&#x000b4;ss, however there are reported cases where it can be up to 400 nt away.</p><p>Recognition of the BPS is thus a crucial step in proper splicing, and sequence variants can disrupt this event, impede lariat formation, and intron excision. The complete list of BPS variants analyzed using the ASSA and ASSEDA server can be found in
<xref ref-type="other" rid="DS0">Supplementary Table 5</xref>. The variants range in distance from 0&#x02013;76 nt from the natural acceptor junction, and either weaken, abolish or strengthen the BPS. When validation assays were performed, the prediction by the server was correct in 9/11 cases. We deemed the two other cases to be partially discordant (NM_004628:c.413-24A&#x0003e;G and NM_005902:IVS8-55A&#x0003e;G). ASSEDA predicted these variants to abolish the BPS, but leaky and normal splicing was observed, respectively. The predictions are partially concordant with experimental findings because ASSEDA also predicted the existence of nearby alternative BPS, which if used, could account for the observed phenotype.</p><p>Although IT-based prediction of a variant effects on BPS has been accurate, the number of validated sites used to compute the ribl is substantially smaller (N = 20), and it is not as reliable as those used to determine
<italic>R
<sub>i</sub></italic> values of natural acceptor and donor sites. Furthermore, these motifs are short and relatively frequent in unspliced mRNA. One possible explanation for the rarity of BPS mutations is that compensatory, alternative BPS sequences can be recognized and used. Furthermore, the weak constraint on the precision of the distance between the BPS and the 3&#x000b4; (acceptor) splice site (
<xref ref-type="fig" rid="f3">Figure 3</xref>) further enables activation of these alternative sites. These factors increase the chance that a variant will be falsely predicted to affect a BPS. For example, variants within donor splice site sequences are routinely predicted to alter strength of false BPS. This error is easily avoidable if the potential recognition sequence is filtered for the genomic context of the variant, as well as its proximity to acceptor splice sites.</p><fig fig-type="figure" id="f3" orientation="portrait" position="float"><label>Figure 3. </label><caption><title>Ribl used for the prediction of a variant&#x02019;s effect on branch-point sites.</title><p>Sequence logo for information model for the branch-point site, created using 20 annotated branch-point sequences.</p></caption><graphic xlink:href="f1000research-3-6038-g0002"/></fig></sec></sec><sec><title>Activation of cryptic splicing</title><p>It has been estimated that 1.6% of disease causing missense mutations can affect splicing and recent predictions suggest that approximately 7% of exonic variants in the general population may disrupt splicing, which includes cryptic splicing
<sup><xref rid="ref-57" ref-type="bibr">57</xref>,
<xref rid="ref-58" ref-type="bibr">58</xref></sup>. The genome is replete with pseudo (or decoy) splice sites with varying degrees of similarity to natural sites that are not recognized in constitutive splicing
<sup><xref rid="ref-59" ref-type="bibr">59</xref></sup>. However, mutations that alter the strengths of either these decoys or the natural splice site of the same polarity may shift the balance of isoforms towards non-constitutive splice isoforms that predominate over or eliminate normal mRNAs (
<xref ref-type="fig" rid="f4">Figure 4</xref>). Mutations can create a cryptic splicing event by creating or strengthening a site in either intronic or exonic regions (
<xref ref-type="fig" rid="f4">Figure 4</xref>, Type 1), weaken the natural site while simultaneously altering an overlapping decoy site (
<xref ref-type="fig" rid="f4">Figure 4</xref>, Type 2), or exclusively weaken the natural site, leading to the activation of a pre-existing decoy site (
<xref ref-type="fig" rid="f4">Figure 4</xref>, Type 3). Although the contributions of cryptic splicing to genetic disease have long been recognized, IT analysis correctly predicts most, but not all, cases (
<xref ref-type="fig" rid="f4">Figure 4</xref>). The challenges in identifying potential cryptic sites or determining activation are attributable to our incomplete understanding of the requirements for activation
<sup><xref rid="ref-60" ref-type="bibr">60</xref>&#x02013;
<xref rid="ref-62" ref-type="bibr">62</xref></sup>, which include exon length, processivity of donor site recognition, and involvement of splicing regulatory factors. A database of aberrant 3&#x000b4; and 5&#x000b4; splice sites has been compiled
<sup><xref rid="ref-62" ref-type="bibr">62</xref></sup>.</p><fig fig-type="figure" id="f4" orientation="portrait" position="float"><label>Figure 4. </label><caption><title>Outcomes of cryptic splicing mutations.</title><p>A prototypical internal exon (in purple) with flanking exons (in blue); introns are represented by black solid, and dashed lines (top). The three types of cryptic splice site activation are then illustrated. Type 1 cryptic splice site activation (left) is caused by the activation (green arrow) of a cryptic site by strengthening a pre-existing site, or by creating a novel splice site (blue). Type 2 (middle) results from the simultaneous weakening or abolition (red arrow) of the natural splice site while strengthening or creating (green arrow) a cryptic site. Type 3 (right) involves the activation of a pre-existing cryptic site due to the weakening or abolition of the natural splice site (indicated by orange triangle). The number of cases that have been reported in the literature that have been analyzed by IT for each type is indicated, with the percent accuracy in parentheses. The bottom row represents the resulting mRNA structure due to the activated cryptic splice site.</p></caption><graphic xlink:href="f1000research-3-6038-g0003"/></fig><fig fig-type="figure" id="f5" orientation="portrait" position="float"><label>Figure 5. </label><caption><title>Distribution of activated cryptic sites.</title><p>The frequency of validated cryptic splice acceptors (
<bold>A</bold>) and donors (
<bold>B</bold>) occurring at positions relative to the natural splice site. Positions are given using ASSEDA coordinates. Lower panel expands the cryptic site distribution of the region circumscribing the natural splice site.</p></caption><graphic xlink:href="f1000research-3-6038-g0004"/></fig><p>Another bioinformatic method for cryptic site recognition relies on a training set composed of cryptic sites that are known to be used
<sup><xref rid="ref-63" ref-type="bibr">63</xref></sup>. There are a number of drawbacks to this approach: the training set is itself not representative of all cryptic sites; and sites that are altered but unused cannot be discriminated from those that are activated (since the latter group also depends on the strength of the corresponding natural splice site). IT-based methods rank cryptic and cognate natural site strength in a way that predicts whether the site will be activated, as well as the abundance of each pair of splice isoforms. Furthermore, the structures of the prospective isoforms are presented by ASSEDA with relative quantitation of each, both prior to and post-mutation.</p><p>During our review, we noted 203 variants with experimental support for cryptic splicing (
<xref ref-type="other" rid="DS0">Supplementary Tables 6&#x02013;8</xref>). Of these, 38 variants resulted in Type 1 cryptic splicing. From those, site activation (existence of the site and strength &#x02265; 2.4 bits
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>) was correctly predicted by ASSEDA in 34 cases (89.5%). We identified 56 variants resulting in Type 2 splicing, 38 of which (67.7%) were accurately predicted, while the remaining 119 variants resulted in Type 3 cryptic splicing and 99 (90.8%) of the alternate splice sites matched predictions.</p><p>Prediction of Type 3 cryptic splicing was more accurate than Types 1 or 2. The criteria for concordance with experimental data were that ASSEDA predicted both the cryptic site and that the variant weakened the natural site. However, the strength of a site is not the sole determinant of whether or not a site is activated. Unlike natural sites, novel cryptic sites are not under selection to maintain binding to the spliceosome, and their genomic context is less constrained than natural splice sites. The presence of cooperative splicing enhancer or repressor elements adjacent to cryptic sites, which could influence cryptic splice site activation, is not yet predictable. Additionally, many of the reported activated cryptic sites have been confirmed using non-quantitative approaches, and these may not constitute the predominant splice forms relative to constitutive exons with stronger natural sites. Finally, certain isoforms may not be detected; as aberrant transcripts are often subject to degradation and the tools used to evaluate functional splicing consequences do not always have sufficient resolution to distinguish small differences in isoform structure. All of these factors can affect the concordance of predicted cryptic site activation with experimental validation.</p><p>We also separated each sub-group of cryptic splice variants by location (intronic vs. exonic) and computed the average difference in strength between pairs of natural (post-mutation) and the activated cryptic sites. For intronic Type 1 variants, activated cryptic sites were 0.86 &#x000b1; 5.28 bits stronger than the corresponding natural site (N = 12). There were eight Type 1 variants (4 at acceptors and 4 at donors) that were missed, because the
<italic>R
<sub>i,final</sub></italic> value of the natural site exceeded the strength of the corresponding cryptic site by &#x02265; 1.0 bits (variants with &#x00394;
<italic>R
<sub>i</sub></italic> &#x0003c; 1.0 bits are not reliably detected experimentally). We hypothesize that these cases could be explained by concomitant changes in surrounding regulatory binding site sequences. Exonic Type 1 variants were often slightly weaker than their cognate natural sites (-1.1 &#x000b1; 3.8 bits; N = 26). Nearly all of these involved ectopic donor site activation (12 of 13), consistent with a processive mechanism for donor site recognition, which searches downstream from the acceptor splice site to the first donor site of sufficient strength to form an exon
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. The opposite pattern was observed with intronic Type 2 cases, in which 20 of 21 exceptions occurred at acceptor sites. On average, the activated cryptic site exceeded the strength of the cognate natural site (1.3 &#x000b1; 4.6 bits; N = 57). Activated, exonic Type 2 acceptor cryptic sites tended to be weaker than their natural site counterparts (-2.2 &#x000b1; 3.3 bits; N = 4). This result may be attributable a low sample size, with 2 of these mutations exhibiting natural sites that were stronger (&#x02265; 1.0 bits) than the corresponding cryptic site (1 donor and 1 acceptor). Finally, Type 3 activated intronic cryptic sites exhibited the greatest difference between the strengths of cryptic sites and cognate natural splice sites (6.3 &#x000b1; 4.9 bits; N = 104). This category contained the fewest number of exceptional cryptic sites, with
<italic>R
<sub>i</sub></italic> values less than those of natural sites (5 acceptors and 3 donors). This is consistent with the idea that the intronic cryptic sites are generally not under selection for adjacent functional regulatory binding sites, and, in order to be activated, are required to be substantially stronger than the natural site. Although
<italic>R
<sub>i,final</sub></italic> values were stronger (2.1 &#x000b1; 1.9 bits; N = 20) than the natural site, exonic Type 3 cryptic splice sites did not show as great a difference in strength with a single exceptional case (of an acceptor). Despite these exceptions, activated cryptic splice sites are generally stronger than the corresponding natural splice sites
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>.</p></sec><sec><title>Combinatorial effects</title><p>While functional natural splice sites and an intact BPS are integral for accurate and efficient splicing, other genetic elements have been shown to make essential contributions to exon definition
<sup><xref rid="ref-64" ref-type="bibr">64</xref></sup>. Introns will often contain more than one potential splice site recognition sequence, but nevertheless, the correct natural site is consistently selected
<sup><xref rid="ref-59" ref-type="bibr">59</xref></sup>. Differences among the strengths of potential sites, as determined by IT analysis, are a major, but not the sole, determinant of splice site utilization. The implication is that additional sequences within the gene are necessary to ensure specificity and precision of exon recognition. Studies of facultatively expressed alternative exon structures have revealed
<italic>cis</italic>-acting sequence elements that function to enhance or repress exon recognition. These sequences cooperate with factors that recognize natural splice sites, whose sequences and relative strengths can vary considerably. Depending on their context, these elements have been referred to as exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs) or intronic splicing silencers (ISSs). In general, these elements serve as binding sites for
<italic>trans</italic>-acting elements, which will either promote or impede the spliceosomal recognition of a splice site. The majority of enhancer elements will act through the recruitment of SR proteins and associate components of the U1 and U2 spliceosomes
<sup><xref rid="ref-65" ref-type="bibr">65</xref>,
<xref rid="ref-66" ref-type="bibr">66</xref></sup>. Silencers are often of the hnRNP class, which act through a diversity of mechanisms including steric hindrance, the formation of dysfunctional complexes, or blocking processiveness
<sup><xref rid="ref-67" ref-type="bibr">67</xref>&#x02013;
<xref rid="ref-69" ref-type="bibr">69</xref></sup>. To add to the complexity of splicing regulation, it has recently been shown that SR protein function is dependent on context, i.e. whether the corresponding binding site is intronic or exonic
<sup><xref rid="ref-70" ref-type="bibr">70</xref>,
<xref rid="ref-71" ref-type="bibr">71</xref></sup>.</p><p>To improve accuracy of exon definition, the strengths of regulatory elements (i.e. their
<italic>R
<sub>i</sub></italic> values) have been incorporated into splicing mutation prediction. The significance of regulatory elements in disease has been demonstrated in many cases. For example, in the
<italic>NF1</italic> gene, ESE disruption is the primary cause of exon skipping
<sup><xref rid="ref-72" ref-type="bibr">72</xref></sup>. Many other genes, including
<italic>APC</italic>,
<italic>SMN</italic>,
<italic>BEST1, PDHA1</italic>
<sup><xref rid="ref-73" ref-type="bibr">73</xref>&#x02013;
<xref rid="ref-76" ref-type="bibr">76</xref></sup> have been proven to harbour variants that disrupt ESEs and have a confirmed impact on mRNA splicing.</p><p>Adding to the complexity, the recognition sequences for these RNA binding factors, while well defined, tend to be short, and can vary to the degree that the same sequence may contain overlapping elements of binding sites for multiple factors. However, this does not necessarily imply that such a sequence is bound with similar affinity by each factor or that it contributes to exon definition. At the same time, these sequences tend to be evolutionarily conserved and may be required for proper splicing
<sup><xref rid="ref-77" ref-type="bibr">77</xref>,
<xref rid="ref-78" ref-type="bibr">78</xref></sup>.</p><p>ASSEDA optionally incorporates PWMs for regulatory binding sites for mutation analysis (
<xref ref-type="table" rid="T1">Table 1</xref>) in addition to the default donor and acceptor sites. The program selects the most proximate predicted ESE/ISS to the natural splice site when calculating
<italic>R
<sub>i,total</sub></italic>. The molecular phenotype, which dictates the splice isoforms that are predicted and their relative abundance, accounts for both the potential effect on the natural site and the most relevant splicing regulatory site. For these regulatory binding sites, a second gap surprisal term specific to the ESE/ISS of interest is applied to the
<italic>R
<sub>i,total</sub></italic> calculation
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. The gap surprisal functions for SF2/ASF and SC35 have been previously described
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>, where the most common distance of the ESE/ISS is within 10nt of the natural site. The gap surprisal penalty gradually increases with distance from the natural site. Gap surprisal distributions for ELAVL1, TIA1 and SRp55 show a similar pattern, while hnRNPA1 and PTB binding sites are strongly clustered around splice junctions. It should be feasible to include the contributions of multiple splicing regulatory binding sites of the same or different RNA binding proteins in determining
<italic>R
<sub>i,total</sub></italic>; however this capability had not yet been implemented. Currently, if multiple sites of the same type are altered, the strongest (before or after mutation) is chosen by ASSEDA software.</p><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1. </label><caption><title>Splicing regulatory protein binding sites ASSEDA scans for and their associated effect on
<break/>splicing.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" rowspan="2" valign="middle" colspan="1">Splicing Factor</th><th rowspan="2" valign="middle" colspan="1">
<italic>R
<sub>sequence</sub></italic> (bits)</th><th rowspan="2" valign="middle" colspan="1">Sequence Logo</th><th align="center" colspan="2" rowspan="1">Location-dependent effect on splicing</th></tr><tr><th align="center" rowspan="1" colspan="1">Intronic</th><th align="center" rowspan="1" colspan="1">Exonic</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">hnRNPH1</td><td align="center" rowspan="1" colspan="1">8.9 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0005"/>
</td><td align="center" rowspan="1" colspan="1">E
<sup><xref rid="ref-79" ref-type="bibr">79</xref>,
<xref rid="ref-80" ref-type="bibr">80</xref></sup> / S
<sup><xref rid="ref-81" ref-type="bibr">81</xref>,
<xref rid="ref-82" ref-type="bibr">82</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>S</underline></bold> / E
<sup><xref rid="ref-83" ref-type="bibr">83</xref></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">hnRNPA1
<sup><xref ref-type="other" rid="note-1">i</xref></sup>
</td><td align="center" rowspan="1" colspan="1">4.6 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0006"/>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>S</underline></bold> / E
<sup><xref rid="ref-84" ref-type="bibr">84</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>S</underline></bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TIA1</td><td align="center" rowspan="1" colspan="1">7.6 &#x000b1; 3.1</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0007"/>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>E</underline></bold>
</td><td align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1">SRSF6 (SRp55)</td><td align="center" rowspan="1" colspan="1">5.2 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0008"/>
</td><td align="center" rowspan="1" colspan="1">E / S
<sup><xref rid="ref-82" ref-type="bibr">82</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>E</underline></bold> / S</td></tr><tr><td align="left" rowspan="1" colspan="1">SRSF5 (SRp40)</td><td align="center" rowspan="1" colspan="1">4.5 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0009"/>
</td><td align="center" rowspan="1" colspan="1">E / S
<sup><xref rid="ref-82" ref-type="bibr">82</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>E</underline></bold> / S
<sup><xref rid="ref-85" ref-type="bibr">85</xref></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SRSF2 (SC35)</td><td align="center" rowspan="1" colspan="1">4.5 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0010"/>
</td><td align="center" rowspan="1" colspan="1">E / S
<sup><xref rid="ref-86" ref-type="bibr">86</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>E</underline></bold> / S
<sup><xref rid="ref-87" ref-type="bibr">87</xref></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SRSF1 (SF2/ASF)
<sup><xref rid="ref-88" ref-type="bibr">88</xref></sup>
</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0011"/>
</td><td align="center" rowspan="1" colspan="1">E / S
<sup><xref rid="ref-86" ref-type="bibr">86</xref>,
<xref rid="ref-89" ref-type="bibr">89</xref>,
<xref rid="ref-90" ref-type="bibr">90</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>E</underline></bold> / S</td></tr><tr><td align="left" rowspan="1" colspan="1">PTB
<sup><xref ref-type="other" rid="note-1">ii</xref></sup>
</td><td align="center" rowspan="1" colspan="1">4.9 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0012"/>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>S</underline></bold> / E
<sup><xref rid="ref-91" ref-type="bibr">91</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>S</underline></bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ELAV1</td><td align="center" rowspan="1" colspan="1">9.6 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">
<graphic xlink:href="f1000research-3-6038-g0013"/>
</td><td align="center" rowspan="1" colspan="1">S / E / N
<sup><xref rid="ref-92" ref-type="bibr">92</xref>,
<xref rid="ref-93" ref-type="bibr">93</xref></sup>
</td><td align="center" rowspan="1" colspan="1">
<bold><underline>S</underline></bold>
</td></tr></tbody></table><table-wrap-foot><fn><p>Reported dominant effect is bolded. E &#x02013; Enhancer; S &#x02013; Silencer; N - Neutral.</p></fn><fn id="note-1"><p>
<sup>i</sup>Enhancer activity by hnRNP A1 occurs at the junction
<sup><xref rid="ref-84" ref-type="bibr">84</xref></sup>.
<sup>ii</sup>PTB does not directly enhance splicing, but can do so indirectly by preventing the binding of splicing repressors
<sup><xref rid="ref-91" ref-type="bibr">91</xref></sup>.</p></fn></table-wrap-foot></table-wrap><p>Although the disruption of splicing regulatory sequences can cause aberrant splicing, the interpretation of variants affecting these sites is not as straightforward. Due to their degenerate nature, short sequence, and a lack of understanding of the context of their use, altered regulatory sites should be functionally validated before being deemed pathogenic
<sup><xref rid="ref-7" ref-type="bibr">7</xref></sup>. Using variants from a number of different studies, ASSEDA accurately predicted experimentally determined changes in binding at a splicing regulatory site 75% of the time (N = 12)
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. However, there were instances where regulatory sequences had been analyzed by IT, and considered to contribute to disease, but the results were not reproducible. For example, K&#x000f6;lsch
<italic>et al.</italic> (2009) described SNPs associated with Alzheimer&#x02019;s Disease, one of which strengthened and created SRp40 and SRp55 sites, respectively, but were reported by authors to be abolished
<sup><xref rid="ref-94" ref-type="bibr">94</xref></sup>. This study did not report any evidence to support the significance of these predictions.</p><p>Functional validation of the effects of these mutations could contribute to understanding the roles of these factors in regulating constitutive splicing. Similarly, there is still little understanding on how multiple regulatory binding sites within the same region function as a unit. Using a pull-down assay, Olsen
<italic>et al.</italic> (2014) demonstrated how different variants affect the binding of multiple regulatory proteins. One mutation was predicted to create and strengthen multiple hnRNPA1 sites and slightly strengthen an SF2/ASF (SRSF1) site. The pull-down studies showed up-regulation of hnRNPA1 binding and a decrease in SF2/ASF binding. However, SF2/ASF binding increased when a mutation disrupting hnRNPA1 affinity was introduced, suggesting that the strong hnRNPA1 sites outcompete the weaker SF2/ASF site.</p><p>In some instances, alterations in regulatory splice site recognition sequence and natural splice strength occurred concomitantly, with both predicted to have similar effects on splicing. Alteration of a regulatory sequence can sometimes provide a plausible explanation for discordant
<italic>in silico</italic> prediction and experimental validation. As an example, Smaoui
<italic>et al.</italic> (2004) analyzed a donor site mutation (NM_001040667:c.1327+4A&#x0003e;G) in
<italic>HSF4</italic> in a family with congenital cataracts
<sup><xref rid="ref-50" ref-type="bibr">50</xref></sup>. This variant was predicted to cause leaky splicing (
<italic>R
<sub>i,final</sub></italic> = 5.4 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = -2.6 bits; 67.5% residual binding), however RT-PCR showed complete exon skipping. Our further analysis showed that it is predicted to also create an overlapping hnRNPA1 site (
<italic>R
<sub>i,final</sub></italic> = 4.2 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = 17.1 bits). Another case involved a mutation in the
<italic>XPC</italic> gene (NM_004628:c.2033+2T&#x0003e;G) that created a novel intronic cryptic site 4 nt downstream of a natural donor site
<sup><xref rid="ref-95" ref-type="bibr">95</xref></sup>. However, a weaker site 68 nt downstream from the natural site was activated. A possible explanation could be that activation of the cryptic site is influenced by a neighbouring hnRNPA1 site that is itself strengthened (
<italic>R
<sub>i,final</sub></italic> = 5.2 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = 2.2 bits) and an SRp55 site that is significantly weakened (
<italic>R
<sub>i,final</sub></italic> = 1.9 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = -4.0 bits).</p><p>The effects of changes in regulatory binding site strengths may ascribe potential functions to previous VUS. For example, Maruszak
<italic>et al.</italic> (2009) present a
<italic>PIN1</italic> variant associated with late-onset Alzheimer&#x02019;s Disease (NM_006221:c.58+64C&#x0003e;T)
<sup><xref rid="ref-96" ref-type="bibr">96</xref></sup>. Based on IT, it is expected to abolish an intronic SC35 site, which could have either an enhancing or silencing effect (
<xref ref-type="table" rid="T1">Table 1</xref>). A 2.82-fold decrease in transcript levels was demonstrated, which is concordant with previous findings reporting decreased
<italic>PIN1</italic> levels in the brains of Alzheimer&#x02019;s Disease patients. Another study described an exonic missense variant within the
<italic>ETFDH</italic> gene in a patient with multiple acyl-CoA dehydrogenase deficiency (NM_004453:c.158A&#x0003e;G) that showed evidence of exon skipping. The variant was predicted to be &#x0201c;benign&#x0201d; or &#x0201c;tolerated&#x0201d; when evaluated with PolyPhen and SIFT
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>. ASSEDA, on the other hand, predicted the creation of an hnRNPA1 site (
<italic>R
<sub>i,final</sub></italic> = 5.9 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = 17.1 bits), a slightly strengthened hnRNPH site (
<italic>R
<sub>i,final</sub></italic> = 4.0 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = 0.2 bits), the abolition of an SRp40 site (
<italic>R
<sub>i,final</sub></italic> = -3.3 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = -6.3 bits) and two novel, weak SF2/ASF sites (
<italic>R
<sub>i</sub></italic>
<sub>,final</sub> = -4.6 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = 0.8 bits and
<italic>R
<sub>i,final</sub></italic> = -2.4 bits; &#x00394;
<italic>R
<sub>i</sub></italic> = 0.4 bits)
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>. The natural donor site was unaltered by the mutation. As indicated earlier, the mutation was confirmed experimentally to increase hnRNPH and hnRNPA1 and decrease SRp40 and SF2/ASF binding.</p></sec><sec><title>Validation of results</title><p>A number of early mutation studies did not perform expression analysis and relied solely on the ASSEDA or ASSA server to interpret potential mutations. This is not recommended, as there are limitations to any
<italic>in silico</italic> predictive method, which impacts accuracy and precision of the prediction. Assuming that the impact of the mutation on expression can be detected, experimental validation of IT-based mutation analysis can reveal its limitations. We describe the various validation methods that were employed in the articles where expression data were available. Below, advantages and disadvantages of these approaches are explored, as well as how lower sensitivity validation can result in misinterpretation. Finally, we determine the accuracy of IT-based prediction, and point out some instructive, discordant cases.</p><sec><title>Validation methods</title><p>The two most widely used methods for validating mutant mRNA splicing isoforms have been RT-PCR analysis of patient mRNA, and transfection of minigene constructs expressing the mutated exon into cell lines, followed by RT-PCR. These assays were, in some cases, accompanied by other techniques such as direct sequencing of cDNA, Western blotting, luciferase expression assays or immunostaining. A number of studies used quantitative RT-PCR or real-time PCR to estimate isoform abundance. RNA or cDNA sequencing and exon expression microarrays were also used in several studies to support
<italic>in silico</italic> predictions. Certain functional assays that we reviewed were unique to a single study, including: allelic instability, exon trapping, immunoprecipitation of splicing factors, and flow cytometry
<sup><xref rid="ref-23" ref-type="bibr">23</xref>,
<xref rid="ref-97" ref-type="bibr">97</xref>&#x02013;
<xref rid="ref-99" ref-type="bibr">99</xref></sup>. Other indirect methods of justifying the association between a splice site variant and disease included fundoscopy, loss of heterozygosity, blood protein levels, and segregation with disease
<sup><xref rid="ref-100" ref-type="bibr">100</xref>&#x02013;
<xref rid="ref-103" ref-type="bibr">103</xref></sup>. Because a variant may result in aberrant splicing but might not be accompanied by a detectable phenotypic change, we excluded the results of indirect assays of phenotype. Indirect measures of phenotype can support disease association, but do not inform about accuracy of splicing prediction.</p><p>Endpoint RT-PCR and minigene assays probe the specific variant in question, but do not reveal relative abundance of each isoform, whereas qPCR does. Neither method resolves mRNA sequence at the nucleotide level, which can fail to confirm predicted splicing mutations, especially in instances where a small number of nucleotides are retained at the constitutive splice junction
<sup><xref rid="ref-104" ref-type="bibr">104</xref></sup>. The resultant frameshifted mRNAs can cause premature truncation of the transcript (PTC), instability, and NMD, leaving no evidence of the mutated isoform (unless the cells had been treated with an NMD inhibitor). A disadvantage is that in cases where the protein is not degraded, but still impaired or dysfunctional, the result will be incorrectly categorized as benign. For example, Wessagowit
<italic>et al.</italic> (2005) used sequencing of a
<italic>COL7A1</italic> variant (NM_000094:c.341G&#x0003e;T) to demonstrate a 87 nt deletion in the cDNA
<sup><xref rid="ref-105" ref-type="bibr">105</xref></sup>. The authors also performed immunostaining of the corresponding protein with a monoclonal antibody, which showed no difference between wild-type and mutant samples because the epitope was not disrupted by the deletion. Had the authors only performed the binding assay, the variant would have likely been disregarded. NMD can be a predominant cause of false-negative results when validating splice variants. When aberrant splicing causes a frameshift and PTC, translation of truncated proteins is prevented, which otherwise can have dominant negative effects or exhibit gain-of-function
<sup><xref rid="ref-106" ref-type="bibr">106</xref></sup>. However, if these transcripts are degraded and only the normal allele is detectable (in the case of a heterozygote or leaky splicing), then the splicing prediction will not be supported. Interestingly, Khan
<italic>et al.</italic> (2004) were able to show that NMD had occurred by comparing levels of total message (qPCR) between wild-type and mutant samples
<sup><xref rid="ref-47" ref-type="bibr">47</xref></sup>. Experimental methods have been developed to stabilize transcripts with premature termination of translation, thus circumventing NMD. The use of emetine, which inhibits translation and stabilizes RNA transcripts, can increase the relative amount of aberrant transcript observed
<sup><xref rid="ref-107" ref-type="bibr">107</xref>,
<xref rid="ref-108" ref-type="bibr">108</xref></sup>. However this approach can induce a stress response within the cell and further transcription must be halted using actinomycin D. This combination was used by Bloethner
<italic>et al.</italic> (2008) in an approach called Gene Identification by NMD Inhibition
<sup><xref rid="ref-109" ref-type="bibr">109</xref></sup>. Similarly, the use of puromycin and cycloheximide were shown to inhibit NMD and restore predicted aberrant splice forms
<sup><xref rid="ref-97" ref-type="bibr">97</xref>,
<xref rid="ref-110" ref-type="bibr">110</xref></sup>. Furthermore, certain mutations proximate to the penultimate exon evade NMD
<sup><xref rid="ref-111" ref-type="bibr">111</xref>,
<xref rid="ref-112" ref-type="bibr">112</xref></sup>.</p></sec><sec><title>Regulatory sequence variants</title><p>A number of assays have been developed to confirm direct effects of variants on splice site recognition, however fewer methods are available to measure effects of mutations at binding sites of splicing regulatory proteins
<sup><xref rid="ref-113" ref-type="bibr">113</xref></sup>. The most reliable approach is to associate a change in splicing with a change in regulatory protein binding. A combination of electrophoretic mobility shift assay and RT-PCR were used to confirm that a predicted change in an SF2/ASF binding site caused exon skipping in the
<italic>CFTR</italic> gene
<sup><xref rid="ref-114" ref-type="bibr">114</xref></sup>. Others performed RNA affinity purification in combination with Western blotting
<sup><xref rid="ref-23" ref-type="bibr">23</xref></sup>.</p><p>Another approach tests multiple variants at the same position through minigene assays. Anczuk&#x000f3;w
<italic>et al.</italic> (2008) observed that two variants at the same position in
<italic>BRCA1</italic> (c.3600G&#x0003e;T and c.3600G&#x0003e;C) predicted different effects on regulatory sequences, as well as different observed effects on splicing
<sup><xref rid="ref-115" ref-type="bibr">115</xref></sup>. The G&#x0003e;T variant predicted abolition of a SRp40 site and weakening of an SF2/ASF site by both ASSA and ESEfinder, and showed a significant reduction in the relative amount of normal transcript. The G&#x0003e;C variant, which did not elicit a change in splicing, was not predicted by ASSA to have a significant effect on either site (although ESEfinder predicted weakening of the SRp40 site below its default threshold). The difference in splicing efficiency could be due to the loss of binding by one or both of these regulatory proteins. This assay associates predicted changes to regulatory protein binding site strength to changes in splicing. A direct binding assay would lend key support for such predictions.</p></sec></sec><sec><title>Accuracy of IT-based prediction</title><p>We previously evaluated the accuracy of IT-based prediction using a set of validated splicing mutations (85.2%; N = 61)
<sup><xref rid="ref-25" ref-type="bibr">25</xref></sup>. Other studies have also evaluated the accuracy of ASSA/ASSEDA while evaluating differences between multiple predictive programs and have shown varying levels of concordance (68.8%, N = 16; 90.1%, N = 22; 100%, N = 24)
<sup><xref rid="ref-51" ref-type="bibr">51</xref>,
<xref rid="ref-104" ref-type="bibr">104</xref>,
<xref rid="ref-116" ref-type="bibr">116</xref></sup>. With a comprehensive list of all published variants analyzed using IT-based methods (
<xref ref-type="other" rid="SM">Supplementary Bibliography</xref>), we perform a meta-analysis of all of these variants to minimize bias in interpretation and impact of ascertainment of specific phenotypes from individual studies. The list of variants is more extensive than any previous study examining accuracy of IT-based methods. The variants are not restricted to a single or even group of diseases, but rather cover over 150 different conditions (see
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>).</p><p>In total, 905 variants were reported in 122 different publications to have been validated for their effects on splicing (1,727 total variants analyzed from 216 papers &#x02013;
<xref ref-type="other" rid="DS0">Supplementary Table 9</xref>). In all cases, the authors performed information analysis; however, the validation experiments were sometimes contained in the original reports and in other cases, later studies. In a minority of mutations, the validation results were either uninformative (N = 36) or the methods did not directly imply an effect on splicing (N = 2); these mutations were therefore excluded in determining the accuracy of predictions (shaded in grey in
<xref ref-type="other" rid="DS0">Supplementary Table 9</xref>).</p><p>More specifically, in order for experimental results and predictions to be considered concordant, one or more of the following criteria had to be met:
<list list-type="simple"><list-item><label>a. </label><p>A variant predicted to abolish a splice site did abolish splicing, with no residual splicing observed. Exceptions to this were assays in which both the mutant and wild-type alleles were expressed in the same cell line or patient sample, and could not be discriminated from one another (i.e. RT-PCR);</p></list-item><list-item><label>b. </label><p>A variant predicted to be leaky exhibited residual normal splicing, with the exception of cases where a much stronger cryptic splice site was activated;</p></list-item><list-item><label>c. </label><p>A variant that strengthened the natural site and showed normal or increased levels of the wild-type isoform, consistent with it having a benign phenotype and/or polymorphic;</p></list-item><list-item><label>d. </label><p>A variant predicted to activate a pre-existing splice site, while also reducing the natural splice site strength, was demonstrated experimentally to result in cryptic splicing, regardless of whether it was predicted it to be the predominant isoform;</p></list-item><list-item><label>e. </label><p>A variant predicted to affect a splicing regulatory protein-binding site was consistent with validation experiments explicitly assessing binding affinity and associated splicing alterations.</p></list-item></list>
</p><p>Cumulatively, 87.9% of variants documented by expression studies (762 of 867) that satisfied these criteria were accurately predicted by ASSEDA. A minority of papers reported variants to be &#x0201c;partially concordant&#x0201d; (3.1%; 27/867), meaning that while the cryptic site observed was predicted, it was not the most likely splice isoform relative to other expressed cryptic exons. Because this method of scoring met our criteria (see point d above), we included these in our determination.</p><sec><title>Predicted mutations discordant with validation results</title><p>Limitations of both the predictive model and the validation data/methods were the primary reasons for discordance. Where information analysis predicted a neutral change or no effect, but validation showed aberrant splicing, we hypothesize that there are either unrecognized splicing regulatory protein binding sites that are weakened or abolished, or that there are underlying mechanisms that are not currently addressed by current information models
<sup><xref rid="ref-23" ref-type="bibr">23</xref>,
<xref rid="ref-35" ref-type="bibr">35</xref>,
<xref rid="ref-50" ref-type="bibr">50</xref>&#x02013;
<xref rid="ref-52" ref-type="bibr">52</xref>,
<xref rid="ref-54" ref-type="bibr">54</xref>,
<xref rid="ref-96" ref-type="bibr">96</xref>,
<xref rid="ref-98" ref-type="bibr">98</xref>,
<xref rid="ref-99" ref-type="bibr">99</xref>,
<xref rid="ref-114" ref-type="bibr">114</xref>,
<xref rid="ref-117" ref-type="bibr">117</xref>&#x02013;
<xref rid="ref-127" ref-type="bibr">127</xref></sup>. The validation methods used can also contribute to discordant results. We note that 41 discordant results originated from one of our own studies
<sup><xref rid="ref-41" ref-type="bibr">41</xref></sup>. This study used RNAseq data to validate predictions, a genome-wide approach that should be used with caution when inferring changes resulting from potential splicing mutations. Until this study was published, IT-based mutation analysis was based on single or candidate disease gene studies. RNAseq reveals all changes in transcript levels for all genes, which although potentially relevant to splicing, may not necessarily contribute to the phenotype in question. This leads to the possibility, especially in cancer phenotypes, of bystander effects (global splicing dysregulation, natural alternative splicing) that are not directly attributable to the predicted mutations. Furthermore, because the sequence reads at splice junctions are short and often limited in number, a relevant splicing aberration may result from a given variant, but it was not detectable. Finally, the predictions of IT can pick up variants that should alter splicing for example, of rare recessive alleles, that that may not have any disease relevance.</p></sec></sec><sec><title>Misinterpretation of variant effects</title><p>While preparing this review, several variants misinterpreted with IT-based tools were noted. These variants have been re-analyzed to disseminate the correct findings and to avoid making similar errors in the analysis of newly discovered variants.
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref> contains these results. The most common problems result from unfounded emphases on altered or pre-existing cryptic sites that are determined to be significantly weaker relative to the cognate natural site
<sup><xref rid="ref-109" ref-type="bibr">109</xref>,
<xref rid="ref-128" ref-type="bibr">128</xref>&#x02013;
<xref rid="ref-132" ref-type="bibr">132</xref></sup>, and from selectively reporting a single change in the
<italic>R
<sub>i</sub></italic> value when, in fact, multiple significant changes can be detected
<sup><xref rid="ref-48" ref-type="bibr">48</xref>,
<xref rid="ref-128" ref-type="bibr">128</xref>,
<xref rid="ref-133" ref-type="bibr">133</xref>&#x02013;
<xref rid="ref-136" ref-type="bibr">136</xref></sup>. An example of the first type of error is exemplified by a variant in
<italic>CGI-58 (ABDH5</italic>), where the natural splice site is 9.1 bits (or &#x02265; 549-fold) stronger than the reported cryptic site
<sup><xref rid="ref-129" ref-type="bibr">129</xref></sup>. Henneman
<italic>et al.</italic> (2008) selectively reported the effect of a mutation that weakens a natural donor splice site in
<italic>APOA5</italic>, however only a change in the information content of an SC35 binding site was indicated.</p><p>Other common problems include incorrect declaration of small &#x00394;
<italic>R
<sub>i</sub></italic> values as significant changes
<sup><xref rid="ref-109" ref-type="bibr">109</xref>,
<xref rid="ref-137" ref-type="bibr">137</xref>,
<xref rid="ref-138" ref-type="bibr">138</xref></sup>, use of incorrect
<italic>R
<sub>i,min</sub></italic> values
<sup><xref rid="ref-139" ref-type="bibr">139</xref>,
<xref rid="ref-140" ref-type="bibr">140</xref></sup>, and the computation of predicted binding strength changes on a linear scale
<sup><xref rid="ref-141" ref-type="bibr">141</xref></sup> rather than the correct exponential function (i.e. &#x02264; 2
<sup>&#x00394;
<italic>Ri</italic></sup>)
<sup><xref rid="ref-18" ref-type="bibr">18</xref></sup>. Smaoui
<italic>et al</italic>. (2004) described an 8.0 bit donor site as weak, which is actually equivalent in strength to
<italic>R
<sub>sequence</sub></italic>, the average strength
<sup><xref rid="ref-33" ref-type="bibr">33</xref></sup>. Allikmets
<italic>et al.</italic> (1998) and Ozaltin
<italic>et al.</italic> (2011) both described an inactivating mutation as leaky, because the weakened site remained above the
<italic>R
<sub>i,min</sub></italic>. However, the variant mutation produces a site with &#x0003c; 0.7% of its original binding affinity, which would substantially reduce exon recognition and lead to exon skipping
<sup><xref rid="ref-116" ref-type="bibr">116</xref></sup>. Also, cryptic sites created in the promoter regions of genes should not be considered to be splicing mutations
<sup><xref rid="ref-142" ref-type="bibr">142</xref></sup>. Variants that are predicted to create a cryptic site upstream or overlapping a natural site of the opposite polarity (i.e. cryptic donor upstream of a natural acceptor) have been reported
<sup><xref rid="ref-131" ref-type="bibr">131</xref>,
<xref rid="ref-132" ref-type="bibr">132</xref>,
<xref rid="ref-143" ref-type="bibr">143</xref></sup>, which would be inconsistent with established splicing mechanisms
<sup><xref rid="ref-35" ref-type="bibr">35</xref></sup>. A rare exception that could render such a site active is to the creation of a cryptic exon that occurs in conjunction with a proximate, correctly oriented, pre-existing cryptic splice site of opposite polarity
<sup><xref rid="ref-22" ref-type="bibr">22</xref>,
<xref rid="ref-30" ref-type="bibr">30</xref></sup>. Insufficient numbers of examples of mutations creating cryptic exons have been reported to date for ASSEDA to accurately predict these exons by default.</p><p>Several results were generated by incorrect entry of mutations in to ASSA/ASSEDA. For example, altered cryptic splice sites have been confused with natural sites
<sup><xref rid="ref-48" ref-type="bibr">48</xref>,
<xref rid="ref-137" ref-type="bibr">137</xref>,
<xref rid="ref-144" ref-type="bibr">144</xref>,
<xref rid="ref-145" ref-type="bibr">145</xref></sup>. Additionally, &#x02018;residual binding strength&#x02019; displayed has been misinterpreted as a percent decrease
<sup><xref rid="ref-144" ref-type="bibr">144</xref>,
<xref rid="ref-146" ref-type="bibr">146</xref></sup>. Strong, pre-existing cryptic sites outside of the default sequence analysis window (54 nt circumscribing the mutation) have also been missed because the window was not expanded to include these sites
<sup><xref rid="ref-147" ref-type="bibr">147</xref></sup>. Although the predicted isoform structure generated by ASSEDA will, by default, display skipping for mutated natural sites with &#x00394;
<italic>R
<sub>i</sub></italic> &#x02265; -7.0 bits (or &#x02265; 128-fold)
<sup><xref rid="ref-116" ref-type="bibr">116</xref></sup>, smaller decreases in natural site strength of an internal exon can sometimes partially induce exon skipping. This value is adjustable, and it may be advisable to explore different thresholds depending on the particular susceptibility of a splice junction to exon skipping. Sharma
<italic>et al.</italic> (2014) used the default threshold from ASSEDA to interpret
<italic>CFTR</italic> mutations c.2988G&#x0003e;A (9.6 to 6.6 bits, natural donor site of exon 18) and c.2657+5G&#x0003e;A (9.1 to 5.6 bits, natural donor site of exon 16), but exon skipping was documented. IT analysis was not discordant for these variants, which significantly weaken the corresponding splice sites by &#x02265;8- and 11-fold, respectively, and has been shown in other genes to lead to exon skipping, leaky splicing, or both of these outcomes. Aissat
<italic>et al.</italic> (2013) tabulated variants that were predicted to affect strengths of ESE binding sites, but did not comprehensively report all findings even though predictions by ASSA and ESEfinder were concordant (eg.
<italic>CFTR</italic>: c.1694A&#x0003e;G). Alternate mutation entry methods, which do not use contextual gene name annotations, such as entry by rsID, report predicted binding changes on both strands. A report indicating abolition of SRp40 binding sites on the antisense strand was confused with binding sites for
<italic>CYP46A1,</italic> which is transcribed from the sense strand
<sup><xref rid="ref-148" ref-type="bibr">148</xref></sup>.</p><p>Other problems include inadvertent mislabelling of splice site type or location
<sup><xref rid="ref-149" ref-type="bibr">149</xref>&#x02013;
<xref rid="ref-151" ref-type="bibr">151</xref></sup>, interchange of the terms information content and change in information (
<italic>R
<sub>i</sub></italic> and &#x00394;
<italic>R
<sub>i</sub></italic>)
<sup><xref rid="ref-122" ref-type="bibr">122</xref></sup>, and unclear variant interpretation (i.e. &#x0201c;run on into the intron&#x0201d;)
<sup><xref rid="ref-152" ref-type="bibr">152</xref></sup>. Moriwaki
<italic>et al.</italic> (2009) claim ASSA did not predict a mutated natural donor site, but in fact, the site was present in our reanalysis
<sup><xref rid="ref-153" ref-type="bibr">153</xref></sup>. Published
<italic>R
<sub>i</sub></italic> values from Rogan
<italic>et al.</italic> (1998) and von Kodolitsch
<italic>et al.</italic> (1999) are in some instances different from current values due to updates of the reference genome sequence. Nevertheless, the overall predicted effect did not change, but initial and final
<italic>R
<sub>i</sub></italic> values were inconsistent. Interpretations of certain mutations could not be reproduced in some instances
<sup><xref rid="ref-103" ref-type="bibr">103</xref>,
<xref rid="ref-145" ref-type="bibr">145</xref>,
<xref rid="ref-154" ref-type="bibr">154</xref>&#x02013;
<xref rid="ref-156" ref-type="bibr">156</xref></sup>. Finally, we noted that ASSEDA can sometimes improperly parse indels entered using c. or IVS notation. Such errors have led to published false results
<sup><xref rid="ref-67" ref-type="bibr">67</xref>,
<xref rid="ref-116" ref-type="bibr">116</xref>,
<xref rid="ref-157" ref-type="bibr">157</xref>,
<xref rid="ref-158" ref-type="bibr">158</xref></sup>.</p></sec><sec><title>Interpretation of published variants in studies that use information analysis</title><sec><title>Genotype-phenotype association</title><p>The severity of phenotype due to splicing mutations can be related to their effects on mRNA splicing, after careful consideration of the overall impact on mRNA levels and protein coding
<sup><xref rid="ref-159" ref-type="bibr">159</xref></sup>. Significant information changes (where &#x00394;
<italic>R
<sub>i</sub></italic> &#x02265; 7.0 bits or where
<italic>R
<sub>i</sub></italic> &#x02264; 2.4 bits) of splicing variants in hemophilia patients (
<italic>F8C</italic> and
<italic>F9</italic>) were shown to correspond to the severe clinical phenotypes of the disease (reduced protein activity, increased clotting time, bleeding frequency)
<sup><xref rid="ref-127" ref-type="bibr">127</xref></sup>. The overall effect on the coding potential of the mutated transcript should be considered, as skipping events that maintain the reading frame commonly lead to milder phenotypes
<sup><xref rid="ref-160" ref-type="bibr">160</xref>&#x02013;
<xref rid="ref-162" ref-type="bibr">162</xref></sup>. Nevertheless, two variants that abolish splice site recognition in
<italic>PTPRO</italic> in Idiopathic Nephritic Syndrome reported by Ozaltin
<italic>et al.</italic> (2011) had similar phenotypes even though one retained the reading frame and the other caused a frameshift. The exon deleted by the in-frame skipping event is highly conserved
<sup><xref rid="ref-53" ref-type="bibr">53</xref></sup>. Exon skipping events that cause frameshifts close to the carboxy-terminus may lead to mild phenotypes, as they avoid NMD
<sup><xref rid="ref-112" ref-type="bibr">112</xref>&#x02013;
<xref rid="ref-163" ref-type="bibr">163</xref></sup>. Dominant negative mutations with either
<italic>R
<sub>i</sub></italic> &#x0003e;
<italic>R
<sub>i,min</sub></italic> or with modest decreases in &#x00394;
<italic>R
<sub>i</sub></italic>, may be less likely to cause severe phenotypes, as a residual amount of the natural isoform continues to be expressed
<sup><xref rid="ref-103" ref-type="bibr">103</xref>,
<xref rid="ref-117" ref-type="bibr">117</xref>,
<xref rid="ref-141" ref-type="bibr">141</xref>,
<xref rid="ref-164" ref-type="bibr">164</xref>&#x02013;
<xref rid="ref-168" ref-type="bibr">168</xref></sup>. The impact of cryptic site-activating variants on phenotype can be similarly assessed. Activated cryptic sites which shift the reading frame have been shown to be more severe clinically relative to those which maintain the same reading frame as the native gene
<sup><xref rid="ref-105" ref-type="bibr">105</xref>,
<xref rid="ref-162" ref-type="bibr">162</xref>,
<xref rid="ref-169" ref-type="bibr">169</xref>,
<xref rid="ref-170" ref-type="bibr">170</xref></sup>.</p><p>IT-based tools exhibit high specificity for analysis of splicing neutral variants in hereditary breast/ovarian cancer and other disorders
<sup><xref rid="ref-116" ref-type="bibr">116</xref></sup>. These predictions can reduce the requirement for experimental validation of low-priority candidate mutations with minimal changes in information content
<sup><xref rid="ref-14" ref-type="bibr">14</xref>,
<xref rid="ref-22" ref-type="bibr">22</xref></sup>. IT analysis has been used in numerous studies to infer neutral effects of variants
<sup><xref rid="ref-14" ref-type="bibr">14</xref>,
<xref rid="ref-34" ref-type="bibr">34</xref>,
<xref rid="ref-97" ref-type="bibr">97</xref>,
<xref rid="ref-109" ref-type="bibr">109</xref>,
<xref rid="ref-116" ref-type="bibr">116</xref>,
<xref rid="ref-119" ref-type="bibr">119</xref>,
<xref rid="ref-128" ref-type="bibr">128</xref>,
<xref rid="ref-129" ref-type="bibr">129</xref>,
<xref rid="ref-151" ref-type="bibr">151</xref>,
<xref rid="ref-156" ref-type="bibr">156</xref>,
<xref rid="ref-157" ref-type="bibr">157</xref>,
<xref rid="ref-171" ref-type="bibr">171</xref>&#x02013;
<xref rid="ref-185" ref-type="bibr">185</xref></sup>. Similarly, variants that strengthen natural splice sites
<sup><xref rid="ref-186" ref-type="bibr">186</xref>&#x02013;
<xref rid="ref-188" ref-type="bibr">188</xref></sup> are also likely to be neutral, though these variants can increase retention of exons that are otherwise frequently alternatively spliced
<sup><xref rid="ref-189" ref-type="bibr">189</xref>,
<xref rid="ref-190" ref-type="bibr">190</xref></sup>. However, binding site variants with minimal splicing information changes may still alter mRNA processing by disrupting mRNA secondary structure
<sup><xref rid="ref-191" ref-type="bibr">191</xref></sup>.</p></sec></sec><sec><title>Polymorphisms and splicing</title><p>Early studies suggested that common polymorphic sequence variations at splice sites corresponded to small &#x00394;
<italic>R
<sub>i</sub></italic> values, consistent with these changes having little impact on mRNA abundance
<sup><xref rid="ref-22" ref-type="bibr">22</xref></sup>. More recently, it has been appreciated that certain rare SNPs have significant genetic loads, can actively alter mRNA splicing profiles, and lead to non-obvious splicing phenotypes
<sup><xref rid="ref-58" ref-type="bibr">58</xref>,
<xref rid="ref-189" ref-type="bibr">189</xref></sup>. Nevertheless, it is not uncommon for reports to solely analyze novel variants and ignore known SNPs
<sup><xref rid="ref-136" ref-type="bibr">136</xref>,
<xref rid="ref-156" ref-type="bibr">156</xref>,
<xref rid="ref-158" ref-type="bibr">158</xref>,
<xref rid="ref-192" ref-type="bibr">192</xref></sup>, or limit results only to those that occur in the vicinity of natural splice sites
<sup><xref rid="ref-184" ref-type="bibr">184</xref></sup>. We find that 56.4% of common SNPs (with population frequencies &#x02265; 1% in
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>) within natural sites significantly alter their strength (12.8% abolish and 28.2% cause leaky splicing, 15.4% modestly strengthen sites [&#x00394;
<italic>R
<sub>i</sub></italic> &#x0003c; 2.6 bits]), and 43.6% have insignificant &#x00394;
<italic>R
<sub>i</sub></italic> values, as expected (N = 39). The mean
<italic>R
<sub>i,final</sub></italic> and &#x00394;
<italic>R
<sub>i</sub></italic> values, for these natural sites are 7.9 &#x000b1; 4.0 bits and -1.4 &#x000b1; 3.0 bits, respectively, which suggests the effects of these polymorphisms on splicing are nil to limited. However, polymorphisms can significantly modulate splicing, as some common SNPs are predicted to abolish natural splicing (
<xref ref-type="other" rid="DS0">Supplementary Table 2</xref>: #1291, 1296, 1431, 1435, and 1436). These include rs10190751 in
<italic>CFLAR</italic>, which modulates the production of two short isoforms, and is associated with an increased risk of lymphoma
<sup><xref rid="ref-189" ref-type="bibr">189</xref>,
<xref rid="ref-193" ref-type="bibr">193</xref></sup>, rs3892097, which alters exon inclusion in
<italic>CYP2D6</italic>
<sup><xref rid="ref-30" ref-type="bibr">30</xref></sup> and leads to a non-functional protein and altered drug metabolism
<sup><xref rid="ref-194" ref-type="bibr">194</xref></sup>, and rs1805377 in
<italic>XRCC4</italic>
<sup><xref rid="ref-34" ref-type="bibr">34</xref></sup>, which has been associated with oral cancer susceptibility
<sup><xref rid="ref-195" ref-type="bibr">195</xref></sup> and increased risk of gliomas
<sup><xref rid="ref-196" ref-type="bibr">196</xref></sup>. There is also experimental support for common SNPs that have been predicted to affect splicing
<sup><xref rid="ref-22" ref-type="bibr">22</xref>,
<xref rid="ref-98" ref-type="bibr">98</xref>,
<xref rid="ref-107" ref-type="bibr">107</xref>,
<xref rid="ref-110" ref-type="bibr">110</xref>,
<xref rid="ref-114" ref-type="bibr">114</xref>,
<xref rid="ref-118" ref-type="bibr">118</xref>,
<xref rid="ref-149" ref-type="bibr">149</xref>,
<xref rid="ref-164" ref-type="bibr">164</xref>,
<xref rid="ref-189" ref-type="bibr">189</xref>,
<xref rid="ref-197" ref-type="bibr">197</xref></sup>. For example, experimental evidence for increased exon inclusion has been described for three of six SNPs that increase strength of natural splice sites
<sup><xref rid="ref-189" ref-type="bibr">189</xref>,
<xref rid="ref-190" ref-type="bibr">190</xref></sup>. Numerous common SNPs, which were either deemed neutral or predicted to affect splicing, have not been confirmed experimentally
<sup><xref rid="ref-14" ref-type="bibr">14</xref>,
<xref rid="ref-22" ref-type="bibr">22</xref>,
<xref rid="ref-25" ref-type="bibr">25</xref>,
<xref rid="ref-34" ref-type="bibr">34</xref>,
<xref rid="ref-52" ref-type="bibr">52</xref>,
<xref rid="ref-94" ref-type="bibr">94</xref>,
<xref rid="ref-99" ref-type="bibr">99</xref>,
<xref rid="ref-131" ref-type="bibr">131</xref>,
<xref rid="ref-133" ref-type="bibr">133</xref>,
<xref rid="ref-144" ref-type="bibr">144</xref>,
<xref rid="ref-145" ref-type="bibr">145</xref>,
<xref rid="ref-148" ref-type="bibr">148</xref>,
<xref rid="ref-151" ref-type="bibr">151</xref>,
<xref rid="ref-165" ref-type="bibr">165</xref>,
<xref rid="ref-166" ref-type="bibr">166</xref>,
<xref rid="ref-168" ref-type="bibr">168</xref>,
<xref rid="ref-179" ref-type="bibr">179</xref>,
<xref rid="ref-183" ref-type="bibr">183</xref>,
<xref rid="ref-185" ref-type="bibr">185</xref>,
<xref rid="ref-188" ref-type="bibr">188</xref>,
<xref rid="ref-198" ref-type="bibr">198</xref>&#x02013;
<xref rid="ref-208" ref-type="bibr">208</xref></sup>. Polymorphisms with significant information changes should be investigated, as they may not be completely benign and can have a significant impact on mRNA splicing.</p></sec><sec><title>Inference of variant pathogenicity by IT analysis</title><p>Recently, American College of Medical Genetics and Genomics recommendations for reporting incidental findings in sequencing have suggested that bioinformatic predictions are not sufficient to declare clinical significance
<sup><xref rid="ref-209" ref-type="bibr">209</xref></sup>. Preceding the publication of these guidelines, numerous peer-reviewed articles suggested variants analyzed by IT to be causative/pathogenic/disease-causing, without confirmation of the predicted splicing effect
<sup><xref rid="ref-101" ref-type="bibr">101</xref>,
<xref rid="ref-135" ref-type="bibr">135</xref>,
<xref rid="ref-137" ref-type="bibr">137</xref>,
<xref rid="ref-150" ref-type="bibr">150</xref>,
<xref rid="ref-160" ref-type="bibr">160</xref>,
<xref rid="ref-167" ref-type="bibr">167</xref>,
<xref rid="ref-178" ref-type="bibr">178</xref>,
<xref rid="ref-205" ref-type="bibr">205</xref>,
<xref rid="ref-210" ref-type="bibr">210</xref>&#x02013;
<xref rid="ref-218" ref-type="bibr">218</xref></sup>. Other authors have qualified the interpretation of bioinformatic results with less certain terms (i.e. &#x02018;suggest&#x02019; and &#x02018;likely&#x02019; pathogenic)
<sup><xref rid="ref-110" ref-type="bibr">110</xref>,
<xref rid="ref-112" ref-type="bibr">112</xref>,
<xref rid="ref-176" ref-type="bibr">176</xref>,
<xref rid="ref-219" ref-type="bibr">219</xref>&#x02013;
<xref rid="ref-223" ref-type="bibr">223</xref></sup>. Leclerc
<italic>et al.</italic> (2002)
<sup><xref rid="ref-165" ref-type="bibr">165</xref></sup> state that a predicted variant confirmed to affect splicing is likely deleterious, but could not be unequivocally shown to cause the observed phenotype. Although IT predictions can relate a sequence change to the resultant phenotype, caution should be exercised when deeming a predicted splicing variant as pathogenic in the absence of other functional evidence. The high level of concordance between IT mutation analysis and experimental findings indicates that this approach, in conjunction with other evidence, can be used to detect splicing effects, which may be used to explain disease phenotypes.</p></sec><sec><title>Comparisons to other software programs</title><p>There are now over a dozen other publically available splicing prediction tools, some using strategies similar (MaxEntScan [MES]) and others, which are quite different (NNsplice) that are compared with IT
<sup><xref rid="ref-224" ref-type="bibr">224</xref>,
<xref rid="ref-225" ref-type="bibr">225</xref></sup>. Vreeswijk
<italic>et al.</italic> (2009) assessed the applicability of different splice prediction programs to diagnose
<italic>BRCA1/2</italic> variants. These authors recommended that the outcome of 3 programs was sufficient for analysis, unless all three predictions were discordant from one another (2 for false positive predictions). Despite the obvious appeal of consensus between different analytical methods, a major caveat in using polling strategies for mutation assessment is that these approaches are prone to both systematic and sampling errors
<sup><xref rid="ref-40" ref-type="bibr">40</xref></sup>.</p><p>We summarize results of 36 publications that used both IT-based prediction tools and one or more alternate prediction tool (14 for 5&#x000b4; and 3&#x000b4; splicing, six for splicing regulatory proteins) to assess mutations
<sup><xref rid="ref-23" ref-type="bibr">23</xref>,
<xref rid="ref-39" ref-type="bibr">39</xref>,
<xref rid="ref-97" ref-type="bibr">97</xref>,
<xref rid="ref-99" ref-type="bibr">99</xref>,
<xref rid="ref-103" ref-type="bibr">103</xref>,
<xref rid="ref-111" ref-type="bibr">111</xref>,
<xref rid="ref-114" ref-type="bibr">114</xref>&#x02013;
<xref rid="ref-117" ref-type="bibr">117</xref>,
<xref rid="ref-123" ref-type="bibr">123</xref>,
<xref rid="ref-130" ref-type="bibr">130</xref>,
<xref rid="ref-132" ref-type="bibr">132</xref>,
<xref rid="ref-141" ref-type="bibr">141</xref>,
<xref rid="ref-147" ref-type="bibr">147</xref>,
<xref rid="ref-156" ref-type="bibr">156</xref>,
<xref rid="ref-158" ref-type="bibr">158</xref>,
<xref rid="ref-165" ref-type="bibr">165</xref>,
<xref rid="ref-166" ref-type="bibr">166</xref>,
<xref rid="ref-171" ref-type="bibr">171</xref>,
<xref rid="ref-179" ref-type="bibr">179</xref>,
<xref rid="ref-185" ref-type="bibr">185</xref>,
<xref rid="ref-189" ref-type="bibr">189</xref>,
<xref rid="ref-197" ref-type="bibr">197</xref>,
<xref rid="ref-210" ref-type="bibr">210</xref>,
<xref rid="ref-218" ref-type="bibr">218</xref>,
<xref rid="ref-226" ref-type="bibr">226</xref>&#x02013;
<xref rid="ref-235" ref-type="bibr">235</xref></sup>. The analysis performed by the authors allowed us to compare the similarity of predictions to those programs and IT in
<xref ref-type="table" rid="T2a">Table 2a</xref> and
<xref ref-type="table" rid="T2b">Table 2b</xref>. Those most commonly used for 5&#x000b4; and 3&#x000b4; splice sites (NNsplice, MES, NG2, HSF and SSF) were highly concordant for natural sites (85.4% for donor and 77.6% for acceptor sites;
<xref ref-type="table" rid="T2a">Table 2a</xref>). Discordance of acceptor predictions may be due to methodologies that do not analyze the complete acceptor site (HSF analyzes only 14 intronic nucleotides upstream of acceptor splice sites)
<sup><xref rid="ref-236" ref-type="bibr">236</xref></sup>. Some programs (SSF, HSF) exhibit greater concordance with IT for cryptic splice site prediction (96% for donor and 76.9% for acceptor sites). The level of discordance between IT and other commonly used software programs (59.5% for donor and 60% for acceptor sites) may be attributable to the empirically-derived scoring thresholds and the validation sets used to predict mutated splice sites. Models that are typically built (or trained) using known natural splice sites may be less sensitive for differentiating true cryptic splice forms from decoys in the genome, which tend to be weaker than natural splice sites. Tools are highly consistent when analyzing variants expected to be neutral with respect to splicing (100%; N = 71). Colombo
<italic>et al.</italic> (2013) compared nine programs to evaluate accuracy in predicting mRNA splicing effects and reported that ASSA, along with HSF, demonstrated 100% informativeness and specificity.</p><p>ASSEDA has also been used to analyze RNA binding proteins that enhance or silence exon recognition (
<xref ref-type="table" rid="T2b">Table 2b</xref>). ESEfinder was used for 42.2% of these mutations in one or more regulatory binding sites
<sup><xref rid="ref-237" ref-type="bibr">237</xref>,
<xref rid="ref-238" ref-type="bibr">238</xref></sup>. However, variants predicted by ESEfinder to have deleterious effects are discordant with some IT predictions (6 of 15;
<xref ref-type="table" rid="T2b">Table 2b</xref>). The discordance with ESEfinder may be associated with differences in the respective analytic methods, as several of the models (SF2/ASF, SC35, SRp40) used by ASSA and ESEfinder were created from the same source of experimental data
<sup><xref rid="ref-87" ref-type="bibr">87</xref>,
<xref rid="ref-239" ref-type="bibr">239</xref></sup>. While the majority of the discordant results were cited in a single study
<sup><xref rid="ref-114" ref-type="bibr">114</xref></sup> (5/6 variants), the small size of the dataset (ranging from 28&#x02013;34 sites) may artificially exacerbate differences between these results. In multiple instances, ASSA has been used to analyze SR proteins, but other programs were used to analyze 5&#x000b4; and 3&#x000b4; splice site mutations
<sup><xref rid="ref-23" ref-type="bibr">23</xref>,
<xref rid="ref-99" ref-type="bibr">99</xref>,
<xref rid="ref-115" ref-type="bibr">115</xref></sup>. This was surprising, since the donor and acceptor
<italic>R
<sub>i</sub></italic> values are generated by default by ASSA and ASSEDA. The advantage of performing both constitutive and regulatory splice site analysis with IT is that all results are reported on the same scale, and the strengths of all interactions, and effects of mutations are directly comparable to one another.</p><table-wrap id="T2a" orientation="portrait" position="anchor"><label>Table 2a. </label><caption><title>Concordance of splice-prediction programs to information theory-based tools for natural and cryptic sites.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">MES
<sup><xref ref-type="other" rid="note-2">1</xref></sup>
</th><th rowspan="1" colspan="1">BDGP
<sup><xref ref-type="other" rid="note-2">1</xref></sup>
</th><th rowspan="1" colspan="1">NG2
<sup><xref ref-type="other" rid="note-2">1</xref></sup>
</th><th rowspan="1" colspan="1">HSF</th><th rowspan="1" colspan="1">SSF
<sup><xref ref-type="other" rid="note-2">1</xref>,
<xref ref-type="other" rid="note-2">2</xref></sup>
</th><th rowspan="1" colspan="1">SSqF
<sup><xref ref-type="other" rid="note-2">1</xref></sup>
</th><th rowspan="1" colspan="1">GS</th><th rowspan="1" colspan="1">SV</th><th rowspan="1" colspan="1">SP</th><th rowspan="1" colspan="1">SS</th><th rowspan="1" colspan="1">GenS</th><th rowspan="1" colspan="1">ASD</th><th rowspan="1" colspan="1">GeneS</th><th rowspan="1" colspan="1">GM</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Nat. Donors</bold>
</td><td align="center" rowspan="1" colspan="1">42/48</td><td align="center" rowspan="1" colspan="1">37/39</td><td align="center" rowspan="1" colspan="1">24/32</td><td align="center" rowspan="1" colspan="1">23/28</td><td align="center" rowspan="1" colspan="1">25/27</td><td align="center" rowspan="1" colspan="1">15/18</td><td align="center" rowspan="1" colspan="1">6/11</td><td align="center" rowspan="1" colspan="1">9/9</td><td align="center" rowspan="1" colspan="1">5/8</td><td align="center" rowspan="1" colspan="1">2/2</td><td align="center" rowspan="1" colspan="1">1/2</td><td align="center" rowspan="1" colspan="1">1/1</td><td align="center" rowspan="1" colspan="1">1/1</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nat. Acc.</bold>
</td><td align="center" rowspan="1" colspan="1">21/26</td><td align="center" rowspan="1" colspan="1">14/19</td><td align="center" rowspan="1" colspan="1">14/20</td><td align="center" rowspan="1" colspan="1">12/16</td><td align="center" rowspan="1" colspan="1">15/18</td><td align="center" rowspan="1" colspan="1">9/11</td><td align="center" rowspan="1" colspan="1">3/5</td><td align="center" rowspan="1" colspan="1">4/5</td><td align="center" rowspan="1" colspan="1">3/5</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cryp. Donors</bold>
</td><td align="center" rowspan="1" colspan="1">16/24</td><td align="center" rowspan="1" colspan="1">4/8</td><td align="center" rowspan="1" colspan="1">5/10</td><td align="center" rowspan="1" colspan="1">16/17</td><td align="center" rowspan="1" colspan="1">8/8</td><td align="center" rowspan="1" colspan="1">0/7</td><td align="center" rowspan="1" colspan="1">2/2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cryp. Acc.</bold>
</td><td align="center" rowspan="1" colspan="1">7/13</td><td align="center" rowspan="1" colspan="1">2/3</td><td align="center" rowspan="1" colspan="1">3/4</td><td align="center" rowspan="1" colspan="1">8/11</td><td align="center" rowspan="1" colspan="1">2/2</td><td align="center" rowspan="1" colspan="1">2/2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">0/1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Neut. Mut.</bold>
</td><td align="center" rowspan="1" colspan="1">31/31</td><td align="center" rowspan="1" colspan="1">8/8</td><td align="center" rowspan="1" colspan="1">4/4</td><td align="center" rowspan="1" colspan="1">26/26</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">2/2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><table-wrap id="T2b" orientation="portrait" position="anchor"><label>Table 2b. </label><caption><title>Concordance of splice-prediction programs to information theory-based tools for splicing regulatory proteins.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><td rowspan="1" colspan="1"/><th rowspan="1" colspan="1">ESEfinder
<sup><xref ref-type="other" rid="note-2">3</xref>,
<xref ref-type="other" rid="note-2">4</xref></sup>
</th><th rowspan="1" colspan="1">Rescue-ESE</th><th rowspan="1" colspan="1">Ex Skip
<sup><xref ref-type="other" rid="note-2">3</xref>,
<xref ref-type="other" rid="note-2">4</xref></sup>
</th><th rowspan="1" colspan="1">ESEsearch</th><th rowspan="1" colspan="1">PESX</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>ESEs (all types)</bold>
</td><td align="center" rowspan="1" colspan="1">9/15</td><td align="center" rowspan="1" colspan="1">3/4</td><td align="center" rowspan="1" colspan="1">4/14</td><td align="center" rowspan="1" colspan="1">2/3</td><td align="center" rowspan="1" colspan="1">1/1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Neut. Mut.</bold>
</td><td align="center" rowspan="1" colspan="1">4/4</td><td align="center" rowspan="1" colspan="1">1/1</td><td align="center" rowspan="1" colspan="1">3/3</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="note-2"><p>Concordance was assessed from the analysis of variants from 36 publications which used IT-based tools and a secondary predictive method. Each value corresponds to the number of variants that were concordant with IT-based tools versus the total number of variants for each category.
<sup>1</sup> &#x02013; includes Vreeswijk
<italic>et al.</italic> (2008), which may not have properly reported predicted cryptic sites, as they did not report any cryptic sites predicted by ASSA beyond the default window size (54 nt) from the mutation.
<sup>2</sup> &#x02013; predictions made using the SSF-like algorithm in the Alamut splicing prediction module were combined with the SSF category (SSF is no longer supported).
<sup>3</sup> &#x02013; Aissat
<italic>et al.</italic> (2013) contributes highly to the discordance of these programs, and may be due to improper reporting/analysis.
<sup>4</sup> &#x02013; Mutations predicted by alternate program to affect SR protein to which ASSEDA has no model (i.e. 9G8) were not included in statistics.</p></fn><fn><p>MES &#x02013; MaxEntScan; BDGP &#x02013; Splice Site Prediction by Neural Network, NNSplice; NG2 &#x02013; NetGene2; HSF &#x02013; Human Splice Finder; SSF &#x02013; Splice Site Finder; SSqF &#x02013; Splicing Sequences Finder; GS - GeneSplicer; SV &#x02013; SpliceView; SP &#x02013; Splice Predictor; SS - Shapiro-Senapathy; GenS &#x02013; GenScan; ASD - ASD-Intron analysis; GeneS &#x02013; GeneScan; GM &#x02013; GeneMark; PESX - Putative Exonic Splicing Enhancers/Silencers.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Other applications of information theory-based splice site analysis</title><p>The use of IT to analyze splicing is not limited to sequence variant analysis. The natural and alternative splicing of several genes have been characterized using this method
<sup><xref rid="ref-107" ref-type="bibr">107</xref>,
<xref rid="ref-200" ref-type="bibr">200</xref>,
<xref rid="ref-240" ref-type="bibr">240</xref></sup>. Khan
<italic>et al.</italic> (2002) scanned all natural sites in the
<italic>XPC</italic> gene and found a weak acceptor (-0.1 bits), and with RT-PCR found that this exon (exon 4) was skipped to a greater extent than another (exon 7), which possessed a strong acceptor, illustrating a relationship between the information content of a natural splice site and its level of alternative splicing. IT has also been used in genetic engineering in the design and alteration of binding sites, and has been used in the design of constructs for transgenic animal models
<sup><xref rid="ref-241" ref-type="bibr">241</xref>&#x02013;
<xref rid="ref-243" ref-type="bibr">243</xref></sup>. Thus, IT-based splice site analysis can be adapted for other important molecular genetic applications.</p></sec><sec><title>Guidelines for information theory-based splicing mutation analyses</title><p>Our comprehensive review of the use of IT in splicing mutation analysis has led us to propose general recommendations, which we formulate as guidelines. Adoption of these guidelines should ensure the accurate and comprehensive results from IT analyses of VUS and other pathogenic variants that alter mRNA splicing.</p><sec><title>Report gene isoform and genomic coordinates</title><p>When analyzing a variant with ASSEDA, the user is prompted to select an mRNA isoform (GenBank or RefSeq accession) from the gene in question. When entering the same variant (in either IVS or c. notation) for different isoforms, either the variant will parse one but not the other representation, or the variant syntax will be processed for both. In the first situation, the user is prompted to verify the position and substitution, which may elicit the realization that the incorrect isoform had been selected. However, in the case where the variant can still be parsed (despite being incorrectly entered for the isoform selected), an incorrect nucleotide may coincidentally have the same sequence, and the user may not necessarily realize that the intended position is not being analyzed. We were unable to reproduce results for several variants, because the mRNA or gene isoform was not reported. This issue could be resolved by comparing the genomic sequence in papers where the context of the mutation was included
<sup><xref rid="ref-50" ref-type="bibr">50</xref>,
<xref rid="ref-95" ref-type="bibr">95</xref>,
<xref rid="ref-141" ref-type="bibr">141</xref>,
<xref rid="ref-179" ref-type="bibr">179</xref>,
<xref rid="ref-244" ref-type="bibr">244</xref>&#x02013;
<xref rid="ref-246" ref-type="bibr">246</xref></sup>. Where flanking sequences were unavailable, the location of the mutation was inferred from either descriptions in the text, the corresponding
<italic>R
<sub>i</sub></italic> value of the splice site, or relative coordinate numbering
<sup><xref rid="ref-144" ref-type="bibr">144</xref>,
<xref rid="ref-247" ref-type="bibr">247</xref>,
<xref rid="ref-248" ref-type="bibr">248</xref></sup>. Although we attempted to reproduce all the results, this was not always possible if the specified sequence was ambiguous or the source was deprecated (GenBank accession numbers, BAC clones, etc.)
<sup><xref rid="ref-48" ref-type="bibr">48</xref>,
<xref rid="ref-97" ref-type="bibr">97</xref>,
<xref rid="ref-172" ref-type="bibr">172</xref>,
<xref rid="ref-179" ref-type="bibr">179</xref>,
<xref rid="ref-180" ref-type="bibr">180</xref>,
<xref rid="ref-208" ref-type="bibr">208</xref>,
<xref rid="ref-227" ref-type="bibr">227</xref>,
<xref rid="ref-232" ref-type="bibr">232</xref>,
<xref rid="ref-249" ref-type="bibr">249</xref>,
<xref rid="ref-250" ref-type="bibr">250</xref></sup>.</p><p>We note that ASSA/ASSEDA cannot account for genes with redacted exons, where the exon numbering or sequence in the original mRNA accession has not been corrected. A well-known example is
<italic>BRCA1,</italic> for which the constitutive isoform lacks the exon designated as number 4. IVS notation beyond this point in this gene must be reduced by one intron. Alternatively, one of the HGVS-approved methods can be used to input variants, or the variant can be designated with the genomic coordinate (g.) format. Review of ASSA/ASSEDA output (coordinates and/or the sequence walker
<sup><xref rid="ref-20" ref-type="bibr">20</xref></sup>) is a prudent approach to confirm that the correct region has been analyzed.</p><p>To eliminate ambiguity, we recommend that reported variants be accompanied by the accession number used in its analysis (consistent with HGVS notation
<sup><xref rid="ref-36" ref-type="bibr">36</xref></sup>) and the genomic coordinates with the corresponding reference genome build. The table of results from ASSEDA or Shannon pipeline output could also be included as supplementary published material. This will ensure that reported results can be reproduced and compared to other experimental or
<italic>in silico</italic> results.</p></sec><sec><title>Report
<italic>R
<sub>i</sub></italic> values</title><p>The results generated by IT software provide
<italic>R
<sub>i,initial</sub></italic>,
<italic>R
<sub>i,final</sub></italic>, and &#x00394;
<italic>R
<sub>i</sub></italic> for donor and acceptor sites by default, and for all other ribl matrices selected. Reporting these values along with the interpretation improves the clarity of said interpretation. Several publications have not reported
<italic>R
<sub>i</sub></italic>, and instead only the interpretation of these values
<sup><xref rid="ref-125" ref-type="bibr">125</xref>,
<xref rid="ref-138" ref-type="bibr">138</xref>,
<xref rid="ref-146" ref-type="bibr">146</xref>,
<xref rid="ref-212" ref-type="bibr">212</xref>,
<xref rid="ref-227" ref-type="bibr">227</xref>,
<xref rid="ref-251" ref-type="bibr">251</xref>,
<xref rid="ref-252" ref-type="bibr">252</xref></sup>. This presumes that the analysis was performed correctly, and accurately interpreted. In one instance, our reanalysis differed from the published interpretation
<sup><xref rid="ref-138" ref-type="bibr">138</xref></sup>. Other publications provide
<italic>R
<sub>i</sub></italic> values, but were incorrectly reported, which resulted in misinterpretations
<sup><xref rid="ref-48" ref-type="bibr">48</xref>,
<xref rid="ref-122" ref-type="bibr">122</xref>,
<xref rid="ref-253" ref-type="bibr">253</xref></sup>. Simply reporting &#x00394;
<italic>R
<sub>i</sub></italic> itself does not provide sufficient information about the context of the mutation or possible cryptic splice sites, which is necessary to fully appreciate the resultant effect on splicing
<sup><xref rid="ref-136" ref-type="bibr">136</xref>,
<xref rid="ref-245" ref-type="bibr">245</xref>,
<xref rid="ref-254" ref-type="bibr">254</xref></sup>. We recommend
<italic>R
<sub>i</sub></italic> values be provided for each variant analyzed. We also suggest that the specific donor and acceptor ribl used for variant analysis be indicated, because of the differences obtained using the genome-wide and original PWMs in IT analysis
<sup><xref rid="ref-30" ref-type="bibr">30</xref>,
<xref rid="ref-33" ref-type="bibr">33</xref></sup>. The distinction can also be significant, when the
<italic>R
<sub>i,final</sub></italic> value of a mutated splice site approaches
<italic>R
<sub>i,min</sub></italic>.</p></sec><sec><title>Consider impact of missense and synonymous mutations on mRNA splicing</title><p>Missense and synonymous mutations can alter natural splicing, create cryptic sites, and alter crucial ESE and ESS binding sites
<sup><xref rid="ref-255" ref-type="bibr">255</xref></sup>. IT tools have been employed to analyze exonic variants that strengthened or create exonic cryptic sites, which were also confirmed experimentally
<sup><xref rid="ref-25" ref-type="bibr">25</xref>,
<xref rid="ref-39" ref-type="bibr">39</xref>,
<xref rid="ref-41" ref-type="bibr">41</xref>,
<xref rid="ref-43" ref-type="bibr">43</xref>,
<xref rid="ref-98" ref-type="bibr">98</xref>,
<xref rid="ref-105" ref-type="bibr">105</xref>,
<xref rid="ref-116" ref-type="bibr">116</xref>,
<xref rid="ref-124" ref-type="bibr">124</xref>,
<xref rid="ref-130" ref-type="bibr">130</xref>,
<xref rid="ref-149" ref-type="bibr">149</xref>,
<xref rid="ref-151" ref-type="bibr">151</xref>,
<xref rid="ref-178" ref-type="bibr">178</xref>,
<xref rid="ref-256" ref-type="bibr">256</xref>,
<xref rid="ref-257" ref-type="bibr">257</xref></sup>. Similarly, IT tools can predict potential effects on strengths of SR and hnRNP protein recognition sites
<sup><xref rid="ref-23" ref-type="bibr">23</xref>,
<xref rid="ref-117" ref-type="bibr">117</xref></sup>. There is no justification for cataloguing intronic and exonic variants, but only assessing splicing effects for the intronic variants or those within natural splice sites
<sup><xref rid="ref-119" ref-type="bibr">119</xref>,
<xref rid="ref-132" ref-type="bibr">132</xref>,
<xref rid="ref-175" ref-type="bibr">175</xref>,
<xref rid="ref-186" ref-type="bibr">186</xref>,
<xref rid="ref-208" ref-type="bibr">208</xref>,
<xref rid="ref-210" ref-type="bibr">210</xref>,
<xref rid="ref-214" ref-type="bibr">214</xref>,
<xref rid="ref-215" ref-type="bibr">215</xref>,
<xref rid="ref-248" ref-type="bibr">248</xref>,
<xref rid="ref-258" ref-type="bibr">258</xref>,
<xref rid="ref-259" ref-type="bibr">259</xref></sup>. We recommend that IT-based analysis should evaluate all variants within a gene for potential splicing mutations.</p></sec><sec><title>Experimentally validate variants</title><p>Many studies have reported only coding changes and the results of IT (or other
<italic>in silico</italic>) analyses without experimental validation. Our review indicated that IT-based splicing predictions are highly concordant with validation results (87.9%) Nevertheless, the discordant mutations support the need for robust post-prediction validation, since even a single discordant result can lead to misdiagnosis. We do not detect any consistent pattern amongst the discordant predictions to provide guidance as to which IT analyses will be erroneous. Experimental verification will mitigate incorrect interpretations of IT predictions and has been recommended by others
<sup><xref rid="ref-26" ref-type="bibr">26</xref></sup>.</p></sec><sec><title>Report the sequence window used in the analysis</title><p>ASSA/ASSEDA allows the user to alter size of sequence window range surrounding the mutation. The default window range has been set to maximize the speed of analysis, which is to some degree dictated by the number of matrices and the length of the sequence analyzed. Arbitrary abbreviation of the sequence analysis window can result in the failure to detect activated intronic or exonic cryptic sites, which can in some instances significantly lengthen (eg. 231 and 313 nucleotide extensions, respectively
<sup><xref rid="ref-166" ref-type="bibr">166</xref>,
<xref rid="ref-171" ref-type="bibr">171</xref></sup>) or shorten the corresponding natural exon. Therefore, we suggest expanding this window if one wishes to assess the possibility that long range, pre-existing cryptic splice sites may be activated.</p><p>We note that unequivocal prediction of cryptic splice site use in large exons (&#x0003e; 1000 nt) can be challenging due to the reliance of these gene regions on splicing enhancers, silencers, and other regulatory elements to prevent ectopic splice site use and ensure fidelity of splicing
<sup><xref rid="ref-260" ref-type="bibr">260</xref></sup>. Di Leo
<italic>et al.</italic> (2007) determined a variant abolishing the natural acceptor for exon 26 of
<italic>APOB</italic> (7572 nt long), which activated a weak cryptic site 1180 nt downstream
<sup><xref rid="ref-261" ref-type="bibr">261</xref></sup>. There are several other stronger candidate cryptic splice sites that occur between the natural and cryptic splice site, but there is no evidence that any are used in the individual carrying this mutation.</p></sec><sec><title>Designate genic rearrangements (insertions, deletions, duplications) with genomic coordinates</title><p>Complex insertions and deletions in IVS or c. notation may occasionally be parsed to the wrong coordinates within a gene. Indels will parse properly when genomic coordinates are used. If IVS or c. notation is used, it is suggested that users confirm that the expected alteration of the mutation is correct by reviewing the sequence walker display generated by ASSEDA for all insertions, deletions and duplications.</p><supplementary-material content-type="local-data" id="DS0"><label>Dataset for mRNA splicing mutations in genetic disease</label><caption><p>All data from the extensive review of the literature presented in the article are reported as Supplementary tables 1 through 10. The following data are provided: 1) articles referring to information theory as a tool for splice site mutation analysis; 2) complete list of reviewed variants; 3) indels, duplications and multinucleotide variants; 4) deleterious natural site variants; 5) branch point variants; 6&#x02013;7) Types 1&#x02013;3 cryptic splice site variants; 9) validated variants; 10) splicing mutation calculator data.</p></caption><media xlink:href="f1000research-3-6038-s0000.tgz"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></sec><sec><title>Data availability</title><p>F1000Research: Dataset 1. Dataset for mRNA splicing mutations in genetic disease,
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5256/f1000research.5654.d38248">10.5256/f1000research.5654.d38248</ext-link>
<sup><xref rid="ref-262" ref-type="bibr">262</xref></sup>
</p></sec><sec><title>Software availability</title><sec><title>Software access</title><p>The Splicing Mutation Calculator (SMC) is available at
<ext-link ext-link-type="uri" xlink:href="http://splicemc.cytognomix.com">http://splicemc.cytognomix.com</ext-link>.</p></sec><sec><title>Latest source code</title><p>
<ext-link ext-link-type="uri" xlink:href="https://github.com/F1000Research/splicemc">https://github.com/F1000Research/splicemc</ext-link>
</p></sec><sec><title>Archived source code as at the time of publication</title><p>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5281/zenodo.12422">http://dx.doi.org/10.5281/zenodo.12422</ext-link>
<sup><xref rid="ref-263" ref-type="bibr">263</xref></sup>
</p></sec><sec><title>License</title><p>GNU GPLv3</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>We would like to gratefully acknowledge the efforts of Shannon Brown and Ben Shirley for creating Splicing Mutation Calculator software (SMC), which has been deposited in Zenodo (DOI:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5281/zenodo.12422">10.5281/zenodo.12422</ext-link>).</p></ack><sec id="SM" sec-type="supplementary-material"><title>Supplementary Material</title><p>
<ext-link ext-link-type="uri" xlink:href="https://f1000researchdata.s3.amazonaws.com/supplementary/5654/64579554-2ece-4728-b637-dc3f57baad56.pdf">Supplementary file</ext-link> containing Supplementary Figure 1 and Supplementary Bibliography.</p></sec><ref-list><ref id="ref-1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>Z</given-names></name><name><surname>Rouchka</surname><given-names>EC</given-names></name><name><surname>Gish</surname><given-names>WR</given-names></name><etal/></person-group>:
<article-title>Gene structure prediction and alternative splicing analysis using genomically aligned ESTs.</article-title><source><italic>Genome Res.</italic></source><year>2001</year>;<volume>11</volume>(<issue>5</issue>):<fpage>889</fpage>&#x02013;<lpage>900</lpage>.
<pub-id pub-id-type="doi">10.1101/gr.155001</pub-id><!--<pub-id pub-id-type="pmcid">311065</pub-id>--><?supplied-pmid 11337482?><pub-id pub-id-type="pmid">11337482</pub-id></mixed-citation></ref><ref id="ref-2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modrek</surname><given-names>B</given-names></name><name><surname>Resch</surname><given-names>A</given-names></name><name><surname>Grasso</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Genome-wide detection of alternative splicing in expressed sequences of human genes.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2001</year>;<volume>29</volume>(<issue>13</issue>):<fpage>2850</fpage>&#x02013;<lpage>2859</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/29.13.2850</pub-id><!--<pub-id pub-id-type="pmcid">55780</pub-id>--><?supplied-pmid 11433032?><pub-id pub-id-type="pmid">11433032</pub-id></mixed-citation></ref><ref id="ref-3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>I</given-names></name><name><surname>Callens</surname><given-names>T</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Complex splicing pattern generates great diversity in human NF1 transcripts.</article-title><source><italic>BMC Genomics.</italic></source><year>2002</year>;<volume>3</volume>:<fpage>13</fpage>.
<pub-id pub-id-type="doi">10.1186/1471-2164-3-13</pub-id><!--<pub-id pub-id-type="pmcid">115845</pub-id>--><?supplied-pmid 12057013?><pub-id pub-id-type="pmid">12057013</pub-id></mixed-citation></ref><ref id="ref-4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frilander</surname><given-names>MJ</given-names></name><name><surname>Steitz</surname><given-names>JA</given-names></name></person-group>:
<article-title>Initial recognition of U12-dependent introns requires both U11/5&#x02019; splice-site and U12/branchpoint interactions.</article-title><source><italic>Genes Dev.</italic></source><year>1999</year>;<volume>13</volume>(<issue>7</issue>):<fpage>851</fpage>&#x02013;<lpage>863</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.13.7.851</pub-id><!--<pub-id pub-id-type="pmcid">316595</pub-id>--><?supplied-pmid 10197985?><pub-id pub-id-type="pmid">10197985</pub-id></mixed-citation></ref><ref id="ref-5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Will</surname><given-names>CL</given-names></name><name><surname>L&#x000fc;hrmann</surname><given-names>R</given-names></name></person-group>:
<article-title>Protein functions in pre-mRNA splicing.</article-title><source><italic>Curr Opin Cell Biol.</italic></source><year>1997</year>;<volume>9</volume>(<issue>3</issue>):<fpage>320</fpage>&#x02013;<lpage>328</lpage>.
<pub-id pub-id-type="doi">10.1016/S0955-0674(97)80003-8</pub-id><?supplied-pmid 9159080?><pub-id pub-id-type="pmid">9159080</pub-id></mixed-citation></ref><ref id="ref-6"><label>6</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Tuschi</surname><given-names>T</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name></person-group>:
<article-title>The RNA World, 2nd Ed.: The Nature of Modern RNA Suggests a Prebiotic RNA World</article-title>.
<italic>(Cold Spring Harbor Press)</italic><year>1999</year>;
<bold>37</bold>:<fpage>525</fpage>&#x02013;<lpage>560</lpage>
<ext-link ext-link-type="uri" xlink:href="http://cshmonographs.org/index.php/monographs/issue/view/087969589.37">Reference Source</ext-link></mixed-citation></ref><ref id="ref-7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>:
<article-title>Distribution of exonic splicing enhancer elements in human genes.</article-title><source><italic>Genomics.</italic></source><year>2005</year>;<volume>86</volume>(<issue>3</issue>):<fpage>329</fpage>&#x02013;<lpage>336</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ygeno.2005.05.011</pub-id><?supplied-pmid 16005179?><pub-id pub-id-type="pmid">16005179</pub-id></mixed-citation></ref><ref id="ref-8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graveley</surname><given-names>BR</given-names></name><name><surname>Hertel</surname><given-names>KJ</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group>:
<article-title>A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers.</article-title><source><italic>EMBO J.</italic></source><year>1998</year>;<volume>17</volume>(<issue>22</issue>):<fpage>6747</fpage>&#x02013;<lpage>6756</lpage>.
<pub-id pub-id-type="doi">10.1093/emboj/17.22.6747</pub-id><!--<pub-id pub-id-type="pmcid">1171020</pub-id>--><?supplied-pmid 9822617?><pub-id pub-id-type="pmid">9822617</pub-id></mixed-citation></ref><ref id="ref-9"><label>9</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Andresen</surname><given-names>BS</given-names></name><name><surname>Krainer</surname><given-names>A</given-names></name></person-group>:
<article-title>When the genetic code is not enough - How sequence variations can affect pre-mRNA splicing and cause (complex) disease. Chapter 15</article-title>.
<italic>Genetics of Complex Human Diseases</italic> (New York, USA: Cold Spring Harbor Laboratory Press),<year>2009</year>
<ext-link ext-link-type="uri" xlink:href="http://findresearcher.sdu.dk:8080/portal/en/publications/when-the-genetic-code-is-not-enough--how-sequence-variations-can-affect-premrna-splicing-and-cause-complex-disease-chapter-15(a592ab10-0fee-11df-aefb-000ea68e967b)/export.html">Reference Source</ext-link></mixed-citation></ref><ref id="ref-10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawczak</surname><given-names>M</given-names></name><name><surname>Reiss</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name></person-group>:
<article-title>The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences.</article-title><source><italic>Hum Genet.</italic></source><year>1992</year>;<volume>90</volume>(<issue>1&#x02013;2</issue>):<fpage>41</fpage>&#x02013;<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1007/BF00210743</pub-id><?supplied-pmid 1427786?><pub-id pub-id-type="pmid">1427786</pub-id></mixed-citation></ref><ref id="ref-11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ars</surname><given-names>E</given-names></name><name><surname>Serra</surname><given-names>E</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.</article-title><source><italic>Hum Mol Genet.</italic></source><year>2000</year>;<volume>9</volume>(<issue>2</issue>):<fpage>237</fpage>&#x02013;<lpage>247</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/9.2.237</pub-id><?supplied-pmid 10607834?><pub-id pub-id-type="pmid">10607834</pub-id></mixed-citation></ref><ref id="ref-12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teraoka</surname><given-names>SN</given-names></name><name><surname>Telatar</surname><given-names>M</given-names></name><name><surname>Becker-Catania</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences.</article-title><source><italic>Am J Hum Genet.</italic></source><year>1999</year>;<volume>64</volume>(<issue>6</issue>):<fpage>1617</fpage>&#x02013;<lpage>1631</lpage>.
<pub-id pub-id-type="doi">10.1086/302418</pub-id><!--<pub-id pub-id-type="pmcid">1377904</pub-id>--><?supplied-pmid 10330348?><pub-id pub-id-type="pmid">10330348</pub-id></mixed-citation></ref><ref id="ref-13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>MB</given-names></name><name><surname>Senapathy</surname><given-names>P</given-names></name></person-group>:
<article-title>RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1987</year>;<volume>15</volume>(<issue>17</issue>):<fpage>7155</fpage>&#x02013;<lpage>7174</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/15.17.7155</pub-id><!--<pub-id pub-id-type="pmcid">306199</pub-id>--><?supplied-pmid 3658675?><pub-id pub-id-type="pmid">3658675</pub-id></mixed-citation></ref><ref id="ref-14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group>:
<article-title>Using information content and base frequencies to distinguish mutations from genetic polymorphisms in splice junction recognition sites.</article-title><source><italic>Hum Mutat.</italic></source><year>1995</year>;<volume>6</volume>(<issue>1</issue>):<fpage>74</fpage>&#x02013;<lpage>76</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.1380060114</pub-id><?supplied-pmid 7550236?><pub-id pub-id-type="pmid">7550236</pub-id></mixed-citation></ref><ref id="ref-15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishel</surname><given-names>R</given-names></name><name><surname>Lescoe</surname><given-names>MK</given-names></name><name><surname>Rao</surname><given-names>MR</given-names></name><etal/></person-group>:
<article-title>The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.</article-title><source><italic>Cell.</italic></source><year>1993</year>;<volume>75</volume>(<issue>5</issue>):<fpage>1027</fpage>&#x02013;<lpage>1038</lpage>.
<pub-id pub-id-type="doi">10.1016/0092-8674(93)90546-3</pub-id><?supplied-pmid 8252616?><pub-id pub-id-type="pmid">8252616</pub-id></mixed-citation></ref><ref id="ref-16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>FS</given-names></name><name><surname>Nicolaides</surname><given-names>NC</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.</article-title><source><italic>Cell.</italic></source><year>1993</year>;<volume>75</volume>(<issue>6</issue>):<fpage>1215</fpage>&#x02013;<lpage>1225</lpage>.
<pub-id pub-id-type="doi">10.1016/0092-8674(93)90330-S</pub-id><?supplied-pmid 8261515?><pub-id pub-id-type="pmid">8261515</pub-id></mixed-citation></ref><ref id="ref-17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group>:
<article-title>Sequence logos, machine/channel capacity, Maxwell&#x02019;s demon, and molecular computers: a review of the theory of molecular machines.</article-title><source><italic>Nanotechnology.</italic></source><year>1994</year>;<volume>5</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1088/0957-4484/5/1/001</pub-id></mixed-citation></ref><ref id="ref-18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group>:
<article-title>Information content of individual genetic sequences.</article-title><source><italic>J Theor Biol.</italic></source><year>1997</year>;<volume>189</volume>(<issue>4</issue>):<fpage>427</fpage>&#x02013;<lpage>441</lpage>.
<pub-id pub-id-type="doi">10.1006/jtbi.1997.0540</pub-id><?supplied-pmid 9446751?><pub-id pub-id-type="pmid">9446751</pub-id></mixed-citation></ref><ref id="ref-19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>Engelbrecht</surname><given-names>J</given-names></name><name><surname>Knudsen</surname><given-names>S</given-names></name></person-group>:
<article-title>Prediction of human mRNA donor and acceptor sites from the DNA sequence.</article-title><source><italic>J Mol Biol.</italic></source><year>1991</year>;<volume>220</volume>(<issue>1</issue>):<fpage>49</fpage>&#x02013;<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1016/0022-2836(91)90380-O</pub-id><?supplied-pmid 2067018?><pub-id pub-id-type="pmid">2067018</pub-id></mixed-citation></ref><ref id="ref-20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group>:
<article-title>Sequence walkers: a graphical method to display how binding proteins interact with DNA or RNA sequences.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1997</year>;<volume>25</volume>(<issue>21</issue>):<fpage>4408</fpage>&#x02013;<lpage>4415</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/25.21.4408</pub-id><!--<pub-id pub-id-type="pmcid">147041</pub-id>--><?supplied-pmid 9336476?><pub-id pub-id-type="pmid">9336476</pub-id></mixed-citation></ref><ref id="ref-21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengen</surname><given-names>PN</given-names></name><name><surname>Bartram</surname><given-names>SL</given-names></name><name><surname>Stewart</surname><given-names>LE</given-names></name><etal/></person-group>:
<article-title>Information analysis of Fis binding sites.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1997</year>;<volume>25</volume>(<issue>24</issue>):<fpage>4994</fpage>&#x02013;<lpage>5002</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/25.24.4994</pub-id><!--<pub-id pub-id-type="pmcid">147151</pub-id>--><?supplied-pmid 9396807?><pub-id pub-id-type="pmid">9396807</pub-id></mixed-citation></ref><ref id="ref-22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Faux</surname><given-names>BM</given-names></name><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group>:
<article-title>Information analysis of human splice site mutations.</article-title><source><italic>Hum Mutat.</italic></source><year>1998</year>;<volume>12</volume>(<issue>3</issue>):<fpage>153</fpage>&#x02013;<lpage>171</lpage>.
<pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(1998)12:3&#x0003c;153::AID-HUMU3&#x0003e;3.0.CO;2-I</pub-id><?supplied-pmid 9711873?><pub-id pub-id-type="pmid">9711873</pub-id></mixed-citation></ref><ref id="ref-23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>RKJ</given-names></name><name><surname>Br&#x000f8;ner</surname><given-names>S</given-names></name><name><surname>Sabaratnam</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>The ETFDH c.158A&#x0003e;G variation disrupts the balanced interplay of ESE- and ESS-binding proteins thereby causing missplicing and multiple Acyl-CoA dehydrogenation deficiency.</article-title><source><italic>Hum Mutat.</italic></source><year>2014</year>;<volume>35</volume>(<issue>1</issue>):<fpage>86</fpage>&#x02013;<lpage>95</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22455</pub-id><?supplied-pmid 24123825?><pub-id pub-id-type="pmid">24123825</pub-id></mixed-citation></ref><ref id="ref-24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homolova</surname><given-names>K</given-names></name><name><surname>Zavadakova</surname><given-names>P</given-names></name><name><surname>Doktor</surname><given-names>TK</given-names></name><etal/></person-group>:
<article-title>The deep intronic c.903+469T&#x0003e;C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria.</article-title><source><italic>Hum Mutat.</italic></source><year>2010</year>;<volume>31</volume>(<issue>4</issue>):<fpage>437</fpage>&#x02013;<lpage>444</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.21206</pub-id><!--<pub-id pub-id-type="pmcid">3429857</pub-id>--><?supplied-pmid 20120036?><pub-id pub-id-type="pmid">20120036</pub-id></mixed-citation></ref><ref id="ref-25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucaki</surname><given-names>EJ</given-names></name><name><surname>Ainsworth</surname><given-names>P</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name></person-group>:
<article-title>Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.</article-title><source><italic>Hum Mutat.</italic></source><year>2011</year>;<volume>32</volume>(<issue>7</issue>):<fpage>735</fpage>&#x02013;<lpage>742</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.21513</pub-id><?supplied-pmid 21523855?><pub-id pub-id-type="pmid">21523855</pub-id></mixed-citation></ref><ref id="ref-26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddalena</surname><given-names>A</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Technical standards and guidelines: molecular genetic testing for ultra-rare disorders.</article-title><source><italic>Genet Med.</italic></source><year>2005</year>;<volume>7</volume>(<issue>8</issue>):<fpage>571</fpage>&#x02013;<lpage>583</lpage>.
<pub-id pub-id-type="doi">10.1097/01.GIM.0000182738.95726.ca</pub-id><?supplied-pmid 16247296?><pub-id pub-id-type="pmid">16247296</pub-id></mixed-citation></ref><ref id="ref-27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>CE</given-names></name></person-group>:
<article-title>A Mathematical Theory of Communication.</article-title><source><italic>Bell Syst Tech J.</italic></source><year>1948</year>;<volume>27</volume>(<issue>3</issue>):<fpage>379</fpage>&#x02013;<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1002/j.1538-7305.1948.tb01338.x</pub-id></mixed-citation></ref><ref id="ref-28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name><name><surname>Stormo</surname><given-names>GD</given-names></name><name><surname>Gold</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Information content of binding sites on nucleotide sequences.</article-title><source><italic>J Mol Biol.</italic></source><year>1986</year>;<volume>188</volume>(<issue>3</issue>):<fpage>415</fpage>&#x02013;<lpage>431</lpage>.
<pub-id pub-id-type="doi">10.1016/0022-2836(86)90165-8</pub-id><?supplied-pmid 3525846?><pub-id pub-id-type="pmid">3525846</pub-id></mixed-citation></ref><ref id="ref-29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name><name><surname>Stephens</surname><given-names>RM</given-names></name></person-group>:
<article-title>Sequence logos: a new way to display consensus sequences.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1990</year>;<volume>18</volume>(<issue>20</issue>):<fpage>6097</fpage>&#x02013;<lpage>6100</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/18.20.6097</pub-id><!--<pub-id pub-id-type="pmcid">332411</pub-id>--><?supplied-pmid 2172928?><pub-id pub-id-type="pmid">2172928</pub-id></mixed-citation></ref><ref id="ref-30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Svojanovsky</surname><given-names>S</given-names></name><name><surname>Leeder</surname><given-names>JS</given-names></name></person-group>:
<article-title>Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations.</article-title><source><italic>Pharmacogenetics.</italic></source><year>2003</year>;<volume>13</volume>(<issue>4</issue>):<fpage>207</fpage>&#x02013;<lpage>218</lpage>.
<pub-id pub-id-type="doi">10.1097/00008571-200304000-00005</pub-id><?supplied-pmid 12668917?><pub-id pub-id-type="pmid">12668917</pub-id></mixed-citation></ref><ref id="ref-31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name><name><surname>Stormo</surname><given-names>GD</given-names></name><name><surname>Haemer</surname><given-names>JS</given-names></name><etal/></person-group>:
<article-title>A design for computer nucleic-acid-sequence storage, retrieval, and manipulation.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1982</year>;<volume>10</volume>(<issue>9</issue>):<fpage>3013</fpage>&#x02013;<lpage>3024</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/10.9.3013</pub-id><!--<pub-id pub-id-type="pmcid">320671</pub-id>--><?supplied-pmid 7099972?><pub-id pub-id-type="pmid">7099972</pub-id></mixed-citation></ref><ref id="ref-32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name><name><surname>Stormo</surname><given-names>GD</given-names></name><name><surname>Yarus</surname><given-names>MA</given-names></name><etal/></person-group>:
<article-title>Delila system tools.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1984</year>;<volume>12</volume>(<issue>1 Pt 1</issue>):<fpage>129</fpage>&#x02013;<lpage>140</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/12.1Part1.129</pub-id><!--<pub-id pub-id-type="pmcid">320990</pub-id>--><?supplied-pmid 6694897?><pub-id pub-id-type="pmid">6694897</pub-id></mixed-citation></ref><ref id="ref-33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>RM</given-names></name><name><surname>Schneider</surname><given-names>TD</given-names></name></person-group>:
<article-title>Features of spliceosome evolution and function inferred from an analysis of the information at human splice sites.</article-title><source><italic>J Mol Biol.</italic></source><year>1992</year>;<volume>228</volume>(<issue>4</issue>):<fpage>1124</fpage>&#x02013;<lpage>1136</lpage>.
<pub-id pub-id-type="doi">10.1016/0022-2836(92)90320-J</pub-id><?supplied-pmid 1474582?><pub-id pub-id-type="pmid">1474582</pub-id></mixed-citation></ref><ref id="ref-34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalla</surname><given-names>VK</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name></person-group>:
<article-title>Automated splicing mutation analysis by information theory.</article-title><source><italic>Hum Mutat.</italic></source><year>2005</year>;<volume>25</volume>(<issue>4</issue>):<fpage>334</fpage>&#x02013;<lpage>342</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20151</pub-id><?supplied-pmid 15776446?><pub-id pub-id-type="pmid">15776446</pub-id></mixed-citation></ref><ref id="ref-35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucaki</surname><given-names>EJ</given-names></name><name><surname>Shirley</surname><given-names>BC</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name></person-group>:
<article-title>Prediction of Mutant mRNA Splice Isoforms by Information Theory-Based Exon Definition.</article-title><source><italic>Hum Mutat.</italic></source><year>2013</year>;<volume>34</volume>(<issue>4</issue>):<fpage>557</fpage>&#x02013;<lpage>565</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22277</pub-id><?supplied-pmid 23348723?><pub-id pub-id-type="pmid">23348723</pub-id></mixed-citation></ref><ref id="ref-36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Den Dunnen</surname><given-names>JT</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name></person-group>:
<article-title>Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.</article-title><source><italic>Hum Mutat.</italic></source><year>2000</year>;<volume>15</volume>(<issue>1</issue>):<fpage>7</fpage>&#x02013;<lpage>12</lpage>.
<?supplied-pmid 10612815?><pub-id pub-id-type="pmid">10612815</pub-id></mixed-citation></ref><ref id="ref-37"><label>37</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tribus</surname><given-names>M</given-names></name></person-group>:
<article-title>Thermostatics and thermodynamics</article-title>. (New York: Van Nostrand, 1961).
<ext-link ext-link-type="uri" xlink:href="http://www.worldcat.org/title/thermostatics-and-thermodynamics/oclc/299616625">Reference Source</ext-link></mixed-citation></ref><ref id="ref-38"><label>38</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cover</surname><given-names>TM</given-names></name><name><surname>Thomas</surname><given-names>JA</given-names></name></person-group>:
<article-title>Elements of Information Theory</article-title>. (John Wiley &#x00026; Sons).<year>2006</year>
<ext-link ext-link-type="uri" xlink:href="http://dl.acm.org/citation.cfm?id=1146355">Reference Source</ext-link></mixed-citation></ref><ref id="ref-39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet-Dupeyron</surname><given-names>MN</given-names></name><name><surname>Combes</surname><given-names>P</given-names></name><name><surname>Santander</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>PLP1 splicing abnormalities identified in Pelizaeus-Merzbacher disease and SPG2 fibroblasts are associated with different types of mutations.</article-title><source><italic>Hum Mutat.</italic></source><year>2008</year>;<volume>29</volume>(<issue>8</issue>):<fpage>1028</fpage>&#x02013;<lpage>1036</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20758</pub-id><?supplied-pmid 18470932?><pub-id pub-id-type="pmid">18470932</pub-id></mixed-citation></ref><ref id="ref-40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Zou</surname><given-names>GY</given-names></name></person-group>:
<article-title>Best practices for evaluating mutation prediction methods.</article-title><source><italic>Hum Mutat.</italic></source><year>2013</year>;<volume>34</volume>(<issue>11</issue>):<fpage>1581</fpage>&#x02013;<lpage>1582</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22401</pub-id><?supplied-pmid 23955774?><pub-id pub-id-type="pmid">23955774</pub-id></mixed-citation></ref><ref id="ref-41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirley</surname><given-names>BC</given-names></name><name><surname>Mucaki</surname><given-names>EJ</given-names></name><name><surname>Whitehead</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Interpretation, stratification and evidence for sequence variants affecting mRNA splicing in complete human genome sequences.</article-title><source><italic>Genomics Proteomics Bioinformatics.</italic></source><year>2013</year>;<volume>11</volume>(<issue>2</issue>):<fpage>77</fpage>&#x02013;<lpage>85</lpage>.
<pub-id pub-id-type="doi">10.1016/j.gpb.2013.01.008</pub-id><?supplied-pmid 23499923?><pub-id pub-id-type="pmid">23499923</pub-id></mixed-citation></ref><ref id="ref-42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benaglio</surname><given-names>P</given-names></name><name><surname>San Jose</surname><given-names>PF</given-names></name><name><surname>Avila-Fernandez</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Mutational screening of splicing factor genes in cases with autosomal dominant retinitis pigmentosa.</article-title><source><italic>Mol Vis.</italic></source><year>2014</year>;<volume>20</volume>:<fpage>843</fpage>&#x02013;<lpage>851</lpage>.
<!--<pub-id pub-id-type="pmcid">4063357</pub-id>--><?supplied-pmid 24959063?><pub-id pub-id-type="pmid">24959063</pub-id></mixed-citation></ref><ref id="ref-43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viner</surname><given-names>C</given-names></name><name><surname>Dorman</surname><given-names>SN</given-names></name><name><surname>Shirley</surname><given-names>BC</given-names></name><etal/></person-group>:
<article-title>Validation of predicted mRNA splicing mutations using high-throughput transcriptome data.</article-title><source><italic>F1000Res.</italic></source><year>2014</year>;<volume>3</volume>:<fpage>8</fpage>.
<pub-id pub-id-type="doi">10.12688/f1000research.3-8.v2</pub-id><!--<pub-id pub-id-type="pmcid">3983938</pub-id>--><?supplied-pmid 24741438?><pub-id pub-id-type="pmid">24741438</pub-id></mixed-citation></ref><ref id="ref-44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorman</surname><given-names>S</given-names></name><name><surname>Viner</surname><given-names>C</given-names></name><name><surname>Rogan</surname><given-names>P</given-names></name></person-group>:
<article-title>Splicing Mutation Analysis Reveals Previously Unrecognized Pathways in Lymph Node-Invasive Breast Cancer</article-title>. In Press.
<source><italic>Sci Rep.</italic></source><year>2014</year>.</mixed-citation></ref><ref id="ref-45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>MR</given-names></name></person-group>:
<article-title>Pre-mRNA splicing.</article-title><source><italic>Annu Rev Genet.</italic></source><year>1986</year>;<volume>20</volume>:<fpage>671</fpage>&#x02013;<lpage>708</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev.ge.20.120186.003323</pub-id><?supplied-pmid 2880558?><pub-id pub-id-type="pmid">2880558</pub-id></mixed-citation></ref><ref id="ref-46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Reed</surname><given-names>R</given-names></name></person-group>:
<article-title>The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing.</article-title><source><italic>Nature.</italic></source><year>1987</year>;<volume>325</volume>(<issue>6106</issue>):<fpage>673</fpage>&#x02013;<lpage>678</lpage>.
<pub-id pub-id-type="doi">10.1038/325673a0</pub-id><?supplied-pmid 2950324?><pub-id pub-id-type="pmid">2950324</pub-id></mixed-citation></ref><ref id="ref-47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>SG</given-names></name><name><surname>Metin</surname><given-names>A</given-names></name><name><surname>Gozukara</surname><given-names>E</given-names></name><etal/></person-group>:
<article-title>Two essential splice lariat branchpoint sequences in one intron in a xeroderma pigmentosum DNA repair gene: mutations result in reduced XPC mRNA levels that correlate with cancer risk.</article-title><source><italic>Hum Mol Genet.</italic></source><year>2004</year>;<volume>13</volume>(<issue>3</issue>):<fpage>343</fpage>&#x02013;<lpage>352</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddh026</pub-id><?supplied-pmid 14662655?><pub-id pub-id-type="pmid">14662655</pub-id></mixed-citation></ref><ref id="ref-48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname><given-names>J</given-names></name></person-group>:
<article-title>Splice Site Mutation-Induced Alteration of Selective Regional Activity Correlates with the Role of a Gene in Cardiomyopathy.</article-title><source><italic>J Clin Exp Cardiol.</italic></source><year>2013</year>;<volume>1</volume>.</mixed-citation></ref><ref id="ref-49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robberson</surname><given-names>BL</given-names></name><name><surname>Cote</surname><given-names>GJ</given-names></name><name><surname>Berget</surname><given-names>SM</given-names></name></person-group>:
<article-title>Exon definition may facilitate splice site selection in RNAs with multiple exons.</article-title><source><italic>Mol Cell Biol.</italic></source><year>1990</year>;<volume>10</volume>(<issue>1</issue>):<fpage>84</fpage>&#x02013;<lpage>94</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.10.1.84</pub-id><!--<pub-id pub-id-type="pmcid">360715</pub-id>--><?supplied-pmid 2136768?><pub-id pub-id-type="pmid">2136768</pub-id></mixed-citation></ref><ref id="ref-50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smaoui</surname><given-names>N</given-names></name><name><surname>Beltaief</surname><given-names>O</given-names></name><name><surname>BenHamed</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>A homozygous splice mutation in the HSF4 gene is associated with an autosomal recessive congenital cataract.</article-title><source><italic>Invest Ophthalmol Vis Sci.</italic></source><year>2004</year>;<volume>45</volume>(<issue>8</issue>):<fpage>2716</fpage>&#x02013;<lpage>2721</lpage>.
<pub-id pub-id-type="doi">10.1167/iovs.03-1370</pub-id><?supplied-pmid 15277496?><pub-id pub-id-type="pmid">15277496</pub-id></mixed-citation></ref><ref id="ref-51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Sosnay</surname><given-names>PR</given-names></name><name><surname>Ramalho</surname><given-names>AS</given-names></name><etal/></person-group>:
<article-title>Experimental assessment of splicing variants using expression minigenes and comparison with
<italic>in silico</italic> predictions.</article-title><source><italic>Hum Mutat.</italic></source><year>2014</year>;<volume>35</volume>(<issue>10</issue>):<fpage>1249</fpage>&#x02013;<lpage>1259</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22624</pub-id><?supplied-pmid 25066652?><pub-id pub-id-type="pmid">25066652</pub-id></mixed-citation></ref><ref id="ref-52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riveira-Munoz</surname><given-names>E</given-names></name><name><surname>Devuyst</surname><given-names>O</given-names></name><name><surname>Belge</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>Evaluating PVALB as a candidate gene for SLC12A3-negative cases of Gitelman&#x02019;s syndrome.</article-title><source><italic>Nephrol Dial Transplant.</italic></source><year>2008</year>;<volume>23</volume>(<issue>10</issue>):<fpage>3120</fpage>&#x02013;<lpage>3125</lpage>.
<pub-id pub-id-type="doi">10.1093/ndt/gfn229</pub-id><?supplied-pmid 18469313?><pub-id pub-id-type="pmid">18469313</pub-id></mixed-citation></ref><ref id="ref-53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaltin</surname><given-names>F</given-names></name><name><surname>Ibsirlioglu</surname><given-names>T</given-names></name><name><surname>Taskiran</surname><given-names>EZ</given-names></name><etal/></person-group>:
<article-title>Disruption of PTPRO causes childhood-onset nephrotic syndrome.</article-title><source><italic>Am J Hum Genet.</italic></source><year>2011</year>;<volume>89</volume>(<issue>1</issue>):<fpage>139</fpage>&#x02013;<lpage>147</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ajhg.2011.05.026</pub-id><!--<pub-id pub-id-type="pmcid">3135805</pub-id>--><?supplied-pmid 21722858?><pub-id pub-id-type="pmid">21722858</pub-id></mixed-citation></ref><ref id="ref-54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Leo</surname><given-names>E</given-names></name><name><surname>Magnolo</surname><given-names>L</given-names></name><name><surname>Pinotti</surname><given-names>E</given-names></name><etal/></person-group>:
<article-title>Functional analysis of two novel splice site mutations of APOB gene in familial hypobetalipoproteinemia.</article-title><source><italic>Mol Genet Metab.</italic></source><year>2009</year>;<volume>96</volume>(<issue>2</issue>):<fpage>66</fpage>&#x02013;<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymgme.2008.10.016</pub-id><?supplied-pmid 19084451?><pub-id pub-id-type="pmid">19084451</pub-id></mixed-citation></ref><ref id="ref-55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behzadnia</surname><given-names>N</given-names></name><name><surname>Golas</surname><given-names>MM</given-names></name><name><surname>Hartmuth</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes.</article-title><source><italic>EMBO J.</italic></source><year>2007</year>;<volume>26</volume>(<issue>6</issue>):<fpage>1737</fpage>&#x02013;<lpage>1748</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.emboj.7601631</pub-id><!--<pub-id pub-id-type="pmcid">1829389</pub-id>--><?supplied-pmid 17332742?><pub-id pub-id-type="pmid">17332742</pub-id></mixed-citation></ref><ref id="ref-56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staley</surname><given-names>JP</given-names></name><name><surname>Guthrie</surname><given-names>C</given-names></name></person-group>:
<article-title>Mechanical devices of the spliceosome: motors, clocks, springs, and things.</article-title><source><italic>Cell.</italic></source><year>1998</year>;<volume>92</volume>(<issue>3</issue>):<fpage>315</fpage>&#x02013;<lpage>326</lpage>.
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80925-3</pub-id><?supplied-pmid 9476892?><pub-id pub-id-type="pmid">9476892</pub-id></mixed-citation></ref><ref id="ref-57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawczak</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>NS</given-names></name><name><surname>Hundrieser</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing.</article-title><source><italic>Hum Mutat.</italic></source><year>2007</year>;<volume>28</volume>(<issue>2</issue>):<fpage>150</fpage>&#x02013;<lpage>158</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20400</pub-id><?supplied-pmid 17001642?><pub-id pub-id-type="pmid">17001642</pub-id></mixed-citation></ref><ref id="ref-58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mort</surname><given-names>M</given-names></name><name><surname>Sterne-Weiler</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>MutPred Splice: machine learning-based prediction of exonic variants that disrupt splicing.</article-title><source><italic>Genome Biol.</italic></source><year>2014</year>;<volume>15</volume>(<issue>1</issue>):<fpage>R19</fpage>.
<pub-id pub-id-type="doi">10.1186/gb-2014-15-1-r19</pub-id><!--<pub-id pub-id-type="pmcid">4054890</pub-id>--><?supplied-pmid 24451234?><pub-id pub-id-type="pmid">24451234</pub-id></mixed-citation></ref><ref id="ref-59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Chasin</surname><given-names>LA</given-names></name></person-group>:
<article-title>Multiple splicing defects in an intronic false exon.</article-title><source><italic>Mol Cell Biol.</italic></source><year>2000</year>;<volume>20</volume>(<issue>17</issue>):<fpage>6414</fpage>&#x02013;<lpage>6425</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.20.17.6414-6425.2000</pub-id><!--<pub-id pub-id-type="pmcid">86117</pub-id>--><?supplied-pmid 10938119?><pub-id pub-id-type="pmid">10938119</pub-id></mixed-citation></ref><ref id="ref-60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treisman</surname><given-names>R</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group>:
<article-title>Specific transcription and RNA splicing defects in five cloned beta-thalassaemia genes.</article-title><source><italic>Nature.</italic></source><year>1983</year>;<volume>302</volume>(<issue>5909</issue>):<fpage>591</fpage>&#x02013;<lpage>596</lpage>.
<pub-id pub-id-type="doi">10.1038/302591a0</pub-id><?supplied-pmid 6188062?><pub-id pub-id-type="pmid">6188062</pub-id></mixed-citation></ref><ref id="ref-61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ElSharawy</surname><given-names>A</given-names></name><name><surname>Hundrieser</surname><given-names>B</given-names></name><name><surname>Brosch</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Systematic evaluation of the effect of common SNPs on pre-mRNA splicing.</article-title><source><italic>Hum Mutat.</italic></source><year>2009</year>;<volume>30</volume>(<issue>4</issue>):<fpage>625</fpage>&#x02013;<lpage>632</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20906</pub-id><?supplied-pmid 19191320?><pub-id pub-id-type="pmid">19191320</pub-id></mixed-citation></ref><ref id="ref-62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E</given-names></name><name><surname>Baralle</surname><given-names>M</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name></person-group>:
<article-title>Defective splicing, disease and therapy: searching for master checkpoints in exon definition.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2006</year>;<volume>34</volume>(<issue>12</issue>):<fpage>3494</fpage>&#x02013;<lpage>3510</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkl498</pub-id><!--<pub-id pub-id-type="pmcid">1524908</pub-id>--><?supplied-pmid 16855287?><pub-id pub-id-type="pmid">16855287</pub-id></mixed-citation></ref><ref id="ref-63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapustin</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Sarkar</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>Cryptic splice sites and split genes.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2011</year>;<volume>39</volume>(<issue>14</issue>):<fpage>5837</fpage>&#x02013;<lpage>5844</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkr203</pub-id><!--<pub-id pub-id-type="pmcid">3152350</pub-id>--><?supplied-pmid 21470962?><pub-id pub-id-type="pmid">21470962</pub-id></mixed-citation></ref><ref id="ref-64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MQ</given-names></name></person-group>:
<article-title>Computational prediction of eukaryotic protein-coding genes.</article-title><source><italic>Nat Rev Genet.</italic></source><year>2002</year>;<volume>3</volume>(<issue>9</issue>):<fpage>698</fpage>&#x02013;<lpage>709</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg890</pub-id><?supplied-pmid 12209144?><pub-id pub-id-type="pmid">12209144</pub-id></mixed-citation></ref><ref id="ref-65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>XD</given-names></name></person-group>:
<article-title>The superfamily of arginine/serine-rich splicing factors.</article-title><source><italic>RNA.</italic></source><year>1995</year>;<volume>1</volume>(<issue>7</issue>):<fpage>663</fpage>&#x02013;<lpage>680</lpage>.
<!--<pub-id pub-id-type="pmcid">1369309</pub-id>--><?supplied-pmid 7585252?><pub-id pub-id-type="pmid">7585252</pub-id></mixed-citation></ref><ref id="ref-66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graveley</surname><given-names>BR</given-names></name></person-group>:
<article-title>Sorting out the complexity of SR protein functions.</article-title><source><italic>RNA.</italic></source><year>2000</year>;<volume>6</volume>(<issue>9</issue>):<fpage>1197</fpage>&#x02013;<lpage>1211</lpage>.
<pub-id pub-id-type="doi">10.1017/S1355838200000960</pub-id><!--<pub-id pub-id-type="pmcid">1369994</pub-id>--><?supplied-pmid 10999598?><pub-id pub-id-type="pmid">10999598</pub-id></mixed-citation></ref><ref id="ref-67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Kohlstaedt</surname><given-names>LA</given-names></name><name><surname>Damianov</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Polypyrimidine tract binding protein controls the transition from exon definition to an intron defined spliceosome.</article-title><source><italic>Nat Struct Mol Biol.</italic></source><year>2008</year>;<volume>15</volume>(<issue>2</issue>):<fpage>183</fpage>&#x02013;<lpage>191</lpage>.
<pub-id pub-id-type="doi">10.1038/nsmb.1375</pub-id><!--<pub-id pub-id-type="pmcid">2546704</pub-id>--><?supplied-pmid 18193060?><pub-id pub-id-type="pmid">18193060</pub-id></mixed-citation></ref><ref id="ref-68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>ZM</given-names></name><name><surname>Huynen</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>CC</given-names></name></person-group>:
<article-title>A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>1998</year>;<volume>95</volume>(<issue>24</issue>):<fpage>14088</fpage>&#x02013;<lpage>14093</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.95.24.14088</pub-id><!--<pub-id pub-id-type="pmcid">24331</pub-id>--><?supplied-pmid 9826658?><pub-id pub-id-type="pmid">9826658</pub-id></mixed-citation></ref><ref id="ref-69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>House</surname><given-names>AE</given-names></name><name><surname>Lynch</surname><given-names>KW</given-names></name></person-group>:
<article-title>An exonic splicing silencer represses spliceosome assembly after ATP-dependent exon recognition.</article-title><source><italic>Nat Struct Mol Biol.</italic></source><year>2006</year>;<volume>13</volume>(<issue>10</issue>):<fpage>937</fpage>&#x02013;<lpage>944</lpage>.
<pub-id pub-id-type="doi">10.1038/nsmb1149</pub-id><?supplied-pmid 16998487?><pub-id pub-id-type="pmid">16998487</pub-id></mixed-citation></ref><ref id="ref-70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Mattox</surname><given-names>W</given-names></name></person-group>:
<article-title>Activation and repression functions of an SR splicing regulator depend on exonic versus intronic-binding position.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2012</year>;<volume>40</volume>(<issue>1</issue>):<fpage>428</fpage>&#x02013;<lpage>437</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkr713</pub-id><!--<pub-id pub-id-type="pmcid">3245930</pub-id>--><?supplied-pmid 21914724?><pub-id pub-id-type="pmid">21914724</pub-id></mixed-citation></ref><ref id="ref-71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkelenz</surname><given-names>S</given-names></name><name><surname>Mueller</surname><given-names>WF</given-names></name><name><surname>Evans</surname><given-names>MS</given-names></name><etal/></person-group>:
<article-title>Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms.</article-title><source><italic>RNA.</italic></source><year>2013</year>;<volume>19</volume>(<issue>1</issue>):<fpage>96</fpage>&#x02013;<lpage>102</lpage>.
<pub-id pub-id-type="doi">10.1261/rna.037044.112</pub-id><!--<pub-id pub-id-type="pmcid">3527730</pub-id>--><?supplied-pmid 23175589?><pub-id pub-id-type="pmid">23175589</pub-id></mixed-citation></ref><ref id="ref-72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zatkova</surname><given-names>A</given-names></name><name><surname>Messiaen</surname><given-names>L</given-names></name><name><surname>Vandenbroucke</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1.</article-title><source><italic>Hum Mutat.</italic></source><year>2004</year>;<volume>24</volume>(<issue>6</issue>):<fpage>491</fpage>&#x02013;<lpage>501</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20103</pub-id><?supplied-pmid 15523642?><pub-id pub-id-type="pmid">15523642</pub-id></mixed-citation></ref><ref id="ref-73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>V</given-names></name><name><surname>Theisen</surname><given-names>P</given-names></name><name><surname>Antunes</surname><given-names>O</given-names></name><etal/></person-group>:
<article-title>A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14.</article-title><source><italic>Mutat Res.</italic></source><year>2009</year>;<volume>662</volume>(<issue>1&#x02013;2</issue>):<fpage>33</fpage>&#x02013;<lpage>36</lpage>.
<pub-id pub-id-type="doi">10.1016/j.mrfmmm.2008.12.001</pub-id><?supplied-pmid 19111562?><pub-id pub-id-type="pmid">19111562</pub-id></mixed-citation></ref><ref id="ref-74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyajima</surname><given-names>H</given-names></name><name><surname>Miyaso</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Identification of a cis-acting element for the regulation of SMN exon 7 splicing.</article-title><source><italic>J Biol Chem.</italic></source><year>2002</year>;<volume>277</volume>(<issue>26</issue>):<fpage>23271</fpage>&#x02013;<lpage>23277</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M200851200</pub-id><?supplied-pmid 11956196?><pub-id pub-id-type="pmid">11956196</pub-id></mixed-citation></ref><ref id="ref-75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>R</given-names></name><name><surname>MacLaren</surname><given-names>RE</given-names></name><name><surname>Davidson</surname><given-names>AE</given-names></name><etal/></person-group>:
<article-title>ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing.</article-title><source><italic>J Med Genet.</italic></source><year>2009</year>;<volume>46</volume>(<issue>9</issue>):<fpage>620</fpage>&#x02013;<lpage>625</lpage>.
<pub-id pub-id-type="doi">10.1136/jmg.2008.059881</pub-id><?supplied-pmid 18611979?><pub-id pub-id-type="pmid">18611979</pub-id></mixed-citation></ref><ref id="ref-76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabut</surname><given-names>M</given-names></name><name><surname>Min&#x000e9;</surname><given-names>M</given-names></name><name><surname>Marsac</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>The SR protein SC35 is responsible for aberrant splicing of the E1alpha pyruvate dehydrogenase mRNA in a case of mental retardation with lactic acidosis.</article-title><source><italic>Mol Cell Biol.</italic></source><year>2005</year>;<volume>25</volume>(<issue>8</issue>):<fpage>3286</fpage>&#x02013;<lpage>3294</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.25.8.3286-3294.2005</pub-id><!--<pub-id pub-id-type="pmcid">1069624</pub-id>--><?supplied-pmid 15798212?><pub-id pub-id-type="pmid">15798212</pub-id></mixed-citation></ref><ref id="ref-77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goren</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Amit</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Overlapping splicing regulatory motifs--combinatorial effects on splicing.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2010</year>;<volume>38</volume>(<issue>10</issue>):<fpage>3318</fpage>&#x02013;<lpage>3327</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkq005</pub-id><!--<pub-id pub-id-type="pmcid">2879502</pub-id>--><?supplied-pmid 20110253?><pub-id pub-id-type="pmid">20110253</pub-id></mixed-citation></ref><ref id="ref-78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahler</surname><given-names>AM</given-names></name><name><surname>Damgaard</surname><given-names>CK</given-names></name><name><surname>Kjems</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing.</article-title><source><italic>J Biol Chem.</italic></source><year>2004</year>;<volume>279</volume>(<issue>11</issue>):<fpage>10077</fpage>&#x02013;<lpage>10084</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M312743200</pub-id><?supplied-pmid 14703516?><pub-id pub-id-type="pmid">14703516</pub-id></mixed-citation></ref><ref id="ref-79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>MY</given-names></name><name><surname>Rooke</surname><given-names>N</given-names></name><name><surname>Turck</surname><given-names>CW</given-names></name><etal/></person-group>:
<article-title>hnRNP H is a component of a splicing enhancer complex that activates a c-src alternative exon in neuronal cells.</article-title><source><italic>Mol Cell Biol.</italic></source><year>1999</year>;<volume>19</volume>(<issue>1</issue>):<fpage>69</fpage>&#x02013;<lpage>77</lpage>.
<!--<pub-id pub-id-type="pmcid">9858532</pub-id>--><?supplied-pmid 9858532?><pub-id pub-id-type="pmid">9858532</pub-id></mixed-citation></ref><ref id="ref-80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the &#x003bc; opioid receptor gene OPRM1 via hnRNPH interactions.</article-title><source><italic>J Neurosci.</italic></source><year>2014</year>;<volume>34</volume>(<issue>33</issue>):<fpage>11048</fpage>&#x02013;<lpage>11066</lpage>.
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3986-13.2014</pub-id><!--<pub-id pub-id-type="pmcid">4131016</pub-id>--><?supplied-pmid 25122903?><pub-id pub-id-type="pmid">25122903</pub-id></mixed-citation></ref><ref id="ref-81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>XD</given-names></name><name><surname>Ares</surname><given-names>M</given-names><suffix>Jr</suffix></name></person-group>:
<article-title>Context-dependent control of alternative splicing by RNA-binding proteins.</article-title><source><italic>Nat Rev Genet.</italic></source><year>2014</year>;<volume>15</volume>(<issue>10</issue>):<fpage>689</fpage>&#x02013;<lpage>701</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg3778</pub-id><?supplied-pmid 25112293?><pub-id pub-id-type="pmid">25112293</pub-id></mixed-citation></ref><ref id="ref-82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercado</surname><given-names>PA</given-names></name><name><surname>Ayala</surname><given-names>YM</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2005</year>;<volume>33</volume>(<issue>18</issue>):<fpage>6000</fpage>&#x02013;<lpage>6010</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gki897</pub-id><!--<pub-id pub-id-type="pmcid">1270946</pub-id>--><?supplied-pmid 16254078?><pub-id pub-id-type="pmid">16254078</pub-id></mixed-citation></ref><ref id="ref-83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huelga</surname><given-names>SC</given-names></name><name><surname>Vu</surname><given-names>AQ</given-names></name><name><surname>Arnold</surname><given-names>JD</given-names></name><etal/></person-group>:
<article-title>Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins.</article-title><source><italic>Cell Rep.</italic></source><year>2012</year>;<volume>1</volume>(<issue>2</issue>):<fpage>167</fpage>&#x02013;<lpage>178</lpage>.
<pub-id pub-id-type="doi">10.1016/j.celrep.2012.02.001</pub-id><!--<pub-id pub-id-type="pmcid">3345519</pub-id>--><?supplied-pmid 22574288?><pub-id pub-id-type="pmid">22574288</pub-id></mixed-citation></ref><ref id="ref-84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavanez</surname><given-names>JP</given-names></name><name><surname>Madl</surname><given-names>T</given-names></name><name><surname>Kooshapur</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>hnRNP A1 proofreads 3&#x000b4; splice site recognition by U2AF.</article-title><source><italic>Mol Cell.</italic></source><year>2012</year>;<volume>45</volume>(<issue>3</issue>):<fpage>314</fpage>&#x02013;<lpage>329</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2011.11.033</pub-id><?supplied-pmid 22325350?><pub-id pub-id-type="pmid">22325350</pub-id></mixed-citation></ref><ref id="ref-85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caputi</surname><given-names>M</given-names></name><name><surname>Freund</surname><given-names>M</given-names></name><name><surname>Kammler</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expression.</article-title><source><italic>J Virol.</italic></source><year>2004</year>;<volume>78</volume>(<issue>12</issue>):<fpage>6517</fpage>&#x02013;<lpage>6526</lpage>.
<pub-id pub-id-type="doi">10.1128/JVI.78.12.6517-6526.2004</pub-id><!--<pub-id pub-id-type="pmcid">416506</pub-id>--><?supplied-pmid 15163745?><pub-id pub-id-type="pmid">15163745</pub-id></mixed-citation></ref><ref id="ref-86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Expert-Bezan&#x000e7;on</surname><given-names>A</given-names></name><name><surname>Sureau</surname><given-names>A</given-names></name><name><surname>Durosay</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B.</article-title><source><italic>J Biol Chem.</italic></source><year>2004</year>;<volume>279</volume>(<issue>37</issue>):<fpage>38249</fpage>&#x02013;<lpage>38259</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.M405377200</pub-id><?supplied-pmid 15208309?><pub-id pub-id-type="pmid">15208309</pub-id></mixed-citation></ref><ref id="ref-87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HX</given-names></name><name><surname>Chew</surname><given-names>SL</given-names></name><name><surname>Cartegni</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Exonic splicing enhancer motif recognized by human SC35 under splicing conditions.</article-title><source><italic>Mol Cell Biol.</italic></source><year>2000</year>;<volume>20</volume>(<issue>3</issue>):<fpage>1063</fpage>&#x02013;<lpage>1071</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.20.3.1063-1071.2000</pub-id><!--<pub-id pub-id-type="pmcid">85223</pub-id>--><?supplied-pmid 10629063?><pub-id pub-id-type="pmid">10629063</pub-id></mixed-citation></ref><ref id="ref-88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandit</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shiue</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing.</article-title><source><italic>Mol Cell.</italic></source><year>2013</year>;<volume>50</volume>(<issue>2</issue>):<fpage>223</fpage>&#x02013;<lpage>235</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2013.03.001</pub-id><!--<pub-id pub-id-type="pmcid">3640356</pub-id>--><?supplied-pmid 23562324?><pub-id pub-id-type="pmid">23562324</pub-id></mixed-citation></ref><ref id="ref-89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>JH</given-names></name><name><surname>Byeon</surname><given-names>CW</given-names></name><etal/></person-group>:
<article-title>SR proteins induce alternative exon skipping through their activities on the flanking constitutive exons.</article-title><source><italic>Mol Cell Biol.</italic></source><year>2011</year>;<volume>31</volume>(<issue>4</issue>):<fpage>793</fpage>&#x02013;<lpage>802</lpage>.
<pub-id pub-id-type="doi">10.1128/MCB.01117-10</pub-id><!--<pub-id pub-id-type="pmcid">3028638</pub-id>--><?supplied-pmid 21135118?><pub-id pub-id-type="pmid">21135118</pub-id></mixed-citation></ref><ref id="ref-90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shultz</surname><given-names>JC</given-names></name><name><surname>Goehe</surname><given-names>RW</given-names></name><name><surname>Murudkar</surname><given-names>CS</given-names></name><etal/></person-group>:
<article-title>SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.</article-title><source><italic>Mol Cancer Res.</italic></source><year>2011</year>;<volume>9</volume>(<issue>7</issue>):<fpage>889</fpage>&#x02013;<lpage>900</lpage>.
<pub-id pub-id-type="doi">10.1158/1541-7786.MCR-11-0061</pub-id><!--<pub-id pub-id-type="pmcid">3140550</pub-id>--><?supplied-pmid 21622622?><pub-id pub-id-type="pmid">21622622</pub-id></mixed-citation></ref><ref id="ref-91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradis</surname><given-names>C</given-names></name><name><surname>Cloutier</surname><given-names>P</given-names></name><name><surname>Shkreta</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>hnRNP I/PTB can antagonize the splicing repressor activity of SRp30c.</article-title><source><italic>RNA.</italic></source><year>2007</year>;<volume>13</volume>(<issue>8</issue>):<fpage>1287</fpage>&#x02013;<lpage>1300</lpage>.
<pub-id pub-id-type="doi">10.1261/rna.403607</pub-id><!--<pub-id pub-id-type="pmcid">1924885</pub-id>--><?supplied-pmid 17548433?><pub-id pub-id-type="pmid">17548433</pub-id></mixed-citation></ref><ref id="ref-92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>N</given-names></name><name><surname>Corcoran</surname><given-names>DL</given-names></name><name><surname>Nusbaum</surname><given-names>JD</given-names></name><etal/></person-group>:
<article-title>Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability.</article-title><source><italic>Mol Cell.</italic></source><year>2011</year>;<volume>43</volume>(<issue>3</issue>):<fpage>327</fpage>&#x02013;<lpage>339</lpage>.
<pub-id pub-id-type="doi">10.1016/j.molcel.2011.06.007</pub-id><!--<pub-id pub-id-type="pmcid">3220597</pub-id>--><?supplied-pmid 21723170?><pub-id pub-id-type="pmid">21723170</pub-id></mixed-citation></ref><ref id="ref-93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uren</surname><given-names>PJ</given-names></name><name><surname>Burns</surname><given-names>SC</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Genomic analyses of the RNA-binding protein Hu antigen R (HuR) identify a complex network of target genes and novel characteristics of its binding sites.</article-title><source><italic>J Biol Chem.</italic></source><year>2011</year>;<volume>286</volume>(<issue>43</issue>):<fpage>37063</fpage>&#x02013;<lpage>37066</lpage>.
<pub-id pub-id-type="doi">10.1074/jbc.C111.266882</pub-id><!--<pub-id pub-id-type="pmcid">3199453</pub-id>--><?supplied-pmid 21890634?><pub-id pub-id-type="pmid">21890634</pub-id></mixed-citation></ref><ref id="ref-94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;lsch</surname><given-names>H</given-names></name><name><surname>L&#x000fc;tjohann</surname><given-names>D</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>CYP46A1 variants influence Alzheimer&#x02019;s disease risk and brain cholesterol metabolism.</article-title><source><italic>Eur Psychiatry.</italic></source><year>2009</year>;<volume>24</volume>(<issue>3</issue>):<fpage>183</fpage>&#x02013;<lpage>190</lpage>.
<pub-id pub-id-type="doi">10.1016/j.eurpsy.2008.12.005</pub-id><?supplied-pmid 19286353?><pub-id pub-id-type="pmid">19286353</pub-id></mixed-citation></ref><ref id="ref-95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>SG</given-names></name><name><surname>Levy</surname><given-names>HL</given-names></name><name><surname>Legerski</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>Xeroderma pigmentosum group C splice mutation associated with autism and hypoglycinemia.</article-title><source><italic>J Invest Dermatol.</italic></source><year>1998</year>;<volume>111</volume>(<issue>5</issue>):<fpage>791</fpage>&#x02013;<lpage>796</lpage>.
<pub-id pub-id-type="doi">10.1046/j.1523-1747.1998.00391.x</pub-id><?supplied-pmid 9804340?><pub-id pub-id-type="pmid">9804340</pub-id></mixed-citation></ref><ref id="ref-96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruszak</surname><given-names>A</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Gustaw</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>PIN1 gene variants in Alzheimer&#x02019;s disease.</article-title><source><italic>BMC Med Genet.</italic></source><year>2009</year>;<volume>10</volume>:<fpage>115</fpage>.
<pub-id pub-id-type="doi">10.1186/1471-2350-10-115</pub-id><!--<pub-id pub-id-type="pmcid">2781804</pub-id>--><?supplied-pmid 19909517?><pub-id pub-id-type="pmid">19909517</pub-id></mixed-citation></ref><ref id="ref-97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caux-Moncoutier</surname><given-names>V</given-names></name><name><surname>Pag&#x000e8;s-Berhouet</surname><given-names>S</given-names></name><name><surname>Michaux</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study.</article-title><source><italic>Eur J Hum Genet.</italic></source><year>2009</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1471</fpage>&#x02013;<lpage>1480</lpage>.
<pub-id pub-id-type="doi">10.1038/ejhg.2009.89</pub-id><!--<pub-id pub-id-type="pmcid">2986693</pub-id>--><?supplied-pmid 19471317?><pub-id pub-id-type="pmid">19471317</pub-id></mixed-citation></ref><ref id="ref-98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vockley</surname><given-names>J</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Anderson</surname><given-names>BD</given-names></name><etal/></person-group>:
<article-title>Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD gene.</article-title><source><italic>Am J Hum Genet.</italic></source><year>2000</year>;<volume>66</volume>(<issue>2</issue>):<fpage>356</fpage>&#x02013;<lpage>367</lpage>.
<pub-id pub-id-type="doi">10.1086/302751</pub-id><!--<pub-id pub-id-type="pmcid">1288088</pub-id>--><?supplied-pmid 10677295?><pub-id pub-id-type="pmid">10677295</pub-id></mixed-citation></ref><ref id="ref-99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vemula</surname><given-names>SR</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>:
<article-title>A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia.</article-title><source><italic>Mol Genet Genomic Med.</italic></source><year>2014</year>;<volume>2</volume>(<issue>3</issue>):<fpage>261</fpage>&#x02013;<lpage>272</lpage>.
<pub-id pub-id-type="doi">10.1002/mgg3.67</pub-id><!--<pub-id pub-id-type="pmcid">4049367</pub-id>--><?supplied-pmid 24936516?><pub-id pub-id-type="pmid">24936516</pub-id></mixed-citation></ref><ref id="ref-100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astuto</surname><given-names>LM</given-names></name><name><surname>Kelley</surname><given-names>PM</given-names></name><name><surname>Askew</surname><given-names>JW</given-names></name><etal/></person-group>:
<article-title>Searching for evidence of DFNB2.</article-title><source><italic>Am J Med Genet.</italic></source><year>2002</year>;<volume>109</volume>(<issue>4</issue>):<fpage>291</fpage>&#x02013;<lpage>297</lpage>.
<pub-id pub-id-type="doi">10.1002/ajmg.10384</pub-id><?supplied-pmid 11992483?><pub-id pub-id-type="pmid">11992483</pub-id></mixed-citation></ref><ref id="ref-101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Jim&#x000e9;nez</surname><given-names>E</given-names></name><name><surname>de Campos</surname><given-names>JM</given-names></name><name><surname>Kusak</surname><given-names>EM</given-names></name><etal/></person-group>:
<article-title>
<italic>SDHC</italic> mutation in an elderly patient without familial antecedents.</article-title><source><italic>Clin Endocrinol (Oxf).</italic></source><year>2008</year>;<volume>69</volume>(<issue>6</issue>):<fpage>906</fpage>&#x02013;<lpage>910</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2265.2008.03368.x</pub-id><?supplied-pmid 18681855?><pub-id pub-id-type="pmid">18681855</pub-id></mixed-citation></ref><ref id="ref-102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baturina</surname><given-names>OA</given-names></name><name><surname>Lukjanova</surname><given-names>TV</given-names></name><name><surname>Tupikin</surname><given-names>AE</given-names></name><etal/></person-group>:
<article-title>PAH And QDPR Deficiency Associated Mutations In The Novosirirsk Rregion Of The Russian Federation: Correlation Of Mutation Type With Sisease Manifestation And Severity.</article-title><source><italic>J Med Biochem.</italic></source><year>2014</year>;<volume>33</volume>(<issue>4</issue>):<fpage>7</fpage>&#x02013;<lpage>14</lpage>
<pub-id pub-id-type="doi">10.2478/jomb-2014-0019</pub-id></mixed-citation></ref><ref id="ref-103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>DP</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>O&#x02019;Prey</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Mutational screening of
<italic>VSX1</italic> in keratoconus patients from the European population.</article-title><source><italic>Eye (Lond).</italic></source><year>2010</year>;<volume>24</volume>(<issue>6</issue>):<fpage>1085</fpage>&#x02013;<lpage>1092</lpage>.
<pub-id pub-id-type="doi">10.1038/eye.2009.217</pub-id><?supplied-pmid 19763142?><pub-id pub-id-type="pmid">19763142</pub-id></mixed-citation></ref><ref id="ref-104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JR</given-names><suffix>Jr</suffix></name><name><surname>Heinrich</surname><given-names>B</given-names></name><name><surname>Mautner</surname><given-names>VF</given-names></name><etal/></person-group>:
<article-title>Effects of splicing mutations on
<italic>NF2</italic>-transcripts: transcript analysis and information theoretic predictions.</article-title><source><italic>Genes Chromosomes Cancer.</italic></source><year>2011</year>;<volume>50</volume>(<issue>8</issue>):<fpage>571</fpage>&#x02013;<lpage>584</lpage>.
<pub-id pub-id-type="doi">10.1002/gcc.20876</pub-id><!--<pub-id pub-id-type="pmcid">3142993</pub-id>--><?supplied-pmid 21563229?><pub-id pub-id-type="pmid">21563229</pub-id></mixed-citation></ref><ref id="ref-105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessagowit</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Woong Oh</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Genotype-phenotype correlation in recessive dystrophic epidermolysis bullosa: when missense doesn't make sense.</article-title><source><italic>J Invest Dermatol.</italic></source><year>2005</year>;<volume>124</volume>(<issue>4</issue>):<fpage>863</fpage>&#x02013;<lpage>866</lpage>.
<pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23650.x</pub-id><?supplied-pmid 15816848?><pub-id pub-id-type="pmid">15816848</pub-id></mixed-citation></ref><ref id="ref-106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YF</given-names></name><name><surname>Imam</surname><given-names>JS</given-names></name><name><surname>Wilkinson</surname><given-names>MF</given-names></name></person-group>:
<article-title>The nonsense-mediated decay RNA surveillance pathway.</article-title><source><italic>Annu Rev Biochem.</italic></source><year>2007</year>;<volume>76</volume>:<fpage>51</fpage>&#x02013;<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1146/annurev.biochem.76.050106.093909</pub-id><?supplied-pmid 17352659?><pub-id pub-id-type="pmid">17352659</pub-id></mixed-citation></ref><ref id="ref-107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>SG</given-names></name><name><surname>Muniz-Medina </surname><given-names>V</given-names></name><name><surname>Shahlavi</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>The human
<italic>XPC</italic> DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2002</year>;<volume>30</volume>(<issue>16</issue>):<fpage>3624</fpage>&#x02013;<lpage>3631</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkf469</pub-id><!--<pub-id pub-id-type="pmcid">134237</pub-id>--><?supplied-pmid 12177305?><pub-id pub-id-type="pmid">12177305</pub-id></mixed-citation></ref><ref id="ref-108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldin</surname><given-names>E</given-names></name><name><surname>Stahl</surname><given-names>S</given-names></name><name><surname>Cooney</surname><given-names>AM</given-names></name><etal/></person-group>:
<article-title>Transfer of a mitochondrial DNA fragment to
<italic>MCOLN1</italic> causes an inherited case of mucolipidosis IV.</article-title><source><italic>Hum Mutat.</italic></source><year>2004</year>;<volume>24</volume>(<issue>6</issue>):<fpage>460</fpage>&#x02013;<lpage>465</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20094</pub-id><?supplied-pmid 15523648?><pub-id pub-id-type="pmid">15523648</pub-id></mixed-citation></ref><ref id="ref-109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloethner</surname><given-names>S</given-names></name><name><surname>Mould</surname><given-names>A</given-names></name><name><surname>Stark</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Identification of
<italic>ARHGEF17</italic>,
<italic>DENND2D</italic>,
<italic>FGFR3</italic>, and
<italic>RB1</italic> mutations in melanoma by inhibition of nonsense-mediated mRNA decay.</article-title><source><italic>Genes Chromosomes Cancer.</italic></source><year>2008</year>;<volume>47</volume>(<issue>12</issue>):<fpage>1076</fpage>&#x02013;<lpage>1085</lpage>.
<pub-id pub-id-type="doi">10.1002/gcc.20598</pub-id><?supplied-pmid 18677770?><pub-id pub-id-type="pmid">18677770</pub-id></mixed-citation></ref><ref id="ref-110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denson</surname><given-names>J</given-names></name><name><surname>Xi</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group>:
<article-title>Screening for inter-individual splicing differences in human GSTM4 and the discovery of a single nucleotide substitution related to the tandem skipping of two exons.</article-title><source><italic>Gene.</italic></source><year>2006</year>;<volume>379</volume>:<fpage>148</fpage>&#x02013;<lpage>155</lpage>.
<pub-id pub-id-type="doi">10.1016/j.gene.2006.05.012</pub-id><?supplied-pmid 16854533?><pub-id pub-id-type="pmid">16854533</pub-id></mixed-citation></ref><ref id="ref-111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Salem</surname><given-names>S</given-names></name><name><surname>Begum</surname><given-names>MA</given-names></name><name><surname>Ali</surname><given-names>BR</given-names></name><etal/></person-group>:
<article-title>A Novel Aberrant Splice Site Mutation in
<italic>RAB23</italic> Leads to an Eight Nucleotide Deletion in the mRNA and Is Responsible for Carpenter Syndrome in a Consanguineous Emirati Family.</article-title><source><italic>Mol Syndromol.</italic></source><year>2013</year>;<volume>3</volume>(<issue>6</issue>):<fpage>255</fpage>&#x02013;<lpage>261</lpage>.
<pub-id pub-id-type="doi">10.1159/000345653</pub-id><!--<pub-id pub-id-type="pmcid">3569107</pub-id>--><?supplied-pmid 23599695?><pub-id pub-id-type="pmid">23599695</pub-id></mixed-citation></ref><ref id="ref-112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Jinda</surname><given-names>W</given-names></name><name><surname>Limwongse</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Run-on mutation in the PAX6 gene and chorioretinal degeneration in autosomal dominant aniridia.</article-title><source><italic>Mol Vis.</italic></source><year>2011</year>;<volume>17</volume>:<fpage>1305</fpage>&#x02013;<lpage>1309</lpage>.
<!--<pub-id pub-id-type="pmcid">3103739</pub-id>--><?supplied-pmid 21633710?><pub-id pub-id-type="pmid">21633710</pub-id></mixed-citation></ref><ref id="ref-113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Giacomo</surname><given-names>D</given-names></name><name><surname>Gaildrat</surname><given-names>P</given-names></name><name><surname>Abuli</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Functional analysis of a large set of
<italic>BRCA2</italic> exon 7 variants highlights the predictive value of hexamer scores in detecting alterations of exonic splicing regulatory elements.</article-title><source><italic>Hum Mutat.</italic></source><year>2013</year>;<volume>34</volume>(<issue>11</issue>):<fpage>1547</fpage>&#x02013;<lpage>1557</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22428</pub-id><?supplied-pmid 23983145?><pub-id pub-id-type="pmid">23983145</pub-id></mixed-citation></ref><ref id="ref-114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aissat</surname><given-names>A</given-names></name><name><surname>de Becdeli&#x000e8;vre</surname><given-names>A</given-names></name><name><surname>Golmard</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Combined computational-experimental analyses of
<italic>CFTR</italic> exon strength uncover predictability of exon-skipping level.</article-title><source><italic>Hum Mutat.</italic></source><year>2013</year>;<volume>34</volume>(<issue>6</issue>):<fpage>873</fpage>&#x02013;<lpage>881</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.22300</pub-id><?supplied-pmid 23420618?><pub-id pub-id-type="pmid">23420618</pub-id></mixed-citation></ref><ref id="ref-115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anczuk&#x000f3;w</surname><given-names>O</given-names></name><name><surname>Buisson</surname><given-names>M</given-names></name><name><surname>Salles</surname><given-names>MJ</given-names></name><etal/></person-group>:
<article-title>Unclassified variants identified in
<italic>BRCA1</italic> exon 11: Consequences on splicing.</article-title><source><italic>Genes Chromosomes Cancer.</italic></source><year>2008</year>;<volume>47</volume>(<issue>5</issue>):<fpage>418</fpage>&#x02013;<lpage>426</lpage>.
<pub-id pub-id-type="doi">10.1002/gcc.20546</pub-id><?supplied-pmid 18273839?><pub-id pub-id-type="pmid">18273839</pub-id></mixed-citation></ref><ref id="ref-116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>De Vecchi</surname><given-names>G</given-names></name><name><surname>Caleca</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Comparative
<italic>in vitro</italic> and
<italic>in silico</italic> analyses of variants in splicing regions of
<italic>BRCA1</italic> and
<italic>BRCA2</italic> genes and characterization of novel pathogenic mutations.</article-title><source><italic>PloS One.</italic></source><year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e57173</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0057173</pub-id><!--<pub-id pub-id-type="pmcid">3579815</pub-id>--><?supplied-pmid 23451180?><pub-id pub-id-type="pmid">23451180</pub-id></mixed-citation></ref><ref id="ref-117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>M</given-names></name><name><surname>Lacaze-Buzy</surname><given-names>L</given-names></name><name><surname>Furio</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Clinical expression and new
<italic>SPINK5</italic> splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations.</article-title><source><italic>J Invest Dermatol.</italic></source><year>2012</year>;<volume>132</volume>(<issue>3 Pt 1</issue>):<fpage>575</fpage>&#x02013;<lpage>582</lpage>.
<pub-id pub-id-type="doi">10.1038/jid.2011.366</pub-id><?supplied-pmid 22089833?><pub-id pub-id-type="pmid">22089833</pub-id></mixed-citation></ref><ref id="ref-118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamba</surname><given-names>V</given-names></name><name><surname>Lamba</surname><given-names>J</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Hepatic CYP2B6 expression: gender and ethnic differences and relationship to
<italic>CYP2B6</italic> genotype and CAR (constitutive androstane receptor) expression.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>2003</year>;<volume>307</volume>(<issue>3</issue>):<fpage>906</fpage>&#x02013;<lpage>922</lpage>.
<pub-id pub-id-type="doi">10.1124/jpet.103.054866</pub-id><?supplied-pmid 14551287?><pub-id pub-id-type="pmid">14551287</pub-id></mixed-citation></ref><ref id="ref-119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Vockley</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Different spectrum of mutations of isovaleryl-CoA dehydrogenase (
<italic>IVD</italic>) gene in Korean patients with isovaleric acidemia.</article-title><source><italic>Mol Genet Metab.</italic></source><year>2007</year>;<volume>92</volume>(<issue>1&#x02013;2</issue>):<fpage>71</fpage>&#x02013;<lpage>77</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymgme.2007.05.003</pub-id><!--<pub-id pub-id-type="pmcid">4136440</pub-id>--><?supplied-pmid 17576084?><pub-id pub-id-type="pmid">17576084</pub-id></mixed-citation></ref><ref id="ref-120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Gu&#x000e9;dard-M&#x000e9;reuze</surname><given-names>S</given-names></name><name><surname>Vach&#x000e9;</surname><given-names>C</given-names></name><name><surname>Molinari</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Sequence contexts that determine the pathogenicity of base substitutions at position +3 of donor splice-sites.</article-title><source><italic>Hum Mutat.</italic></source><year>2009</year>;<volume>30</volume>(<issue>9</issue>):<fpage>1329</fpage>&#x02013;<lpage>1339</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.21070</pub-id><?supplied-pmid 19606495?><pub-id pub-id-type="pmid">19606495</pub-id></mixed-citation></ref><ref id="ref-121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tournier</surname><given-names>I</given-names></name><name><surname>Vezain</surname><given-names>M</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>A large fraction of unclassified variants of the mismatch repair genes
<italic>MLH1</italic> and
<italic>MSH2</italic> is associated with splicing defects.</article-title><source><italic>Hum Mutat.</italic></source><year>2008</year>;<volume>29</volume>(<issue>12</issue>):<fpage>1412</fpage>&#x02013;<lpage>1424</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20796</pub-id><?supplied-pmid 18561205?><pub-id pub-id-type="pmid">18561205</pub-id></mixed-citation></ref><ref id="ref-122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La&#x00161;&#x00161;uthov&#x000e1;</surname><given-names>P</given-names></name><name><surname>Zaliov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Three New
<italic>PLP1</italic> Splicing Mutations Demonstrate Pathogenic and Phenotypic Diversity of Pelizaeus-Merzbacher Disease.</article-title><source><italic>J Child Neurol.</italic></source><year>2013</year>;<volume>29</volume>(<issue>7</issue>):<fpage>924</fpage>&#x02013;<lpage>931</lpage>.
<pub-id pub-id-type="doi">10.1177/0883073813492387</pub-id><?supplied-pmid 23771846?><pub-id pub-id-type="pmid">23771846</pub-id></mixed-citation></ref><ref id="ref-123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hefferon</surname><given-names>TW</given-names></name><name><surname>Broackes-Carter</surname><given-names>FC</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Atypical 5&#x02019; splice sites cause CFTR exon 9 to be vulnerable to skipping.</article-title><source><italic>Am J Hum Genet.</italic></source><year>2002</year>;<volume>71</volume>(<issue>2</issue>):<fpage>294</fpage>&#x02013;<lpage>303</lpage>.
<pub-id pub-id-type="doi">10.1086/341664</pub-id><!--<pub-id pub-id-type="pmcid">379162</pub-id>--><?supplied-pmid 12068373?><pub-id pub-id-type="pmid">12068373</pub-id></mixed-citation></ref><ref id="ref-124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>JP</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name><name><surname>Cariello</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Mutations that alter RNA splicing of the human
<italic>HPRT</italic> gene: a review of the spectrum.</article-title><source><italic>Mutat. Res.</italic></source><year>1998</year>;<volume>411</volume>(<issue>3</issue>):<fpage>179</fpage>&#x02013;<lpage>214</lpage>.
<pub-id pub-id-type="doi">10.1016/S1383-5742(98)00013-1</pub-id><?supplied-pmid 9804951?><pub-id pub-id-type="pmid">9804951</pub-id></mixed-citation></ref><ref id="ref-125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasim</surname><given-names>MT</given-names></name><name><surname>Ogo</surname><given-names>T</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.</article-title><source><italic>Hum Mutat.</italic></source><year>2011</year>;<volume>32</volume>(<issue>12</issue>):<fpage>1385</fpage>&#x02013;<lpage>1389</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.21605</pub-id><?supplied-pmid 21898662?><pub-id pub-id-type="pmid">21898662</pub-id></mixed-citation></ref><ref id="ref-126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocchi</surname><given-names>L</given-names></name><name><surname>Pisciotta</surname><given-names>L</given-names></name><name><surname>Fasano</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Multiple abnormally spliced ABCA1 mRNAs caused by a novel splice site mutation of ABCA1 gene in a patient with Tangier disease.</article-title><source><italic>Clin Chim Acta.</italic></source><year>2010</year>;<volume>411</volume>(<issue>7&#x02013;8</issue>):<fpage>524</fpage>&#x02013;<lpage>530</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cca.2010.01.008</pub-id><?supplied-pmid 20093111?><pub-id pub-id-type="pmid">20093111</pub-id></mixed-citation></ref><ref id="ref-127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Kodolitsch</surname><given-names>Y</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name></person-group>:
<article-title>Predicting severity of haemophilia A and B splicing mutations by information analysis.</article-title><source><italic>Haemophilia.</italic></source><year>2006</year>;<volume>12</volume>(<issue>3</issue>):<fpage>258</fpage>&#x02013;<lpage>262</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2516.2006.01216.x</pub-id><?supplied-pmid 16643211?><pub-id pub-id-type="pmid">16643211</pub-id></mixed-citation></ref><ref id="ref-128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hageman</surname><given-names>GS</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name><name><surname>Johnson</surname><given-names>LV</given-names></name><etal/></person-group>:
<article-title>A common haplotype in the complement regulatory gene factor H (
<italic>HF1/CFH</italic>) predisposes individuals to age-related macular degeneration.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>2005</year>;<volume>102</volume>(<issue>20</issue>):<fpage>7227</fpage>&#x02013;<lpage>7232</lpage>.
<pub-id pub-id-type="doi">10.1073/pnas.0501536102</pub-id><!--<pub-id pub-id-type="pmcid">1088171</pub-id>--><?supplied-pmid 15870199?><pub-id pub-id-type="pmid">15870199</pub-id></mixed-citation></ref><ref id="ref-129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Selma</surname><given-names>Z</given-names></name><name><surname>Yilmaz</surname><given-names>S</given-names></name><name><surname>Schischmanoff</surname><given-names>PO</given-names></name><etal/></person-group>:
<article-title>A novel S115G mutation of CGI-58 in a Turkish patient with Dorfman-Chanarin syndrome.</article-title><source><italic>J Invest Dermatol.</italic></source><year>2007</year>;<volume>127</volume>(<issue>9</issue>):<fpage>2273</fpage>&#x02013;<lpage>2276</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.jid.5700860</pub-id><?supplied-pmid 17495960?><pub-id pub-id-type="pmid">17495960</pub-id></mixed-citation></ref><ref id="ref-130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux-Buisson</surname><given-names>N</given-names></name><name><surname>Rendu</surname><given-names>J</given-names></name><name><surname>Denjoy</surname><given-names>I</given-names></name><etal/></person-group>:
<article-title>Functional analysis reveals splicing mutations of the
<italic>CASQ2</italic> gene in patients with CPVT: implication for genetic counselling and clinical management.</article-title><source><italic>Hum Mutat.</italic></source><year>2011</year>;<volume>32</volume>(<issue>9</issue>):<fpage>995</fpage>&#x02013;<lpage>999</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.21537</pub-id><?supplied-pmid 21618644?><pub-id pub-id-type="pmid">21618644</pub-id></mixed-citation></ref><ref id="ref-131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Systematic polymorphism analysis of the
<italic>CYP2D6</italic> gene in four different geographical Han populations in mainland China.</article-title><source><italic>Genomics.</italic></source><year>2008</year>;<volume>92</volume>(<issue>3</issue>):<fpage>152</fpage>&#x02013;<lpage>158</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ygeno.2008.05.004</pub-id><?supplied-pmid 18632250?><pub-id pub-id-type="pmid">18632250</pub-id></mixed-citation></ref><ref id="ref-132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaweda-Walerych</surname><given-names>K</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Maruszak</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Mitochondrial transcription factor A variants and the risk of Parkinson&#x02019;s disease.</article-title><source><italic>Neurosci Lett.</italic></source><year>2010</year>;<volume>469</volume>(<issue>1</issue>):<fpage>24</fpage>&#x02013;<lpage>29</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neulet.2009.11.037</pub-id><?supplied-pmid 19925850?><pub-id pub-id-type="pmid">19925850</pub-id></mixed-citation></ref><ref id="ref-133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>CR</given-names></name><name><surname>Doris</surname><given-names>PA</given-names></name><etal/></person-group>:
<article-title>The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.</article-title><source><italic>Hum Mol Genet.</italic></source><year>2005</year>;<volume>14</volume>(<issue>19</issue>):<fpage>2829</fpage>&#x02013;<lpage>2837</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddi315</pub-id><!--<pub-id pub-id-type="pmcid">1343524</pub-id>--><?supplied-pmid 16115816?><pub-id pub-id-type="pmid">16115816</pub-id></mixed-citation></ref><ref id="ref-134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allikmets</surname><given-names>R</given-names></name><name><surname>Wasserman</surname><given-names>WW</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Organization of the
<italic>ABCR</italic> gene: analysis of promoter and splice junction sequences.</article-title><source><italic>Gene.</italic></source><year>1998</year>;<volume>215</volume>(<issue>1</issue>):<fpage>111</fpage>&#x02013;<lpage>122</lpage>.
<pub-id pub-id-type="doi">10.1016/S0378-1119(98)00269-8</pub-id><?supplied-pmid 9666097?><pub-id pub-id-type="pmid">9666097</pub-id></mixed-citation></ref><ref id="ref-135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>MA</given-names></name><name><surname>Hsu</surname><given-names>R</given-names></name><name><surname>Keir</surname><given-names>LS</given-names></name><etal/></person-group>:
<article-title>Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development.</article-title><source><italic>Am J Hum Genet.</italic></source><year>2007</year>;<volume>81</volume>(<issue>5</issue>):<fpage>906</fpage>&#x02013;<lpage>912</lpage>.
<!--<pub-id pub-id-type="pmcid">2265657</pub-id>--><?supplied-pmid 17924334?><pub-id pub-id-type="pmid">17924334</pub-id></mixed-citation></ref><ref id="ref-136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henneman</surname><given-names>P</given-names></name><name><surname>Schaap</surname><given-names>FG</given-names></name><name><surname>Rensen</surname><given-names>PC</given-names></name><etal/></person-group>:
<article-title>Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient.</article-title><source><italic>J Intern Med.</italic></source><year>2008</year>;<volume>263</volume>(<issue>1</issue>):<fpage>107</fpage>&#x02013;<lpage>108</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2796.2007.01889.x</pub-id><?supplied-pmid 18088255?><pub-id pub-id-type="pmid">18088255</pub-id></mixed-citation></ref><ref id="ref-137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>K</given-names></name><name><surname>Rama Devi</surname><given-names>AR</given-names></name><name><surname>Lai-Cheong</surname><given-names>JE</given-names></name><etal/></person-group>:
<article-title>Infantile systemic hyalinosis associated with a putative splice-site mutation in the
<italic>ANTXR2</italic> gene.</article-title><source><italic>Clin Exp Dermatol.</italic></source><year>2012</year>;<volume>37</volume>(<issue>6</issue>):<fpage>635</fpage>&#x02013;<lpage>638</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2230.2011.04287.x</pub-id><?supplied-pmid 22300424?><pub-id pub-id-type="pmid">22300424</pub-id></mixed-citation></ref><ref id="ref-138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>DA</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Ro</surname><given-names>JY</given-names></name><etal/></person-group>:
<article-title>Novel mutations of epidermal growth factor receptor in localized prostate cancer.</article-title><source><italic>Front Biosci.</italic></source><year>2006</year>;<volume>11</volume>:<fpage>2518</fpage>&#x02013;<lpage>2525</lpage>.
<?supplied-pmid 16720329?><pub-id pub-id-type="pmid">16720329</pub-id></mixed-citation></ref><ref id="ref-139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaedigk</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>DW</given-names></name><name><surname>Totah</surname><given-names>RA</given-names></name><etal/></person-group>:
<article-title>Variability of CYP2J2 expression in human fetal tissues.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>2006</year>;<volume>319</volume>(<issue>2</issue>):<fpage>523</fpage>&#x02013;<lpage>532</lpage>.
<pub-id pub-id-type="doi">10.1124/jpet.106.109215</pub-id><!--<pub-id pub-id-type="pmcid">1876721</pub-id>--><?supplied-pmid 16868033?><pub-id pub-id-type="pmid">16868033</pub-id></mixed-citation></ref><ref id="ref-140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabet</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ghandour</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B.</article-title><source><italic>Neurology.</italic></source><year>2006</year>;<volume>67</volume>(<issue>7</issue>):<fpage>1141</fpage>&#x02013;<lpage>1146</lpage>.
<?supplied-pmid 17030746?><pub-id pub-id-type="pmid">17030746</pub-id></mixed-citation></ref><ref id="ref-141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concolino</surname><given-names>P</given-names></name><name><surname>Vendittelli</surname><given-names>F</given-names></name><name><surname>Mello</surname><given-names>E</given-names></name><etal/></person-group>:
<article-title>Functional analysis of two rare
<italic>CYP21A2</italic> mutations detected in Italian patients with a mildest form of congenital adrenal hyperplasia.</article-title><source><italic>Clin Endocrinol (Oxf).</italic></source><year>2009</year>;<volume>71</volume>(<issue>4</issue>):<fpage>470</fpage>&#x02013;<lpage>476</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2265.2008.03517.x</pub-id><?supplied-pmid 19170707?><pub-id pub-id-type="pmid">19170707</pub-id></mixed-citation></ref><ref id="ref-142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marras</surname><given-names>E</given-names></name><name><surname>Willems</surname><given-names>P</given-names></name><name><surname>Vandersickel</surname><given-names>V</given-names></name><etal/></person-group>:
<article-title>Discrepancies between
<italic>in silico</italic> and
<italic>in vitro</italic> data in the functional analysis of a breast cancer-associated polymorphism in the XRCC6/Ku70 gene.</article-title><source><italic>Mol Med Rep.</italic></source><year>2008</year>;<volume>1</volume>(<issue>6</issue>):<fpage>805</fpage>&#x02013;<lpage>812</lpage>.
<pub-id pub-id-type="doi">10.3892/mmr_00000032</pub-id><?supplied-pmid 21479489?><pub-id pub-id-type="pmid">21479489</pub-id></mixed-citation></ref><ref id="ref-143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Munier</surname><given-names>FL</given-names></name><etal/></person-group>:
<article-title>Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene
<italic>CYP4V2</italic>.</article-title><source><italic>Am J Hum Genet.</italic></source><year>2004</year>;<volume>74</volume>(<issue>5</issue>):<fpage>817</fpage>&#x02013;<lpage>826</lpage>.
<!--<pub-id pub-id-type="pmcid">1181977</pub-id>--><?supplied-pmid 15042513?><pub-id pub-id-type="pmid">15042513</pub-id></mixed-citation></ref><ref id="ref-144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Archetti</surname><given-names>S</given-names></name><name><surname>Alberici</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series.</article-title><source><italic>Neurogenetics.</italic></source><year>2008</year>;<volume>9</volume>(<issue>3</issue>):<fpage>197</fpage>&#x02013;<lpage>205</lpage>.
<pub-id pub-id-type="doi">10.1007/s10048-008-0127-3</pub-id><?supplied-pmid 18392865?><pub-id pub-id-type="pmid">18392865</pub-id></mixed-citation></ref><ref id="ref-145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;lsch</surname><given-names>H</given-names></name><name><surname>L&#x000fc;tjohann</surname><given-names>D</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>RXRA gene variations influence Alzheimer&#x02019;s disease risk and cholesterol metabolism.</article-title><source><italic>J Cell Mol Med.</italic></source><year>2009</year>;<volume>13</volume>(<issue>3</issue>):<fpage>589</fpage>&#x02013;<lpage>598</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00383.x</pub-id><?supplied-pmid 19374686?><pub-id pub-id-type="pmid">19374686</pub-id></mixed-citation></ref><ref id="ref-146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>GW</given-names></name><name><surname>Kwon</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><etal/></person-group>:
<article-title>Clinical and genetic analysis of a Korean patient with X-linked chondrodysplasia punctata: identification of a novel splicing mutation in the ARSE gene.</article-title><source><italic>Ann Clin Lab Sci.</italic></source><year>2013</year>;<volume>43</volume>(<issue>1</issue>):<fpage>70</fpage>&#x02013;<lpage>75</lpage>.
<?supplied-pmid 23462608?><pub-id pub-id-type="pmid">23462608</pub-id></mixed-citation></ref><ref id="ref-147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vreeswijk</surname><given-names>MP</given-names></name><name><surname>Kraan</surname><given-names>JN</given-names></name><name><surname>van der Klift</surname><given-names>HM</given-names></name><etal/></person-group>:
<article-title>Intronic variants in
<italic>BRCA1</italic> and
<italic>BRCA2</italic> that affect RNA splicing can be reliably selected by splice-site prediction programs.</article-title><source><italic>Hum Mutat.</italic></source><year>2009</year>;<volume>30</volume>(<issue>1</issue>):<fpage>107</fpage>&#x02013;<lpage>114</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20811</pub-id><?supplied-pmid 18693280?><pub-id pub-id-type="pmid">18693280</pub-id></mixed-citation></ref><ref id="ref-148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;lsch</surname><given-names>H</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Association of SORL1 gene variants with Alzheimer&#x02019;s disease.</article-title><source><italic>Brain Res.</italic></source><year>2009</year>;<volume>1264</volume>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.brainres.2009.01.044</pub-id><?supplied-pmid 19368828?><pub-id pub-id-type="pmid">19368828</pub-id></mixed-citation></ref><ref id="ref-149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>MY</given-names></name><etal/></person-group>:
<article-title>
<italic>COL7A1</italic> mutational analysis in Korean patients with dystrophic epidermolysis bullosa.</article-title><source><italic>Br J Dermatol.</italic></source><year>2007</year>;<volume>157</volume>(<issue>6</issue>):<fpage>1260</fpage>&#x02013;<lpage>1264</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2133.2007.08191.x</pub-id><?supplied-pmid 17916216?><pub-id pub-id-type="pmid">17916216</pub-id></mixed-citation></ref><ref id="ref-150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanggaard</surname><given-names>KM</given-names></name><name><surname>Rendtorff</surname><given-names>ND</given-names></name><name><surname>Kjaer</surname><given-names>KW</given-names></name><etal/></person-group>:
<article-title>Branchio-oto-renal syndrome: detection of
<italic>EYA1</italic> and
<italic>SIX1</italic> mutations in five out of six Danish families by combining linkage, MLPA and sequencing analyses.</article-title><source><italic>Eur J Hum Genet.</italic></source><year>2007</year>;<volume>15</volume>(<issue>11</issue>):<fpage>1121</fpage>&#x02013;<lpage>1131</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201900</pub-id><?supplied-pmid 17637804?><pub-id pub-id-type="pmid">17637804</pub-id></mixed-citation></ref><ref id="ref-151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessagowit</surname><given-names>V</given-names></name><name><surname>Nalla</surname><given-names>VK</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name><etal/></person-group>:
<article-title>Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases.</article-title><source><italic>J Dermatol Sci.</italic></source><year>2005</year>;<volume>40</volume>(<issue>2</issue>):<fpage>73</fpage>&#x02013;<lpage>84</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jdermsci.2005.05.006</pub-id><!--<pub-id pub-id-type="pmcid">1351063</pub-id>--><?supplied-pmid 16054339?><pub-id pub-id-type="pmid">16054339</pub-id></mixed-citation></ref><ref id="ref-152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slavotinek</surname><given-names>AM</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Schanze</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Manitoba-oculo-tricho-anal (MOTA) syndrome is caused by mutations in FREM1.</article-title><source><italic>J Med Genet.</italic></source><year>2011</year>;<volume>48</volume>(<issue>6</issue>):<fpage>375</fpage>&#x02013;<lpage>382</lpage>.
<pub-id pub-id-type="doi">10.1136/jmg.2011.089631</pub-id><?supplied-pmid 21507892?><pub-id pub-id-type="pmid">21507892</pub-id></mixed-citation></ref><ref id="ref-153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriwaki</surname><given-names>K</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name><etal/></person-group>:
<article-title>Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling.</article-title><source><italic>Gastroenterology.</italic></source><year>2009</year>;<volume>137</volume>(<issue>1</issue>):<fpage>188</fpage>&#x02013;<lpage>198</lpage>, 198.e1&#x02013;2.
<pub-id pub-id-type="doi">10.1053/j.gastro.2009.04.002</pub-id><?supplied-pmid 19361506?><pub-id pub-id-type="pmid">19361506</pub-id></mixed-citation></ref><ref id="ref-154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000f6;er</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>CG</given-names></name><name><surname>Kowalczuk</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters.</article-title><source><italic>J Clin Invest.</italic></source><year>2008</year>;<volume>118</volume>(<issue>12</issue>):<fpage>3881</fpage>&#x02013;<lpage>3892</lpage>.
<pub-id pub-id-type="doi">10.1172/JCI36625</pub-id><!--<pub-id pub-id-type="pmcid">2579706</pub-id>--><?supplied-pmid 19033659?><pub-id pub-id-type="pmid">19033659</pub-id></mixed-citation></ref><ref id="ref-155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>MJ</given-names></name><name><surname>Baek</surname><given-names>W</given-names></name><name><surname>Ki</surname><given-names>CS</given-names></name><etal/></person-group>:
<article-title>Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS.</article-title><source><italic>Neurobiol Aging.</italic></source><year>2012</year>;<volume>33</volume>(<issue>5</issue>):<fpage>1017.e17</fpage>&#x02013;<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.12.003</pub-id><?supplied-pmid 22244934?><pub-id pub-id-type="pmid">22244934</pub-id></mixed-citation></ref><ref id="ref-156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>GR</given-names></name><name><surname>Crowe</surname><given-names>P</given-names></name><name><surname>Muszynska</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Development of a diagnostic genetic test for simplex and autosomal recessive retinitis pigmentosa.</article-title><source><italic>Ophthalmology.</italic></source><year>2010</year>;<volume>117</volume>(<issue>11</issue>):<fpage>2169</fpage>&#x02013;<lpage>2177.e3</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ophtha.2010.02.029</pub-id><?supplied-pmid 20591486?><pub-id pub-id-type="pmid">20591486</pub-id></mixed-citation></ref><ref id="ref-157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolini</surname><given-names>S</given-names></name><name><surname>Pisciotta</surname><given-names>L</given-names></name><name><surname>Rabacchi</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.</article-title><source><italic>Atherosclerosis.</italic></source><year>2013</year>;<volume>227</volume>(<issue>2</issue>):<fpage>342</fpage>&#x02013;<lpage>348</lpage>.
<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.01.007</pub-id><?supplied-pmid 23375686?><pub-id pub-id-type="pmid">23375686</pub-id></mixed-citation></ref><ref id="ref-158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catucci</surname><given-names>I</given-names></name><name><surname>Peterlongo</surname><given-names>P</given-names></name><name><surname>Ciceri</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo.</article-title><source><italic>Genet Med</italic></source><year>2014</year>;<volume>16</volume>(<issue>9</issue>):<fpage>688</fpage>&#x02013;<lpage>694</lpage>.
<pub-id pub-id-type="doi">10.1038/gim.2014.13</pub-id><?supplied-pmid 24556926?><pub-id pub-id-type="pmid">24556926</pub-id></mixed-citation></ref><ref id="ref-159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faustino</surname><given-names>NA</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name></person-group>:
<article-title>Pre-mRNA splicing and human disease.</article-title><source><italic>Genes Dev.</italic></source><year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>419</fpage>&#x02013;<lpage>437</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.1048803</pub-id><?supplied-pmid 12600935?><pub-id pub-id-type="pmid">12600935</pub-id></mixed-citation></ref><ref id="ref-160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><etal/></person-group>:
<article-title>Novel mutations of the PAX6 gene identified in Chinese patients with aniridia.</article-title><source><italic>Mol Vis.</italic></source><year>2006</year>;<volume>12</volume>:<fpage>644</fpage>&#x02013;<lpage>648</lpage>.
<?supplied-pmid 16785853?><pub-id pub-id-type="pmid">16785853</pub-id></mixed-citation></ref><ref id="ref-161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Molecular and clinical characterization in Japanese and Korean patients with Hailey-Hailey disease: six new mutations in the ATP2C1 gene.</article-title><source><italic>J Dermatol Sci.</italic></source><year>2008</year>;<volume>51</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>36</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jdermsci.2008.02.003</pub-id><?supplied-pmid 18372165?><pub-id pub-id-type="pmid">18372165</pub-id></mixed-citation></ref><ref id="ref-162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baturina</surname><given-names>OA</given-names></name><name><surname>Tupikin</surname><given-names>AE</given-names></name><name><surname>Lukjanova</surname><given-names>TV</given-names></name><etal/></person-group>:
<article-title>PAH and QDPR Deficiency Associated Mutations in the Novosibirsk Region of the Russian Federation: Correlation of Mutation Type with Disease Manifestation and Severity.</article-title><source><italic>J Med Biochem.</italic></source><year>2014</year>;<volume>33</volume>(<issue>4</issue>):<fpage>333</fpage>&#x02013;<lpage>340</lpage>
<pub-id pub-id-type="doi">10.2478/jomb-2014-0019</pub-id></mixed-citation></ref><ref id="ref-163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>SB</given-names></name></person-group>:
<article-title>Recent insights into the Smith-Lemli-Opitz syndrome.</article-title><source><italic>Clin Genet.</italic></source><year>2005</year>;<volume>68</volume>(<issue>5</issue>):<fpage>383</fpage>&#x02013;<lpage>391</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2005.00515.x</pub-id><!--<pub-id pub-id-type="pmcid">1350989</pub-id>--><?supplied-pmid 16207203?><pub-id pub-id-type="pmid">16207203</pub-id></mixed-citation></ref><ref id="ref-164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russcher</surname><given-names>H</given-names></name><name><surname>Smit</surname><given-names>P</given-names></name><name><surname>van Rossum</surname><given-names>EF</given-names></name><etal/></person-group>:
<article-title>Strategies for the characterization of disorders in cortisol sensitivity.</article-title><source><italic>J Clin Endocrinol Metab.</italic></source><year>2006</year>;<volume>91</volume>(<issue>2</issue>):<fpage>694</fpage>&#x02013;<lpage>701</lpage>.
<pub-id pub-id-type="doi">10.1210/jc.2005-2212</pub-id><?supplied-pmid 16317053?><pub-id pub-id-type="pmid">16317053</pub-id></mixed-citation></ref><ref id="ref-165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leclerc</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Ellis</surname><given-names>JR</given-names></name><etal/></person-group>:
<article-title>Is the SLC7A10 gene on chromosome 19 a candidate locus for cystinuria?</article-title><source><italic>Mol Genet Metab.</italic></source><year>2001</year>;<volume>73</volume>(<issue>4</issue>):<fpage>333</fpage>&#x02013;<lpage>339</lpage>.
<pub-id pub-id-type="doi">10.1006/mgme.2001.3209</pub-id><?supplied-pmid 11509015?><pub-id pub-id-type="pmid">11509015</pub-id></mixed-citation></ref><ref id="ref-166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leclerc</surname><given-names>D</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><name><surname>Suh</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>SLC7A9 mutations in all three cystinuria subtypes.</article-title><source><italic>Kidney Int.</italic></source><year>2002</year>;<volume>62</volume>(<issue>5</issue>):<fpage>1550</fpage>&#x02013;<lpage>1559</lpage>.
<pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00602.x</pub-id><?supplied-pmid 12371955?><pub-id pub-id-type="pmid">12371955</pub-id></mixed-citation></ref><ref id="ref-167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchal</surname><given-names>A</given-names></name><name><surname>Goffinetb</surname><given-names>L</given-names></name><name><surname>Charlesworth</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Un cas particulier d&#x02019;&#x000e9;pidermolyse bulleuse dystrophique.</article-title><source><italic>Ann Dermatol Venereol.</italic></source><year>2011</year>;<volume>138</volume>(<issue>12</issue>):<fpage>A168</fpage>&#x02013;<lpage>A169</lpage>
<pub-id pub-id-type="doi">10.1016/j.annder.2011.10.114</pub-id></mixed-citation></ref><ref id="ref-168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Kodolitsch</surname><given-names>Y</given-names></name><name><surname>Pyeritz</surname><given-names>RE</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name></person-group>:
<article-title>Splice-Site mutations in atherosclerosis candidate genes: relating individual information to phenotype.</article-title><source><italic>Circulation.</italic></source><year>1999</year>;<volume>100</volume>(<issue>7</issue>):<fpage>693</fpage>&#x02013;<lpage>699</lpage>.
<pub-id pub-id-type="doi">10.1161/01.CIR.100.7.693</pub-id><?supplied-pmid 10449689?><pub-id pub-id-type="pmid">10449689</pub-id></mixed-citation></ref><ref id="ref-169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>KS</given-names></name><name><surname>Khan</surname><given-names>SG</given-names></name><name><surname>Jaspers</surname><given-names>NG</given-names></name><etal/></person-group>:
<article-title>Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): xeroderma pigmentosum without and with Cockayne syndrome.</article-title><source><italic>Hum Mutat.</italic></source><year>2006</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1092</fpage>&#x02013;<lpage>1103</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20392</pub-id><?supplied-pmid 16947863?><pub-id pub-id-type="pmid">16947863</pub-id></mixed-citation></ref><ref id="ref-170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>BC</given-names></name><name><surname>Ki</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><etal/></person-group>:
<article-title>Fukutin mutations in congenital muscular dystrophies with defective glycosylation of dystroglycan in Korea.</article-title><source><italic>Neuromuscul Disord NMD.</italic></source><year>2010</year>;<volume>20</volume>(<issue>8</issue>):<fpage>524</fpage>&#x02013;<lpage>530</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nmd.2010.06.005</pub-id><?supplied-pmid 20620061?><pub-id pub-id-type="pmid">20620061</pub-id></mixed-citation></ref><ref id="ref-171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marco</surname><given-names>EJ</given-names></name><name><surname>Abidi</surname><given-names>FE</given-names></name><name><surname>Bristow</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>ARHGEF9 disruption in a female patient is associated with X linked mental retardation and sensory hyperarousal.</article-title><source><italic>J Med Genet.</italic></source><year>2008</year>;<volume>45</volume>(<issue>2</issue>):<fpage>100</fpage>&#x02013;<lpage>105</lpage>.
<?supplied-pmid 17893116?><pub-id pub-id-type="pmid">17893116</pub-id></mixed-citation></ref><ref id="ref-172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gemignani</surname><given-names>F</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Landi</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA.</article-title><source><italic>Oncogene.</italic></source><year>2003</year>;<volume>23</volume>(<issue>10</issue>):<fpage>1954</fpage>&#x02013;<lpage>1956</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.onc.1207305</pub-id><?supplied-pmid 14647431?><pub-id pub-id-type="pmid">14647431</pub-id></mixed-citation></ref><ref id="ref-173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luquin</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Saunderson</surname><given-names>RB</given-names></name><etal/></person-group>:
<article-title>Genetic variants in the promoter of TARDBP in sporadic amyotrophic lateral sclerosis.</article-title><source><italic>Neuromuscul Disord.</italic></source><year>2009</year>;<volume>19</volume>(<issue>10</issue>):<fpage>696</fpage>&#x02013;<lpage>700</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nmd.2009.07.005</pub-id><?supplied-pmid 19695877?><pub-id pub-id-type="pmid">19695877</pub-id></mixed-citation></ref><ref id="ref-174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnolo</surname><given-names>L</given-names></name><name><surname>Najah</surname><given-names>M</given-names></name><name><surname>Fancello</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>Novel mutations in SAR1B and MTTP genes in Tunisian children with chylomicron retention disease and abetalipoproteinemia.</article-title><source><italic>Gene.</italic></source><year>2013</year>;<volume>512</volume>(<issue>1</issue>):<fpage>28</fpage>&#x02013;<lpage>34</lpage>.
<pub-id pub-id-type="doi">10.1016/j.gene.2012.09.117</pub-id><?supplied-pmid 23043934?><pub-id pub-id-type="pmid">23043934</pub-id></mixed-citation></ref><ref id="ref-175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname><given-names>N</given-names></name><name><surname>Bichet</surname><given-names>DG</given-names></name><name><surname>Hoefs</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus.</article-title><source><italic>J Am Soc Nephrol.</italic></source><year>2002</year>;<volume>13</volume>(<issue>9</issue>):<fpage>2267</fpage>&#x02013;<lpage>2277</lpage>.
<pub-id pub-id-type="doi">10.1097/01.ASN.0000027355.41663.14</pub-id><?supplied-pmid 12191971?><pub-id pub-id-type="pmid">12191971</pub-id></mixed-citation></ref><ref id="ref-176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naiya</surname><given-names>T</given-names></name><name><surname>Misra</surname><given-names>AK</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Occurrence of GCH1 gene mutations in a group of Indian dystonia patients.</article-title><source><italic>J Neural Transm.</italic></source><year>2012</year>;<volume>119</volume>(<issue>11</issue>):<fpage>1343</fpage>&#x02013;<lpage>1350</lpage>.
<pub-id pub-id-type="doi">10.1007/s00702-012-0777-z</pub-id><?supplied-pmid 22373569?><pub-id pub-id-type="pmid">22373569</pub-id></mixed-citation></ref><ref id="ref-177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>T</given-names></name><name><surname>Bocchi</surname><given-names>L</given-names></name><name><surname>Pisciotta</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Denaturing high-performance liquid chromatography in the detection of ABCA1 gene mutations in familial HDL deficiency.</article-title><source><italic>J Lipid Res.</italic></source><year>2005</year>;<volume>46</volume>(<issue>4</issue>):<fpage>817</fpage>&#x02013;<lpage>822</lpage>.
<pub-id pub-id-type="doi">10.1194/jlr.D400038-JLR200</pub-id><?supplied-pmid 15722566?><pub-id pub-id-type="pmid">15722566</pub-id></mixed-citation></ref><ref id="ref-178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosetto</surname><given-names>E</given-names></name><name><surname>Ghiggeri</surname><given-names>GM</given-names></name><name><surname>Emma</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>Phenotypic and genetic heterogeneity in Dent&#x02019;s disease--the results of an Italian collaborative study.</article-title><source><italic>Nephrol Dial Transplant.</italic></source><year>2006</year>;<volume>21</volume>(<issue>9</issue>):<fpage>2452</fpage>&#x02013;<lpage>2463</lpage>.
<pub-id pub-id-type="doi">10.1093/ndt/gfl274</pub-id><?supplied-pmid 16822791?><pub-id pub-id-type="pmid">16822791</pub-id></mixed-citation></ref><ref id="ref-179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosetto</surname><given-names>E</given-names></name><name><surname>Ceol</surname><given-names>M</given-names></name><name><surname>Mezzabotta</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>Novel mutations of the CLCN5 gene including a complex allele and A 5&#x02019; UTR mutation in Dent disease 1.</article-title><source><italic>Clin Genet.</italic></source><year>2009</year>;<volume>76</volume>(<issue>4</issue>):<fpage>413</fpage>&#x02013;<lpage>416</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2009.01212.x</pub-id><?supplied-pmid 19673950?><pub-id pub-id-type="pmid">19673950</pub-id></mixed-citation></ref><ref id="ref-180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tram</surname><given-names>E</given-names></name><name><surname>Ibrahim-Zada</surname><given-names>I</given-names></name><name><surname>Briollais</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR).</article-title><source><italic>Breast Cancer Res.</italic></source><year>2011</year>;<volume>13</volume>(<issue>4</issue>):<fpage>R77</fpage>.
<pub-id pub-id-type="doi">10.1186/bcr2926</pub-id><!--<pub-id pub-id-type="pmcid">3236341</pub-id>--><?supplied-pmid 21835029?><pub-id pub-id-type="pmid">21835029</pub-id></mixed-citation></ref><ref id="ref-181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><etal/></person-group>:
<article-title>Sequence variations of GRM6 in patients with high myopia.</article-title><source><italic>Mol Vis.</italic></source><year>2009</year>;<volume>15</volume>:<fpage>2094</fpage>&#x02013;<lpage>2100</lpage>.
<!--<pub-id pub-id-type="pmcid">2765235</pub-id>--><?supplied-pmid 19862333?><pub-id pub-id-type="pmid">19862333</pub-id></mixed-citation></ref><ref id="ref-182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pink</surname><given-names>AE</given-names></name><name><surname>Simpson</surname><given-names>MA</given-names></name><name><surname>Desai</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Mutations in the &#x003b3;-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa).</article-title><source><italic>J Invest Dermatol.</italic></source><year>2012</year>;<volume>132</volume>(<issue>10</issue>):<fpage>2459</fpage>&#x02013;<lpage>2461</lpage>.
<pub-id pub-id-type="doi">10.1038/jid.2012.162</pub-id><?supplied-pmid 22622421?><pub-id pub-id-type="pmid">22622421</pub-id></mixed-citation></ref><ref id="ref-183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LJ</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Tham</surname><given-names>CC</given-names></name><etal/></person-group>:
<article-title>Evaluation of SPARC as a candidate gene of juvenile-onset primary open-angle glaucoma by mutation and copy number analyses.</article-title><source><italic>Mol Vis.</italic></source><year>2010</year>;<volume>16</volume>:<fpage>2016</fpage>&#x02013;<lpage>2025</lpage>.
<!--<pub-id pub-id-type="pmcid">2965575</pub-id>--><?supplied-pmid 21042566?><pub-id pub-id-type="pmid">21042566</pub-id></mixed-citation></ref><ref id="ref-184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China.</article-title><source><italic>Pharmacogenomics.</italic></source><year>2008</year>;<volume>9</volume>(<issue>6</issue>):<fpage>691</fpage>&#x02013;<lpage>702</lpage>.
<pub-id pub-id-type="doi">10.2217/14622416.9.6.691</pub-id><?supplied-pmid 18518848?><pub-id pub-id-type="pmid">18518848</pub-id></mixed-citation></ref><ref id="ref-185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>Z</given-names></name><etal/></person-group>:
<article-title>The association of LRP5 gene polymorphisms with ankylosing spondylitis in a Chinese Han population.</article-title><source><italic>J Rheumatol.</italic></source><year>2011</year>;<volume>38</volume>(<issue>12</issue>):<fpage>2616</fpage>&#x02013;<lpage>2618</lpage>.
<pub-id pub-id-type="doi">10.3899/jrheum.111117</pub-id><?supplied-pmid 21885484?><pub-id pub-id-type="pmid">21885484</pub-id></mixed-citation></ref><ref id="ref-186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deen</surname><given-names>PM</given-names></name><name><surname>Dahl</surname><given-names>N</given-names></name><name><surname>Caplan</surname><given-names>MJ</given-names></name></person-group>:
<article-title>The aquaporin-2 water channel in autosomal dominant primary nocturnal enuresis.</article-title><source><italic>J Urol.</italic></source><year>2002</year>;<volume>167</volume>(<issue>3</issue>):<fpage>1447</fpage>&#x02013;<lpage>1450</lpage>.
<pub-id pub-id-type="doi">10.1016/S0022-5347(05)65341-4</pub-id><?supplied-pmid 11832768?><pub-id pub-id-type="pmid">11832768</pub-id></mixed-citation></ref><ref id="ref-187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonaf&#x000e9;</surname><given-names>L</given-names></name><name><surname>Giunta</surname><given-names>C</given-names></name><name><surname>Gassner</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>A cluster of autosomal recessive spondylocostal dysostosis caused by three newly identified DLL3 mutations segregating in a small village.</article-title><source><italic>Clin Genet.</italic></source><year>2003</year>;<volume>64</volume>(<issue>1</issue>):<fpage>28</fpage>&#x02013;<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1034/j.1399-0004.2003.00085.x</pub-id><?supplied-pmid 12791036?><pub-id pub-id-type="pmid">12791036</pub-id></mixed-citation></ref><ref id="ref-188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megremis</surname><given-names>S</given-names></name><name><surname>Mitsioni</surname><given-names>A</given-names></name><name><surname>Mitsioni</surname><given-names>AG</given-names></name><etal/></person-group>:
<article-title>Nucleotide variations in the
<italic>NPHS2</italic> gene in Greek children with steroid-resistant nephrotic syndrome.</article-title><source><italic>Genet Test Mol Biomark.</italic></source><year>2009</year>;<volume>13</volume>(<issue>2</issue>):<fpage>249</fpage>&#x02013;<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1089/gtmb.2008.0083</pub-id></mixed-citation></ref><ref id="ref-189"><label>189</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rogan</surname><given-names>P</given-names></name><name><surname>Mucaki</surname><given-names>E</given-names></name></person-group>:
<article-title>Population Fitness and Genetic Load of Single Nucleotide Polymorphisms Affecting mRNA splicing</article-title>.
<italic>ArXiv11070716 Q-Bio</italic><year>2011</year>
<ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/1107.0716">Reference Source</ext-link></mixed-citation></ref><ref id="ref-190"><label>190</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Day</surname><given-names>IN</given-names></name><name><surname>Kralovicova</surname><given-names>J</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><etal/></person-group>:
<article-title>IDDM2 locus: 5&#x02019; noncoding intron I splicing and translational efficiency effects of INS -23HphI - more than a tag for the INS promoter VNTR</article-title>. HUGO's 11th Human Genome Meeting (HGM2006), Helsinki Finland.<year>2006</year><year>2011</year>
<ext-link ext-link-type="uri" xlink:href="http://hgm2006.hgu.mrc.ac.uk/Abstracts/Publish/WorkshopPosters/WorkshopPosters11/hgm221.html">Reference Source</ext-link></mixed-citation></ref><ref id="ref-191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taube</surname><given-names>JR</given-names></name><name><surname>Sperle</surname><given-names>K</given-names></name><name><surname>Banser</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing.</article-title><source><italic>Hum Mol Genet.</italic></source><year>2014</year>;<volume>23</volume>(<issue>20</issue>):<fpage>5464</fpage>&#x02013;<lpage>5478</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddu271</pub-id><!--<pub-id pub-id-type="pmcid">4168831</pub-id>--><?supplied-pmid 24890387?><pub-id pub-id-type="pmid">24890387</pub-id></mixed-citation></ref><ref id="ref-192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luquin</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Trent</surname><given-names>RJ</given-names></name><etal/></person-group>:
<article-title>An analysis of the entire SOD1 gene in sporadic ALS.</article-title><source><italic>Neuromuscul Disord.</italic></source><year>2008</year>;<volume>18</volume>(<issue>7</issue>):<fpage>545</fpage>&#x02013;<lpage>552</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nmd.2008.04.013</pub-id><?supplied-pmid 18504130?><pub-id pub-id-type="pmid">18504130</pub-id></mixed-citation></ref><ref id="ref-193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueffing</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>KK</given-names></name><name><surname>Christians</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>A single nucleotide polymorphism determines protein isoform production of the human c-FLIP protein.</article-title><source><italic>Blood.</italic></source><year>2009</year>;<volume>114</volume>(<issue>3</issue>):<fpage>572</fpage>&#x02013;<lpage>579</lpage>.
<pub-id pub-id-type="doi">10.1182/blood-2009-02-204230</pub-id><?supplied-pmid 19439735?><pub-id pub-id-type="pmid">19439735</pub-id></mixed-citation></ref><ref id="ref-194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batty</surname><given-names>JA</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>White</surname><given-names>HL</given-names></name><etal/></person-group>:
<article-title>An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.</article-title><source><italic>Clin Pharmacol Ther.</italic></source><year>2014</year>;<volume>95</volume>(<issue>3</issue>):<fpage>321</fpage>&#x02013;<lpage>330</lpage>.
<pub-id pub-id-type="doi">10.1038/clpt.2013.193</pub-id><?supplied-pmid 24193112?><pub-id pub-id-type="pmid">24193112</pub-id></mixed-citation></ref><ref id="ref-195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>CF</given-names></name><name><surname>Tsai</surname><given-names>MH</given-names></name><name><surname>Tseng</surname><given-names>HC</given-names></name><etal/></person-group>:
<article-title>A novel single nucleotide polymorphism in XRCC4 gene is associated with oral cancer susceptibility in Taiwanese patients.</article-title><source><italic>Oral Oncol.</italic></source><year>2008</year>;<volume>44</volume>(<issue>9</issue>):<fpage>898</fpage>&#x02013;<lpage>902</lpage>.
<pub-id pub-id-type="doi">10.1016/j.oraloncology.2007.11.007</pub-id><?supplied-pmid 18164646?><pub-id pub-id-type="pmid">18164646</pub-id></mixed-citation></ref><ref id="ref-196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Zou</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility.</article-title><source><italic>BMC Cancer.</italic></source><year>2013</year>;<volume>13</volume>:<fpage>234</fpage>.
<pub-id pub-id-type="doi">10.1186/1471-2407-13-234</pub-id><!--<pub-id pub-id-type="pmcid">3655843</pub-id>--><?supplied-pmid 23663450?><pub-id pub-id-type="pmid">23663450</pub-id></mixed-citation></ref><ref id="ref-197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dr&#x000f6;gem&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Philipp</surname><given-names>U</given-names></name><name><surname>Haase</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>A noncoding melanophilin gene (MLPH) SNP at the splice donor of exon 1 represents a candidate causal mutation for coat color dilution in dogs.</article-title><source><italic>J Hered.</italic></source><year>2007</year>;<volume>98</volume>(<issue>5</issue>):<fpage>468</fpage>&#x02013;<lpage>473</lpage>.
<pub-id pub-id-type="doi">10.1093/jhered/esm021</pub-id><?supplied-pmid 17519392?><pub-id pub-id-type="pmid">17519392</pub-id></mixed-citation></ref><ref id="ref-198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;lsch</surname><given-names>H</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer&#x02019;s disease.</article-title><source><italic>Neurosci Lett.</italic></source><year>2008</year>;<volume>440</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neulet.2008.05.049</pub-id><?supplied-pmid 18541377?><pub-id pub-id-type="pmid">18541377</pub-id></mixed-citation></ref><ref id="ref-199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Crusius</surname><given-names>JB</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name><etal/></person-group>:
<article-title>Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease.</article-title><source><italic>World J Gastroenterol.</italic></source><year>2005</year>;<volume>11</volume>(<issue>38</issue>):<fpage>6003</fpage>&#x02013;<lpage>6008</lpage>.
<?supplied-pmid 16273614?><pub-id pub-id-type="pmid">16273614</pub-id></mixed-citation></ref><ref id="ref-200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name></person-group>: Breast Cancer Linkage Consortium.
<article-title>Cancer Incidence in BRCA1 mutation carriers.</article-title><source><italic>J Natl Cancer Inst.</italic></source><year>2002</year>;<volume>94</volume>(<issue>18</issue>):<fpage>1358</fpage>&#x02013;<lpage>1365</lpage>.
<pub-id pub-id-type="doi">10.1093/jnci/94.18.1358</pub-id><?supplied-pmid 12237281?><pub-id pub-id-type="pmid">12237281</pub-id></mixed-citation></ref><ref id="ref-201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomino-Doza</surname><given-names>J</given-names></name><name><surname>Rahman</surname><given-names>TJ</given-names></name><name><surname>Avery</surname><given-names>PJ</given-names></name><etal/></person-group>:
<article-title>Ambulatory blood pressure is associated with polymorphic variation in P2X receptor genes.</article-title><source><italic>Hypertension.</italic></source><year>2008</year>;<volume>52</volume>(<issue>5</issue>):<fpage>980</fpage>&#x02013;<lpage>985</lpage>.
<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.113282</pub-id><?supplied-pmid 18852390?><pub-id pub-id-type="pmid">18852390</pub-id></mixed-citation></ref><ref id="ref-202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China.</article-title><source><italic>Genomics.</italic></source><year>2011</year>;<volume>97</volume>(<issue>5</issue>):<fpage>277</fpage>&#x02013;<lpage>281</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ygeno.2010.11.004</pub-id><?supplied-pmid 21126569?><pub-id pub-id-type="pmid">21126569</pub-id></mixed-citation></ref><ref id="ref-203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Skogh</surname><given-names>E</given-names></name><name><surname>Scordo</surname><given-names>MG</given-names></name><etal/></person-group>:
<article-title>Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.</article-title><source><italic>J Clin Psychopharmacol.</italic></source><year>2012</year>;<volume>32</volume>(<issue>2</issue>):<fpage>287</fpage>&#x02013;<lpage>289</lpage>.
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31824997a8</pub-id><?supplied-pmid 22388157?><pub-id pub-id-type="pmid">22388157</pub-id></mixed-citation></ref><ref id="ref-204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiller</surname><given-names>M</given-names></name><name><surname>Huse</surname><given-names>K</given-names></name><name><surname>Szafranski</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Phylogenetically widespread alternative splicing at unusual GYNGYN donors.</article-title><source><italic>Genome Biol.</italic></source><year>2006</year>;<volume>7</volume>(<issue>7</issue>):<fpage>R65</fpage>.
<pub-id pub-id-type="doi">10.1186/gb-2006-7-7-r65</pub-id><!--<pub-id pub-id-type="pmcid">1779574</pub-id>--><?supplied-pmid 16869967?><pub-id pub-id-type="pmid">16869967</pub-id></mixed-citation></ref><ref id="ref-205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasvolsky</surname><given-names>R</given-names></name><name><surname>Feigelson</surname><given-names>SW</given-names></name><name><surname>Kilic</surname><given-names>SS</given-names></name><etal/></person-group>:
<article-title>A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets.</article-title><source><italic>J Exp Med.</italic></source><year>2007</year>;<volume>204</volume>(<issue>7</issue>):<fpage>1571</fpage>&#x02013;<lpage>1582</lpage>.
<pub-id pub-id-type="doi">10.1084/jem.20070058</pub-id><!--<pub-id pub-id-type="pmcid">2118641</pub-id>--><?supplied-pmid 17576779?><pub-id pub-id-type="pmid">17576779</pub-id></mixed-citation></ref><ref id="ref-206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartault</surname><given-names>F</given-names></name><name><surname>Nava</surname><given-names>C</given-names></name><name><surname>Malbrunot</surname><given-names>AC</given-names></name><etal/></person-group>:
<article-title>A new
<italic>XPC</italic> gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patients.</article-title><source><italic>DNA Repair (Amst).</italic></source><year>2011</year>;<volume>10</volume>(<issue>6</issue>):<fpage>577</fpage>&#x02013;<lpage>585</lpage>.
<pub-id pub-id-type="doi">10.1016/j.dnarep.2011.03.005</pub-id><?supplied-pmid 21482201?><pub-id pub-id-type="pmid">21482201</pub-id></mixed-citation></ref><ref id="ref-207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>S&#x000f6;nnerborg</surname><given-names>A</given-names></name><name><surname>Rane</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.</article-title><source><italic>Pharmacogenet Genomics.</italic></source><year>2006</year>;<volume>16</volume>(<issue>3</issue>):<fpage>191</fpage>&#x02013;<lpage>198</lpage>.
<?supplied-pmid 16495778?><pub-id pub-id-type="pmid">16495778</pub-id></mixed-citation></ref><ref id="ref-208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaedigk</surname><given-names>A</given-names></name><name><surname>Bhathena</surname><given-names>A</given-names></name><name><surname>Ndjountch&#x000e9;</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Identification and characterization of novel sequence variations in the cytochrome P4502D6 (
<italic>CYP2D6</italic>) gene in African Americans.</article-title><source><italic>Pharmacogenomics J.</italic></source><year>2005</year>;<volume>5</volume>(<issue>3</issue>):<fpage>173</fpage>&#x02013;<lpage>182</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.tpj.6500305</pub-id><!--<pub-id pub-id-type="pmcid">1440720</pub-id>--><?supplied-pmid 15768052?><pub-id pub-id-type="pmid">15768052</pub-id></mixed-citation></ref><ref id="ref-209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Berg</surname><given-names>JS</given-names></name><name><surname>Grody</surname><given-names>WW</given-names></name><etal/></person-group>:
<article-title>ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.</article-title><source><italic>Genet Med.</italic></source><year>2013</year>;<volume>15</volume>(<issue>7</issue>):<fpage>565</fpage>&#x02013;<lpage>574</lpage>.
<pub-id pub-id-type="doi">10.1038/gim.2013.73</pub-id><!--<pub-id pub-id-type="pmcid">3727274</pub-id>--><?supplied-pmid 23788249?><pub-id pub-id-type="pmid">23788249</pub-id></mixed-citation></ref><ref id="ref-210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gonzalez</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>JG</given-names></name><name><surname>Allen</surname><given-names>SK</given-names></name><etal/></person-group>:
<article-title>Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease.</article-title><source><italic>Mol Genet Metab.</italic></source><year>2007</year>;<volume>92</volume>(<issue>1&#x02013;2</issue>):<fpage>160</fpage>&#x02013;<lpage>167</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymgme.2007.05.004</pub-id><!--<pub-id pub-id-type="pmcid">2085355</pub-id>--><?supplied-pmid 17574468?><pub-id pub-id-type="pmid">17574468</pub-id></mixed-citation></ref><ref id="ref-211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leman</surname><given-names>AR</given-names></name><name><surname>Pearce</surname><given-names>DA</given-names></name><name><surname>Rothberg</surname><given-names>PG</given-names></name></person-group>:
<article-title>Gene symbol: CLN3. Disease: Juvenile neuronal ceroid lipofuscinosis (Batten disease).</article-title><source><italic>Hum Genet.</italic></source><year>2005</year>;<volume>116</volume>(<issue>6</issue>):<fpage>544</fpage>.
<?supplied-pmid 15991331?><pub-id pub-id-type="pmid">15991331</pub-id></mixed-citation></ref><ref id="ref-212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname><given-names>B</given-names></name><name><surname>Suzuki</surname><given-names>OT</given-names></name><name><surname>G&#x000e9;rard-Blanluet</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>CNS malformations in Knobloch syndrome with splice mutation in
<italic>COL18A1</italic> gene.</article-title><source><italic>Am J Med Genet A.</italic></source><year>2007</year>;<volume>143A</volume>(<issue>13</issue>):<fpage>1514</fpage>&#x02013;<lpage>1518</lpage>.
<pub-id pub-id-type="doi">10.1002/ajmg.a.31784</pub-id><?supplied-pmid 17546652?><pub-id pub-id-type="pmid">17546652</pub-id></mixed-citation></ref><ref id="ref-213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>Y</given-names></name><name><surname>Ozer</surname><given-names>I</given-names></name><name><surname>Demirkol</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9
<italic>AGL</italic> mutations.</article-title><source><italic>J Hum Genet.</italic></source><year>2009</year>;<volume>54</volume>(<issue>11</issue>):<fpage>681</fpage>&#x02013;<lpage>686</lpage>.
<pub-id pub-id-type="doi">10.1038/jhg.2009.100</pub-id><?supplied-pmid 19834502?><pub-id pub-id-type="pmid">19834502</pub-id></mixed-citation></ref><ref id="ref-214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>AKY</given-names></name><name><surname>Fung</surname><given-names>CW</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><etal/></person-group>:
<article-title>Identification of
<italic>SCN1A</italic> and
<italic>PCDH19</italic> mutations in Chinese children with Dravet syndrome.</article-title><source><italic>PLoS One.</italic></source><year>2012</year>;<volume>7</volume>(<issue>7</issue>):<fpage>e41802</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0041802</pub-id><!--<pub-id pub-id-type="pmcid">3405017</pub-id>--><?supplied-pmid 22848613?><pub-id pub-id-type="pmid">22848613</pub-id></mixed-citation></ref><ref id="ref-215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Detection of variants in 15 genes in 87 unrelated Chinese patients with Leber congenital amaurosis.</article-title><source><italic>PLoS One.</italic></source><year>2011</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e19458</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0019458</pub-id><!--<pub-id pub-id-type="pmcid">3094346</pub-id>--><?supplied-pmid 21602930?><pub-id pub-id-type="pmid">21602930</pub-id></mixed-citation></ref><ref id="ref-216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caridi</surname><given-names>G</given-names></name><name><surname>Dagnino</surname><given-names>M</given-names></name><name><surname>Dalgic</surname><given-names>B</given-names></name><etal/></person-group>:
<article-title>Analbuminemia Zonguldak: case report and mutational analysis.</article-title><source><italic>Clin Biochem.</italic></source><year>2008</year>;<volume>41</volume>(<issue>4&#x02013;5</issue>):<fpage>288</fpage>&#x02013;<lpage>291</lpage>.
<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2007.11.016</pub-id><?supplied-pmid 18154732?><pub-id pub-id-type="pmid">18154732</pub-id></mixed-citation></ref><ref id="ref-217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>J</given-names></name><name><surname>Kovacs</surname><given-names>ME</given-names></name><name><surname>Olah</surname><given-names>E</given-names></name></person-group>:
<article-title>Germline
<italic>MLH1</italic> and
<italic>MSH2</italic> mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing.</article-title><source><italic>World J Gastroenterol.</italic></source><year>2007</year>;<volume>13</volume>(<issue>19</issue>):<fpage>2727</fpage>&#x02013;<lpage>2732</lpage>.
<pub-id pub-id-type="doi">10.3748/wjg.v13.i19.2727</pub-id><!--<pub-id pub-id-type="pmcid">4147123</pub-id>--><?supplied-pmid 17569143?><pub-id pub-id-type="pmid">17569143</pub-id></mixed-citation></ref><ref id="ref-218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Bonnefond</surname><given-names>A</given-names></name><name><surname>Manzoor</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Novel
<italic>LEPR</italic> mutations in obese Pakistani children identified by PCR-based enrichment and next generation sequencing.</article-title><source><italic>Obesity (Silver Spring).</italic></source><year>2014</year>;<volume>22</volume>(<issue>4</issue>):<fpage>1112</fpage>&#x02013;<lpage>1117</lpage>.
<pub-id pub-id-type="doi">10.1002/oby.20667</pub-id><?supplied-pmid 24319006?><pub-id pub-id-type="pmid">24319006</pub-id></mixed-citation></ref><ref id="ref-219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soran</surname><given-names>H</given-names></name><name><surname>Charlton-Menys</surname><given-names>V</given-names></name><name><surname>Hegele</surname><given-names>R</given-names></name><etal/></person-group>:
<article-title>Proteinuria and severe mixed dyslipidemia associated with a novel
<italic>APOAV</italic> gene mutation.</article-title><source><italic>J Clin Lipidol.</italic></source><year>2010</year>;<volume>4</volume>(<issue>4</issue>):<fpage>310</fpage>&#x02013;<lpage>313</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jacl.2010.06.004</pub-id><?supplied-pmid 21122665?><pub-id pub-id-type="pmid">21122665</pub-id></mixed-citation></ref><ref id="ref-220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sznajer</surname><given-names>Y</given-names></name><name><surname>Cold&#x000e9;a</surname><given-names>C</given-names></name><name><surname>Meire</surname><given-names>F</given-names></name><etal/></person-group>:
<article-title>A
<italic>de novo</italic>
<italic>SOX10</italic> mutation causing severe type 4 Waardenburg syndrome without Hirschsprung disease.</article-title><source><italic>Am J Med Genet A.</italic></source><year>2008</year>;<volume>146A</volume>(<issue>8</issue>):<fpage>1038</fpage>&#x02013;<lpage>1041</lpage>.
<pub-id pub-id-type="doi">10.1002/ajmg.a.32247</pub-id><?supplied-pmid 18348267?><pub-id pub-id-type="pmid">18348267</pub-id></mixed-citation></ref><ref id="ref-221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichers</surname><given-names>ER</given-names></name><name><surname>Green</surname><given-names>JS</given-names></name><name><surname>Stockton</surname><given-names>DW</given-names></name><etal/></person-group>:
<article-title>Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in
<italic>RLBP1</italic>.</article-title><source><italic>Am J Hum Genet.</italic></source><year>2002</year>;<volume>70</volume>(<issue>4</issue>):<fpage>955</fpage>&#x02013;<lpage>964</lpage>.
<pub-id pub-id-type="doi">10.1086/339688</pub-id><!--<pub-id pub-id-type="pmcid">379124</pub-id>--><?supplied-pmid 11868161?><pub-id pub-id-type="pmid">11868161</pub-id></mixed-citation></ref><ref id="ref-222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dua-Awereh</surname><given-names>MB</given-names></name><name><surname>Shimomura</surname><given-names>Y</given-names></name><name><surname>Kraemer</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Mutations in the desmoglein 1 gene in five Pakistani families with striate palmoplantar keratoderma.</article-title><source><italic>J Dermatol Sci.</italic></source><year>2009</year>;<volume>53</volume>(<issue>3</issue>):<fpage>192</fpage>&#x02013;<lpage>197</lpage>.
<pub-id pub-id-type="doi">10.1016/j.jdermsci.2008.11.005</pub-id><!--<pub-id pub-id-type="pmcid">3986861</pub-id>--><?supplied-pmid 19157795?><pub-id pub-id-type="pmid">19157795</pub-id></mixed-citation></ref><ref id="ref-223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampson</surname><given-names>G</given-names></name><name><surname>Konrad</surname><given-names>MA</given-names></name><name><surname>Scoble</surname><given-names>J</given-names></name></person-group>:
<article-title>Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (
<italic>CLDN16</italic>) gene.</article-title><source><italic>BMC Nephrol.</italic></source><year>2008</year>;<volume>9</volume>:<fpage>12</fpage>.
<pub-id pub-id-type="doi">10.1186/1471-2369-9-12</pub-id><!--<pub-id pub-id-type="pmcid">2562370</pub-id>--><?supplied-pmid 18816383?><pub-id pub-id-type="pmid">18816383</pub-id></mixed-citation></ref><ref id="ref-224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>G</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group>:
<article-title>Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.</article-title><source><italic>J Comput Biol.</italic></source><year>2004</year>;<volume>11</volume>(<issue>2&#x02013;3</issue>):<fpage>377</fpage>&#x02013;<lpage>394</lpage>.
<pub-id pub-id-type="doi">10.1089/1066527041410418</pub-id><?supplied-pmid 15285897?><pub-id pub-id-type="pmid">15285897</pub-id></mixed-citation></ref><ref id="ref-225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>MG</given-names></name><name><surname>Eeckman</surname><given-names>FH</given-names></name><name><surname>Kulp</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Improved splice site detection in Genie.</article-title><source><italic>J Comput Biol.</italic></source><year>1997</year>;<volume>4</volume>(<issue>3</issue>):<fpage>311</fpage>&#x02013;<lpage>323</lpage>.
<pub-id pub-id-type="doi">10.1089/cmb.1997.4.311</pub-id><?supplied-pmid 9278062?><pub-id pub-id-type="pmid">9278062</pub-id></mixed-citation></ref><ref id="ref-226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beetz</surname><given-names>C</given-names></name><name><surname>Sch&#x000fc;le</surname><given-names>R</given-names></name><name><surname>Deconinck</surname><given-names>T</given-names></name><etal/></person-group>:
<article-title>REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31.</article-title><source><italic>Brain.</italic></source><year>2008</year>;<volume>131</volume>(<issue>Pt 4</issue>):<fpage>1078</fpage>&#x02013;<lpage>1086</lpage>.
<pub-id pub-id-type="doi">10.1093/brain/awn026</pub-id><!--<pub-id pub-id-type="pmcid">2841798</pub-id>--><?supplied-pmid 18321925?><pub-id pub-id-type="pmid">18321925</pub-id></mixed-citation></ref><ref id="ref-227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Fern&#x000e1;ndez-Seara</surname><given-names>MA</given-names></name><name><surname>Seijo-Mart&#x000ed;nez</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Cortical atrophy and language network reorganization associated with a novel
<italic>progranulin</italic> mutation.</article-title><source><italic>Cereb Cortex.</italic></source><year>2009</year>;<volume>19</volume>(<issue>8</issue>):<fpage>1751</fpage>&#x02013;<lpage>1760</lpage>.
<pub-id pub-id-type="doi">10.1093/cercor/bhn202</pub-id><?supplied-pmid 19020205?><pub-id pub-id-type="pmid">19020205</pub-id></mixed-citation></ref><ref id="ref-228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martoni</surname><given-names>E</given-names></name><name><surname>Urciuolo</surname><given-names>A</given-names></name><name><surname>Sabatelli</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>Identification and characterization of novel collagen VI non-canonical splicing mutations causing Ullrich congenital muscular dystrophy.</article-title><source><italic>Hum Mutat.</italic></source><year>2009</year>;<volume>30</volume>(<issue>5</issue>):<fpage>E662</fpage>&#x02013;<lpage>672</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.21022</pub-id><?supplied-pmid 19309692?><pub-id pub-id-type="pmid">19309692</pub-id></mixed-citation></ref><ref id="ref-229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naruse</surname><given-names>H</given-names></name><name><surname>Ikawa</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay.</article-title><source><italic>Fam Cancer.</italic></source><year>2009</year>;<volume>8</volume>(<issue>4</issue>):<fpage>509</fpage>&#x02013;<lpage>517</lpage>.
<pub-id pub-id-type="doi">10.1007/s10689-009-9280-6</pub-id><?supplied-pmid 19685281?><pub-id pub-id-type="pmid">19685281</pub-id></mixed-citation></ref><ref id="ref-230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelucchi</surname><given-names>S</given-names></name><name><surname>Mariani</surname><given-names>R</given-names></name><name><surname>Trombini</surname><given-names>P</given-names></name><etal/></person-group>:
<article-title>Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2.</article-title><source><italic>Haematologica.</italic></source><year>2009</year>;<volume>94</volume>(<issue>2</issue>):<fpage>276</fpage>&#x02013;<lpage>279</lpage>.
<pub-id pub-id-type="doi">10.3324/haematol.13576</pub-id><!--<pub-id pub-id-type="pmcid">2635389</pub-id>--><?supplied-pmid 19144662?><pub-id pub-id-type="pmid">19144662</pub-id></mixed-citation></ref><ref id="ref-231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>C</given-names></name><name><surname>Sestini</surname><given-names>R</given-names></name><name><surname>Provenzano</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Schwannomatosis associated with multiple meningiomas due to a familial
<italic>SMARCB1</italic> mutation.</article-title><source><italic>Neurogenetics.</italic></source><year>2010</year>;<volume>11</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1007/s10048-009-0204-2</pub-id><?supplied-pmid 19582488?><pub-id pub-id-type="pmid">19582488</pub-id></mixed-citation></ref><ref id="ref-232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torregrossa</surname><given-names>R</given-names></name><name><surname>Anglani</surname><given-names>F</given-names></name><name><surname>Fabris</surname><given-names>A</given-names></name><etal/></person-group>:
<article-title>Identification of GDNF gene sequence variations in patients with medullary sponge kidney disease.</article-title><source><italic>Clin J Am Soc Nephrol.</italic></source><year>2010</year>;<volume>5</volume>(<issue>7</issue>):<fpage>1205</fpage>&#x02013;<lpage>1210</lpage>.
<pub-id pub-id-type="doi">10.2215/CJN.07551009</pub-id><!--<pub-id pub-id-type="pmcid">2893072</pub-id>--><?supplied-pmid 20448065?><pub-id pub-id-type="pmid">20448065</pub-id></mixed-citation></ref><ref id="ref-233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>B</given-names></name><name><surname>Chervinsky</surname><given-names>E</given-names></name><name><surname>Jabaly-Habib</surname><given-names>H</given-names></name><etal/></person-group>:
<article-title>A novel splice site mutation of
<italic>CDHR1</italic> in a consanguineous Israeli Christian Arab family segregating autosomal recessive cone-rod dystrophy.</article-title><source><italic>Mol Vis.</italic></source><year>2012</year>;<volume>18</volume>:<fpage>2915</fpage>&#x02013;<lpage>2921</lpage>.
<!--<pub-id pub-id-type="pmcid">3519373</pub-id>--><?supplied-pmid 23233793?><pub-id pub-id-type="pmid">23233793</pub-id></mixed-citation></ref><ref id="ref-234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>T</given-names></name><name><surname>Pisciotta</surname><given-names>L</given-names></name><name><surname>Bocchi</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Lysosomal lipase deficiency: molecular characterization of eleven patients with Wolman or cholesteryl ester storage disease.</article-title><source><italic>Mol Genet Metab.</italic></source><year>2012</year>;<volume>105</volume>(<issue>3</issue>):<fpage>450</fpage>&#x02013;<lpage>456</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ymgme.2011.12.008</pub-id><?supplied-pmid 22227072?><pub-id pub-id-type="pmid">22227072</pub-id></mixed-citation></ref><ref id="ref-235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pernet</surname><given-names>C</given-names></name><name><surname>Bessis</surname><given-names>D</given-names></name><name><surname>Savignac</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Genitoperineal papular acantholytic dyskeratosis is allelic to Hailey-Hailey disease.</article-title><source><italic>Br J Dermatol.</italic></source><year>2012</year>;<volume>167</volume>(<issue>1</issue>):<fpage>210</fpage>&#x02013;<lpage>212</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.10810.x</pub-id><?supplied-pmid 22229453?><pub-id pub-id-type="pmid">22229453</pub-id></mixed-citation></ref><ref id="ref-236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desmet</surname><given-names>FO</given-names></name><name><surname>Hamroun</surname><given-names>D</given-names></name><name><surname>Lalande</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Human Splicing Finder: an online bioinformatics tool to predict splicing signals.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2009</year>;<volume>37</volume>(<issue>9</issue>):<fpage>e67</fpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkp215</pub-id><!--<pub-id pub-id-type="pmcid">2685110</pub-id>--><?supplied-pmid 19339519?><pub-id pub-id-type="pmid">19339519</pub-id></mixed-citation></ref><ref id="ref-237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group>:
<article-title>Disruption of an SF2/ASF-dependent exonic splicing enhancer in
<italic>SMN2</italic> causes spinal muscular atrophy in the absence of
<italic>SMN1</italic>.</article-title><source><italic>Nat Genet.</italic></source><year>2002</year>;<volume>30</volume>(<issue>4</issue>):<fpage>377</fpage>&#x02013;<lpage>384</lpage>.
<pub-id pub-id-type="doi">10.1038/ng854</pub-id><?supplied-pmid 11925564?><pub-id pub-id-type="pmid">11925564</pub-id></mixed-citation></ref><ref id="ref-238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PJ</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers.</article-title><source><italic>Hum Mol Genet.</italic></source><year>2006</year>;<volume>15</volume>(<issue>16</issue>):<fpage>2490</fpage>&#x02013;<lpage>2508</lpage>.
<pub-id pub-id-type="doi">10.1093/hmg/ddl171</pub-id><?supplied-pmid 16825284?><pub-id pub-id-type="pmid">16825284</pub-id></mixed-citation></ref><ref id="ref-239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HX</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group>:
<article-title>Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins.</article-title><source><italic>Genes Dev.</italic></source><year>1998</year>;<volume>12</volume>(<issue>13</issue>):<fpage>1998</fpage>&#x02013;<lpage>2012</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.12.13.1998</pub-id><!--<pub-id pub-id-type="pmcid">316967</pub-id>--><?supplied-pmid 9649504?><pub-id pub-id-type="pmid">9649504</pub-id></mixed-citation></ref><ref id="ref-240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.</article-title><source><italic>Hum Genet.</italic></source><year>2012</year>;<volume>131</volume>(<issue>9</issue>):<fpage>1453</fpage>&#x02013;<lpage>1466</lpage>.
<pub-id pub-id-type="doi">10.1007/s00439-012-1182-2</pub-id><!--<pub-id pub-id-type="pmcid">3956317</pub-id>--><?supplied-pmid 22661295?><pub-id pub-id-type="pmid">22661295</pub-id></mixed-citation></ref><ref id="ref-241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin</surname><given-names>CA</given-names></name><name><surname>Gluba</surname><given-names>W</given-names></name><name><surname>Scrable</surname><given-names>H</given-names></name></person-group>:
<article-title>The
<italic>lac</italic> operator-repressor system is functional in the mouse.</article-title><source><italic>Genes Dev.</italic></source><year>2001</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1506</fpage>&#x02013;<lpage>1517</lpage>.
<pub-id pub-id-type="doi">10.1101/gad.892001</pub-id><!--<pub-id pub-id-type="pmcid">312721</pub-id>--><?supplied-pmid 11410531?><pub-id pub-id-type="pmid">11410531</pub-id></mixed-citation></ref><ref id="ref-242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Dimova</surname><given-names>N</given-names></name><name><surname>Cambi</surname><given-names>F</given-names></name></person-group>:
<article-title>PLP/DM20 ratio is regulated by hnRNPH and F and a novel G-rich enhancer in oligodendrocytes.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2007</year>;<volume>35</volume>(<issue>12</issue>):<fpage>4164</fpage>&#x02013;<lpage>4178</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gkm387</pub-id><!--<pub-id pub-id-type="pmcid">1919487</pub-id>--><?supplied-pmid 17567613?><pub-id pub-id-type="pmid">17567613</pub-id></mixed-citation></ref><ref id="ref-243"><label>243</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>TD</given-names></name><name><surname>Rogan</surname><given-names>PK</given-names></name></person-group>:
<article-title>Computational analysis of nucleic acid information defines binding sites</article-title>.<year>1999</year>
<ext-link ext-link-type="uri" xlink:href="https://docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5867402.pdf">Reference Source</ext-link></mixed-citation></ref><ref id="ref-244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botta</surname><given-names>E</given-names></name><name><surname>Nardo</surname><given-names>T</given-names></name><name><surname>Orioli</surname><given-names>D</given-names></name><etal/></person-group>:
<article-title>Genotype-phenotype relationships in trichothiodystrophy patients with novel splicing mutations in the
<italic>XPD</italic> gene.</article-title><source><italic>Hum Mutat.</italic></source><year>2009</year>;<volume>30</volume>(<issue>3</issue>):<fpage>438</fpage>&#x02013;<lpage>445</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.20912</pub-id><?supplied-pmid 19085937?><pub-id pub-id-type="pmid">19085937</pub-id></mixed-citation></ref><ref id="ref-245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lietman</surname><given-names>SA</given-names></name></person-group>:
<article-title>Preimplantation genetic diagnosis for hereditary endocrine disease.</article-title><source><italic>Endocr Pract.</italic></source><year>2011</year>;<volume>17</volume>(<issue>Suppl 3</issue>):<fpage>28</fpage>&#x02013;<lpage>32</lpage>.
<pub-id pub-id-type="doi">10.4158/EP11056.RA</pub-id><?supplied-pmid 21550946?><pub-id pub-id-type="pmid">21550946</pub-id></mixed-citation></ref><ref id="ref-246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellerud</surname><given-names>C</given-names></name><name><surname>Burlina</surname><given-names>A</given-names></name><name><surname>Gabelli</surname><given-names>C</given-names></name><etal/></person-group>:
<article-title>Glycerol metabolism and the determination of triglycerides--clinical, biochemical and molecular findings in six subjects.</article-title><source><italic>Clin Chem Lab Med.</italic></source><year>2003</year>;<volume>41</volume>(<issue>1</issue>):<fpage>46</fpage>&#x02013;<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1515/CCLM.2003.009</pub-id><?supplied-pmid 12636049?><pub-id pub-id-type="pmid">12636049</pub-id></mixed-citation></ref><ref id="ref-247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Titeux</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><etal/></person-group>:
<article-title>DNA-based prenatal diagnosis of harlequin ichthyosis and characterization of
<italic>ABCA12</italic> mutation consequences.</article-title><source><italic>J Invest Dermatol.</italic></source><year>2007</year>;<volume>127</volume>(<issue>3</issue>):<fpage>568</fpage>&#x02013;<lpage>573</lpage>.
<pub-id pub-id-type="doi">10.1038/sj.jid.5700617</pub-id><?supplied-pmid 17082782?><pub-id pub-id-type="pmid">17082782</pub-id></mixed-citation></ref><ref id="ref-248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luquin</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Saunderson</surname><given-names>RB</given-names></name><etal/></person-group>:
<article-title>Genetic variants in the promoter of
<italic>TARDBP</italic> in sporadic amyotrophic lateral sclerosis.</article-title><source><italic>Neuromuscul Disord.</italic></source><year>2009</year>;<volume>19</volume>(<issue>10</issue>):<fpage>696</fpage>&#x02013;<lpage>700</lpage>.
<pub-id pub-id-type="doi">10.1016/j.nmd.2009.07.005</pub-id><?supplied-pmid 19695877?><pub-id pub-id-type="pmid">19695877</pub-id></mixed-citation></ref><ref id="ref-249"><label>249</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukouritaki</surname><given-names>SB</given-names></name><name><surname>Poch</surname><given-names>MT</given-names></name><name><surname>Cabacungan</surname><given-names>ET</given-names></name><etal/></person-group>:
<article-title>Discovery of novel flavin-containing monooxygenase 3 (
<italic>FMO3</italic>) single nucleotide polymorphisms and functional analysis of upstream haplotype variants.</article-title><source><italic>Mol Pharmacol.</italic></source><year>2005</year>;<volume>68</volume>(<issue>2</issue>):<fpage>383</fpage>&#x02013;<lpage>392</lpage>.
<pub-id pub-id-type="doi">10.1124/mol.105.012062</pub-id><?supplied-pmid 15858076?><pub-id pub-id-type="pmid">15858076</pub-id></mixed-citation></ref><ref id="ref-250"><label>250</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaca</surname><given-names>M</given-names></name><name><surname>Hismi</surname><given-names>B</given-names></name><name><surname>Ozgul</surname><given-names>RK</given-names></name><etal/></person-group>:
<article-title>High prevalence of cerebral venous sinus thrombosis (CVST) as presentation of cystathionine beta-synthase deficiency in childhood: molecular and clinical findings of Turkish probands.</article-title><source><italic>Gene.</italic></source><year>2014</year>;<volume>534</volume>(<issue>2</issue>):<fpage>197</fpage>&#x02013;<lpage>203</lpage>.
<pub-id pub-id-type="doi">10.1016/j.gene.2013.10.060</pub-id><?supplied-pmid 24211323?><pub-id pub-id-type="pmid">24211323</pub-id></mixed-citation></ref><ref id="ref-251"><label>251</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najah</surname><given-names>M</given-names></name><name><surname>Di Leo</surname><given-names>E</given-names></name><name><surname>Awatef</surname><given-names>J</given-names></name><etal/></person-group>:
<article-title>Identification of patients with abetalipoproteinemia and homozygous familial hypobetalipoproteinemia in Tunisia.</article-title><source><italic>Clin Chim Acta.</italic></source><year>2009</year>;<volume>401</volume>(<issue>1&#x02013;2</issue>):<fpage>51</fpage>&#x02013;<lpage>56</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cca.2008.11.012</pub-id><?supplied-pmid 19056372?><pub-id pub-id-type="pmid">19056372</pub-id></mixed-citation></ref><ref id="ref-252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funghini</surname><given-names>S</given-names></name><name><surname>Thusberg</surname><given-names>J</given-names></name><name><surname>Spada</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Carbamoyl phosphate synthetase 1 deficiency in Italy: clinical and genetic findings in a heterogeneous cohort.</article-title><source><italic>Gene.</italic></source><year>2012</year>;<volume>493</volume>(<issue>2</issue>):<fpage>228</fpage>&#x02013;<lpage>234</lpage>.
<pub-id pub-id-type="doi">10.1016/j.gene.2011.11.052</pub-id><?supplied-pmid 22173106?><pub-id pub-id-type="pmid">22173106</pub-id></mixed-citation></ref><ref id="ref-253"><label>253</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name></person-group>:
<article-title>Splice site mutation-induced alteration of selective regional activity correlates with the role of a gene in cardiomyopathy.</article-title><source><italic>J Clin Exp Cardiol.</italic></source><year>2013</year>; (S12).
<pub-id pub-id-type="doi">10.4172/2155-9880.S12-004</pub-id></mixed-citation></ref><ref id="ref-254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><etal/></person-group>:
<article-title>Clinical and genetic analysis of Korean patients with congenital insensitivity to pain with anhidrosis.</article-title><source><italic>Muscle Nerve.</italic></source><year>2009</year>;<volume>40</volume>(<issue>5</issue>):<fpage>855</fpage>&#x02013;<lpage>859</lpage>.
<pub-id pub-id-type="doi">10.1002/mus.21340</pub-id><?supplied-pmid 19618435?><pub-id pub-id-type="pmid">19618435</pub-id></mixed-citation></ref><ref id="ref-255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>F</given-names></name><name><surname>Baralle</surname><given-names>FE</given-names></name></person-group>:
<article-title>Genomic variants in exons and introns: identifying the splicing spoilers.</article-title><source><italic>Nat Rev Genet.</italic></source><year>2004</year>;<volume>5</volume>(<issue>5</issue>):<fpage>389</fpage>&#x02013;<lpage>396</lpage>.
<pub-id pub-id-type="doi">10.1038/nrg1327</pub-id><?supplied-pmid 15168696?><pub-id pub-id-type="pmid">15168696</pub-id></mixed-citation></ref><ref id="ref-256"><label>256</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadt</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>JY</given-names></name><etal/></person-group>:
<article-title>A cryptic
<italic>BAP1</italic> splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.</article-title><source><italic>Pigment Cell Melanoma Res.</italic></source><year>2012</year>;<volume>25</volume>(<issue>6</issue>):<fpage>815</fpage>&#x02013;<lpage>818</lpage>.
<pub-id pub-id-type="doi">10.1111/pcmr.12006</pub-id><?supplied-pmid 22889334?><pub-id pub-id-type="pmid">22889334</pub-id></mixed-citation></ref><ref id="ref-257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titeux</surname><given-names>M</given-names></name><name><surname>Mej&#x000ed;a</surname><given-names>JE</given-names></name><name><surname>Mejlumian</surname><given-names>L</given-names></name><etal/></person-group>:
<article-title>Recessive dystrophic epidermolysis bullosa caused by COL7A1 hemizygosity and a missense mutation with complex effects on splicing.</article-title><source><italic>Hum Mutat.</italic></source><year>2006</year>;<volume>27</volume>(<issue>3</issue>):<fpage>291</fpage>&#x02013;<lpage>292</lpage>.
<pub-id pub-id-type="doi">10.1002/humu.9406</pub-id><?supplied-pmid 16470588?><pub-id pub-id-type="pmid">16470588</pub-id></mixed-citation></ref><ref id="ref-258"><label>258</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertecant</surname><given-names>JL</given-names></name><name><surname>Ben-Rebeh</surname><given-names>I</given-names></name><name><surname>Marah</surname><given-names>MA</given-names></name><etal/></person-group>:
<article-title>Clinical and molecular analysis of isovaleric acidemia patients in the United Arab Emirates reveals remarkable phenotypes and four novel mutations in the
<italic>IVD</italic> gene.</article-title><source><italic>Eur J Med Genet.</italic></source><year>2012</year>;<volume>55</volume>(<issue>12</issue>):<fpage>671</fpage>&#x02013;<lpage>676</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejmg.2012.08.001</pub-id><?supplied-pmid 22960500?><pub-id pub-id-type="pmid">22960500</pub-id></mixed-citation></ref><ref id="ref-259"><label>259</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Hong</surname><given-names>YH</given-names></name><etal/></person-group>:
<article-title>Identification of a novel splicing mutation in the
<italic>ARSA</italic> gene in a patient with late-infantile form of metachromatic leukodystrophy.</article-title><source><italic>Korean J Lab Med.</italic></source><year>2010</year>;<volume>30</volume>(<issue>5</issue>):<fpage>516</fpage>&#x02013;<lpage>520</lpage>.
<pub-id pub-id-type="doi">10.3343/kjlm.2010.30.5.516</pub-id><?supplied-pmid 20890085?><pub-id pub-id-type="pmid">20890085</pub-id></mixed-citation></ref><ref id="ref-260"><label>260</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolisetty</surname><given-names>MT</given-names></name><name><surname>Beemon</surname><given-names>KL</given-names></name></person-group>:
<article-title>Splicing of internal large exons is defined by novel
<italic>cis</italic>-acting sequence elements.</article-title><source><italic>Nucleic Acids Res.</italic></source><year>2012</year>;<volume>40</volume>(<issue>18</issue>):<fpage>9244</fpage>&#x02013;<lpage>9254</lpage>.
<pub-id pub-id-type="doi">10.1093/nar/gks652</pub-id><?supplied-pmid 22790982?><pub-id pub-id-type="pmid">22790982</pub-id></mixed-citation></ref><ref id="ref-261"><label>261</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Leo</surname><given-names>E</given-names></name><name><surname>Magnolo</surname><given-names>L</given-names></name><name><surname>Lancellotti</surname><given-names>S</given-names></name><etal/></person-group>:
<article-title>Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia.</article-title><source><italic>J Med Genet.</italic></source><year>2007</year>;<volume>44</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>224</lpage>.
<pub-id pub-id-type="doi">10.1136/jmg.2006.046359</pub-id><!--<pub-id pub-id-type="pmcid">2598025</pub-id>--><?supplied-pmid 17158591?><pub-id pub-id-type="pmid">17158591</pub-id></mixed-citation></ref><ref id="ref-262"><label>262</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caminsky</surname><given-names>N</given-names></name><name><surname>Mucaki</surname><given-names>E</given-names></name><name><surname>Rogan</surname><given-names>P</given-names></name></person-group>:
<article-title>Dataset 1. Dataset for mRNA splicing mutations in genetic disease.</article-title><source><italic>F1000Research.</italic></source><year>2014</year>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5256/f1000research.5654.d38248">Data Source</ext-link></mixed-citation></ref><ref id="ref-263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Shirley</surname><given-names>B</given-names></name><name><surname>Caminsky</surname><given-names>N</given-names></name><etal/></person-group>:
<article-title>Splicing Mutation Calculator (splicemc.cytognomix.com): Initial release.</article-title><source><italic>Zenodo.</italic></source><year>2014</year>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5281/zenodo.12422">Data Source</ext-link></mixed-citation></ref></ref-list></back><sub-article id="report7225" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.6038.r7225</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wierenga</surname><given-names>Klaas</given-names></name><xref ref-type="aff" rid="r7225a1">1</xref><role>Referee</role></contrib><aff id="r7225a1"><label>1</label>Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA</aff></contrib-group><author-notes><fn fn-type="conflict"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>9</day><month>2</month><year>2015</year></pub-date><related-article id="d35e16044" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.5654.1">Version </related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The paper by Caminsky
<italic>et al. </italic>is a welcome and timely review of the complexities of pre-mRNA splicing, the relationship between splicing mutations, detection thereof by IT and/or laboratory, and new challenges posed by next generation sequencing.</p><p>It is a rather lengthy and somewhat intimidating review, and I can imagine that many readers, even interested ones, may not make it all the way to the end, certainly not in one session. On the other hand, the review paper is likely to reside on the desk of molecular laboratory directors and and other genetics professionals with an interest in the molecular aspects of genetics.</p><p>The review is well written, and the order to topics discussed is logical. Maybe the introduction to splicing is a little short, e.g. little space is dedicated to discussing the spliceosome. The review of the various splice 'sensing' software, and the technology underlying these was in depth.</p><p>The relationship between IT predicting splice mutations and laboratory studies to confirm the actual results of aberrant splicing was very well done, and the discussion of NMD and other causes of technical issues relating to demonstrating mutant mRNA resulting from splicing mutations was delightful.</p><p>The discussion about laboratory standards (also related to ACMG recommendations) regarding splicing was excellent.</p><p>Lastly, the discussion of the impact of splicing mutations and IT in the era of large datasets, including NGS was concise and accurate.</p><p>In summary, this review ought to be mandatory reading for all genetics professionals in molecular laboratories, incl. those involved in whole exome/genome sequencing.</p><p>The figures were well-selected, and the tables were helpful.</p><p>One minor remark: I would mention PLP1 as the gene associated with Pelizaeus-Merzbacher disease (p6, R, middle para).</p><p>I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body></sub-article><sub-article id="report6917" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.6038.r6917</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Titeux</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="r6917a1">1</xref><role>Referee</role></contrib><aff id="r6917a1"><label>1</label>Paris Descartes - Sorbonne Paris Cit&#x000e9; University, Imagine Institute, Paris, France</aff></contrib-group><author-notes><fn fn-type="conflict"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2014</year></pub-date><related-article id="d35e16111" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.5654.1">Version </related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p>The manuscript by Caminsky
<italic>et al.</italic> reviews the use of Information Theory (IT) based tools to predict splicing and splicing defects and their possible consequences on the matured transcripts. It is well written and well organized to guide the reader.</p><p>Following an introduction covering the basics of the splicing mechanism and signals on the pre-mRNA used by the spliceosome to define the exonic and intronic sequences, the authors described the mathematics behind
<italic>in silico</italic> prediction and then focus on the use of their tools (ASSEDA, SMC and Shannon pipeline) and their evolution over the past decade. They review the possibilities and limitations of such tools and compare them to other splicing prediction softwares (HSF, SSF, NNsplice, ESEFinder, RESCUE-ESE&#x02026;).</p><p>Over the years, IT-based splicing predictions have made progress and the overall rate of predictions concordant with experimental validations is around 88%. It has thus become a valuable tool for geneticists and molecular biologists. The authors also list the most common mistakes made by researchers while using their tools, and the ways to avoid them. They also stress the difficulties in predicting the consequences of splicing defect in particular cases due to poorly defined ESE/ESS sequences, combinatorial effects of splicing regulatory proteins (SR proteins and hnRNPs) and large exonic sequence which contains a large number of cryptic donor and splice sites and thus their definition is dependent on the binding of these regulatory proteins.</p><p>The manuscript is therefore of great importance for people that use such splicing prediction software as it presents their possibilities, limitations and the best way to report the results. Experimentally validated variants, associated with their predictions(should the authors properly report how the prediction was performed) will help to refine the tools.</p><p>Such
<italic>in silico</italic> tools are even more valuable in a genomic era where large number of variants are identified by deep sequencing (exomes, whole genome sequencing...) some of which being of unknown significance. Adding better splicing&#x000a0;defects prediction (apart from the 2 bp most conserved in the natural splice sites) to the filters used in the prioritization pipeline of next generation sequencing projects should be considered.</p><p>I therefore recommend the manuscript for indexation without reservations, if small minor issues listed below can be addressed.</p><p>Minor issues :
<list list-type="bullet"><list-item><p>Figure 5 is not called in the text.</p></list-item><list-item><p>Since the journal uses a numbered formatting style for the references, please add the number of the reference in sentences like &#x0201c;Smaoui
<italic>et al.</italic> 2004 described&#x02026;.&#x0201d; (page 17), since it is easier to find the given reference among over 260.</p></list-item><list-item><p>In the supplementary table 2, in the column &#x0201c;concordance (Y/N)&#x0201d; there is in some cases a &#x0201c;P&#x0201d; indicated whose meaning is not clear.</p></list-item></list>
</p><p>I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p></body></sub-article></article>